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 Summary 
 
 
The design and synthesis of conformationally restrained amino acids has been the 
focus of extensive research, because these compounds mimic or induce specific secondary 
structural features of peptides and proteins. Since the discovery of the crucial role of proline 
in protein structure, cyclic α-amino acids containing a heterocyclic ring have attracted 
considerable attention both from synthetic and medicinal chemists. The first part of this Ph D 
project is dedicated to the design and synthesis of a new cyclic α-amino acid; 5-
Oxopiperazine carboxylic acid (so called “Pca”). Herein we will report a practical synthesis of 
(R)- and (S)-N-Boc-5-Oxo-piperazine-2-carboxylic acid, its introduction into peptidomimetic 
structures by a solution-phase peptide-synthesis strategy, and a conformational analysis of 
tetrapeptide mimics incoroporating a Pca residue. 
  
Oligomers that adopt predictable conformations (so called “foldamers”) are subject of 
increasing interest from the perspectives of both fundamental research and applications. In 
this context, the second part of this Ph D work is focused on the structural behaviour of 
another unnatural cyclic amino acid, previously synthesized in the group of Pr. Reiser. This 
second scaffold is a delta amino acid constrained in its center by a γ−butyro lactone ring. We 
have investigated the structural role of this building block in homo-δ-oligomers as well as 
dipeptide surrogates in α-amino acid sequences.  These oligomers were synthesized using 
both solution and solid phase peptide chemistry and secondary structural features of these new 
molecules were defined using NMR, IR, CD data as well as molecular modelling.  
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                                               ABBREVIATIONS   
 
 
 
Ac   acetyl 
CAN   acetonitrile 
Bn   benzyl 
Boc   tert-Butyloxycarbonyl 
CAN   cerium ammonium nitrate 
Cbz   benzyloxycarbonyl 
CD   circular dicroism 
COSY   correlation spectroscopy 
DCM   dichloromethane 
DIPEA  diisopropylethylamine 
DMF   dimethylformamide 
DMSO                        dimethylsulfoxyde 
DNA              desoxyribonucleic acid 
EDC                            N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide   
DCC   N,N′-Dicyclohexylcarbodiimide 
ESI   electrospray ionization 
Fmoc                          fluorenyl-9-methoxycarbonyl 
HATU             O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HBTU   O-(1-benzotriazolyl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HOBt                         hydroxybenzotriazole 
HOAt                         1-Hydroxy-7-azabenzotriazole 
HPLC                         high pressure liquid chromatography     
IBX                         2-Iodoxybenzoic acid  
IR                               infra red spectroscopy 
LDA   Lithium diisopropylamide 
MALDI-Tof             matrix-assisted-laser-desorptionionization time of flight 
MBHA  methylbenzhydrylamine 
Mp                              melting point 
NBS                            N-Bromosuccinimide 
NMR   nuclear magnetic resonance 
NOESY  nuclear Overhauser effect      
Pbf                              2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl  
PMB                           Para-Methoxy-Benzyl 
Pca                             Piperazinone carboxylique acid 
SN2                                          Nucleophilic substitution of type 2  
RNA                           Ribonucleic acid 
TEA                            Triethylamine                           
TFA   trifluoroacetic acid 
TFE   2,2,2-trifluorethanol 
THF   tetrahydrofurane 
TIS   triisopropylsilane 
TOCSY  total correlation spectroscopy 
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tR    retention time 
UV             ultraviolet 
TACE                        TNF-a Converting Enzyme 
TNF-α                       Tumor necrosis factor 
TLC                            Thin-layer chromatography 
 
Amino Acid Codes  
 
 
                         One-Letter                          Three-Letter       Amino Acid 
                            Code                                        Code  
       
 
 
       
 
A  Ala  Alanine  
C  Cys  Cysteine  
D  Asp  Aspartic acid  
E  Glu  Glutamic acid  
F  Phe  Phenylalanine  
G  Gly  Glycine  
H  His  Histidine  
I  Ile  Isoleucine  
K  Lys  Lysine  
L  Leu  Leucine  
M  Met  Methionine  
N  Asn  Asparagine  
P  Pro  Proline  
Q  Gln  Glutamine  
R  Arg  Arginine  
S  Ser  Serine  
T  Thr  Threonine  
V  Val  Valine  
W  Trp  Tryptophan  
Y  
Unspecified  
amino acid 
Tyr  
X 
Tyrosine  
Xaa 
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I - INTRODUCTION 
 
 
The function of peptides and proteins in living systems is strictly related to their three-
dimensional architecture. As it is now well described, the structural organisation of proteins 
can be divided in three subtypes of structures. Primary structure involves the direct sequence 
of amino acids. The term “secondary structure” refers to a local conformational preferences of 
the poly (α-amino acid) backbone. The most common regular elements of secondary 
structures include α-helices, β-turns and β-strands. The tertiary structure of a protein is the 
way in which various elements of regular secondary structure, and irregular connecting 
segments are packed together. Scientists from different fields, have worked together to study 
and understand these incredible folding properties of proteins, but it is until now, still not 
possible to predict the exact organisation that will take a simple sequence of amino acids to 
fold in a extremely complicated tertiary structure, leading to the biological activity.  
 
 
 
Figure I-1 Various level of structural organisation observed in protein structures 
(Reproduced with the agreement of ACS publisher) 
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It is therefore always more and more important to develop new synthetic tools mimicking the 
structure and activity of biologically interesting peptide and protein in order to design new 
effective drugs on the one hand and on the other hand to understand better the architecture of 
these crucial polymers that are proteins.  
In the last decade, many efforts have been made to design oligomers, so-called foldamers, 
which are able to adopt predictable and well-defined conformations.1,2 
 
This PhD project is tightly connected to this context. The whole work performed during this 
PhD thesis deals with the study of modifications, synthetically introduced into the natural 
amino acids backbone, and its influence on the conformation of natural peptide sequences. 
 
Two classes of peptidomimetics were studied. 
During the first part of my PhD thesis, in Como we focused on the design, synthesis and 
structural evaluation of a new cyclic α-amino acid; 5-Oxopiperazine carboxylic acid.  
Considering the widespread use of cyclic aminoacids in peptidomimetics, we focused our 
efforts towards the synthesis of new chiral piperazinone-5-carboxylic acids as proline analogs 
(Figure I-2). The synthesis of 4-tert-Butoxycarbonyl-piperazin-2-one-5-carboxylic acid 
derivatives was obtained in few steps and good yields starting from Boc-L-serine tert-butyl 
ester. 
 
Figure I-2 Structure of 4-tert-Butoxycarbonyl-piperazin-2-one-5-carboxylic acid 
 
The synthesis of peptidomimetics containing our piperazin-2-one-5-carboxylic acid was then 
realized, and their conformation in solution was studied by analytical and computational 
methods. 3 
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In the second part of this PhD we focused our studies on structural properties of a new class 
of lactone δ-amino acid derivatives as inducer of secondary structures. Two pentalactone-
containing derivatives, 1a and 1b (Figure I-3) were prepared and their strucutral features 
studied.  
 
Figure I-3 Structures of pentalactone compounds 1a and 1b and of glycyl-glycine. 
 
On the one hand, these cyclic scaffolds can be described as delta-amino acids bearing a 
lactone ring at gamma- and delta-positions. On the other hand, they mimic a glycyl-glycyl 
dipeptide unit, in which the amide bond is replaced by a lactone ring.  
We have investigated, by CD, NMR, FT-IR and molecular modelling, the properties of these 
building blocks as dipeptide surrogates in α-amino acid sequences and revealed that they 
possess a high propensity to induce stable secondary structures.  
 
 
 (1) Gellman, S. H. Acc. Chem. Res. 1998, 31, 173-180. 
 (2) Venkatraman, J.; Shankaramma, S. C.; Balaram, P. Chem. Rev. 2001, 101, 
3131-3152. 
 (3) Hayashi, T.; Asai, T.; Ogoshi, H. Tet. Lett. 1997, 38, 3039-3042. 
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II - PROLINE 
 
Among the twenty amino acids that are coded in proteins, proline occupies a unique 
position. Indeed, it is the only mammalian amino acid where the side chain is cyclised onto 
the backbone α-nitrogen atom. The cyclic structure of proline itself leads to three important 
consequences. 
N
H
R
H2N COOH COOH
Φ Ψ ΨΦ
χχ
19 α-amino acids 1 cyclic α-amino acid
proline
 
Scheme II-1 
 
First, the amino acid skeleton itself is considerably restricted.  Thus the characteristic amino 
acid φ and ψ angles in proline take only particular values (Scheme II-1).  Since φ dihedral 
angle is part of the ring, it is tightly restricted to a small range around -65°. As for ψ, it is able 
to populate either the α−helical region (ψ=-40°), or the β-sheet region(ψ= +150°) see figure 
1.1,2 
 
Figure II- 1 : Ramachandran plot for Proline and proteine secondary structures 
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Second, the bulkiness of CH2-N region of the ring induce a consequent restriction in the 
amino acid preceding proline.3 For instance, in α-helices the presence of a proline residue will 
sterically affect the conformational behaviour of its C-terminal neighbour preventing it from 
making a hydrogen bond with a carbonyl in the preceding turn of the helix . This will create a 
kink in the helix and introduce a deviation of 20° in the helix tube. This disfavouring effect of 
proline over  α-helix conformation,4 is illustrated in Figure II-2. 
 
 
 
 
 
Figure II-2 : Deviation introduced by the presence of a proline residue in a helical structure 
 
Third, in peptides and proteins, the α-nitrogen of proline is involved in three covalent bonds; 
so that the nitrogen amide can not act as a hydrogen donor. 
These three facts point out that proline structure will have a direct impact on peptides and 
proteins secondary structures. 
The other facet of proline is its ability to adopt cis or trans amide conformation at its N-
terminal part (Scheme II-2). Unlike non cyclic natural amino acids that are linked to each 
other by trans peptide bonds. Proline introduces heterogeneity in protein backbones since 
both cis and trans conformations of the peptide bond are allowed. The lack of one hydrogen 
on the amide bond in Xaa-Pro segments significantly lowers the energy difference between 
the cis and trans rotamers, while the activation barrier for isomerisation remain significant 
(Scheme II-2).  
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Scheme II-2 : Cis ans trans confromations of proline in peptides 
 
 
It is also to note that the cis /trans conversion in Xaa-proline segments in nature is catalysed 
by the specific peptidyl-prolyl cis trans isomerase5 wich attest the importance of the geometry 
around this amino acid. All these caracteristics combined, are giving to proline a crucial role 
in the recognition, reactivity, and stability of polypeptides and proteins. 
 
II-1 Proline in peptides and proteins: biological activity 
 
 
II-1.1 Proline in peptides biological activity 
 
Proline is found in many biologically synthetic and natural important peptides.6 Most 
of the small peptides showing an immuno-pharmaceutical activity contain proline residues. 
By interfering with immuno modulation processes, such peptides lead to immuno suppression 
or immuno stimulation.7,8 Oligopeptides containing proline are also found to be active in 
coagulation phenomena: actually the tetrapetide Gly-Pro-Arg-Pro prevent polymerisation of 
fibrin and therefore its aggregation with platelets to form fibrinogen clots.9 And bactenecins: 
peptides located in neutrophiles granules, repeating several times the Arg-Pro-Pro motif have 
shown antimicrobial activity enhancing permeabilization of bacterian membranes (Table II-
1).10 
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Structure Activity 
Thr-Lys-Pro-Arg (tuftsin) Enhances the phagocytosis by monocytes and 
macrophages8 
Leu-Pro-Pro-Ser-Arg Drives B lymphocytes to immunoglobulin secretion7               
Gly-Pro-Arg-Pro Prevents polymerization of fibrin and association 
with platelets9 
Arg-Phe-Arg-Pro-Pro-Ile-Arg-Arg-Pro-Pro-Ile-
Arg-Pro-Pro 
Bactenin 5 potent antimicrobial and cytotoxic 
activity10 
Table II-1 : Peptides containing proline with an immuno pharmaceutical activities 
 
II-1.2 Peptides containing proline toward enzymes 
 
Proline plays a crucial role in the proteolytic maturation of peptides11 from their 
inactive precursors to its biologically active form. It is the case for the peptidic hormone 
Angiotensin (involved in blood pressure regulation) where the presence of proline direct the 
cleavage of the peptide precursor Angiotensin I to form the active molecule Angiotensin II. 
This example highlights the specificity and versatility of proline regarding enzymes. Only a 
limited number of peptidases are known to be able to hydrolyze proline adjacent bonds (table 
2). On the one hand proline may serve as recognition site for prolyl specific peptidase 
(angiotensin, substance P, neuropeptide Y….), but on the other hand the restricted skeleton of 
this cyclic amino acid can be used to protect peptides from non specific proteolysis 
degradation (especially useful for the preservation of peptide or protein extremities) table 2. 
For instance it has been previously demonstrated that a great number of active peptides, like 
Growth factor and interleukins12 possess a N-terminal X-Pro motif protecting the end of 
peptides from degradation. 
 
Motifs Examples  of biological function 
Proline trans configuration 
X-Pro-Y Protection against specific N-terminal degradations 
-Pro-X- Brain: Hydrolysis of post Pro bond in hormones by prolyloligopeptidase. 
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X-Pro-Y-Pro-Z By two step action of dipeptidyl peptidase IV, maturation of substance P 
and Inter leukin 6 
-Pro-Pro- Bonds between to Pro possess a high resistance to all proteolytic systems 
in human 
Cis conformation of 
proline 
 
-X-Pro Protein folding and intracellular signalling by peptidyl prolyl cis-trans 
isomerases, translocation of ions in transport channels 
Table II-2 : Effects and function of proline motifs 
 
II-2 Proline in proteins  
 
II-2.1 Proline rich proteins (PRPs)  
 
PRPs 13 are widely found in both procaryote and eucaryote proteins. These sequences 
containing proline can be located in different part of the proteins and occupy from small 
domains to the entire part of the protein chain. Depending on their position and their length 
these proline rich regions (PRRs) lead to different functions. 
II-2.1.1 Tandemly repeated sequences: Binding and coating function 
 
Salivary PRPs which constitutes 70% of the Saliva proteins contain PQGPPQQGG sequences 
of great length repeated in tandem many times. In such proteins, the proline section 
constitutes almost the entire protein. These proteins’s major function is to capture polyphenols 
(Figure II-3) coming from the diet and decrease their harmful effects by forming 
precipitates14. Mamalian epithelial mucins are made of large proteins containing although 
quite long, tandemly repeated sequences of prolines. These proteins are forming large 
networks coating and lubricating the epithelial layer15.  
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Figure II-3 Capture of polyphenols by proline rich region in salivery proteins. 
 
II-2.1.2 Multi Proline rich regions (PRR) systems: Transcription initiation 
 
As it has been described before proline sequences are involved in binding phenomena 
interacting with different motifs. But there are also examples showing protein-protein 
interaction involving the contact between two different PRRs. Thus RNA-Polymerase II, 
which possess in its C-terminal domain 26 or 27 copies of the Y-S-P-T-Y-S-P-S motif, will 
interact with DNA by means of another protein TATA box containing also proline rich 
sequences (Figure II-4). This protein-protein interaction will lead to the initiation of 
transcription. 16 
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Figure II-4 : Transcription initiation, role of the proline rich segment in RNA polymerase 
 
II-2.1.3 Proline/Hydroxyproline (Hyp) rich proteins : A structural role 
 
Collagen is the major class of insoluble fibrous protein in extracellular matrix and connective 
tissue such as tendons and skin. The primary structure of collagen is mainly composed of 
three amino acids occurring as trimer repeats Gly-X-Y. Glycin constitute one third of the 
protein, the imino acids Proline and Hydroxyproline (Hyp) are then located respectively in X 
and Y position. Hyp derived from proline residue post-traductionnally modified by proline 
hydroxilases. The secondary structure of a single strand of collagen is adopting a left handed 
extended polyproline II helix conformation. In the tertiary structure, three polyproline II 
chains are interlaced around each other to form a right handed triple helix.17 This triple helix 
packing is then stabilized by hydrogen bonds between glycine of each chain (Figure II-5). 
This specific shape is known to be essential to cell adherence and migration. 18  
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Figure II- 5 : Collagen fibre organisation 
 
 
II-3 Proline role in secondary structures 
 
In the past years, studies of biological phenomena have shown that the incredible 
properties of proline are mostly related to its ability to induce specific secondary structures in 
peptides and proteins.  
 
II-3.1 Proline in helices 
 
II-3.1.1 Polyproline helices 
There are two types of polyproline helices: the polyproline I (PPI) and polyproline II (PPII) 
helices. The originality of such polypeptide is that both helices are made of a succession of 
proline residues unable to make H-bonds. Therefore, the stabilization of these particular 
secondary structures results from the restriction induced by proline pyrrolidine ring only.  
 
II-3.1.1.1 Polyproline I (PPI) 
 
This helix adopts a right handed compact helical conformation (Figure II-6) and contain 3,3 
residues per turns (103 helix). In this particular structure proline residue’s dihedral angles 
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adopt the same repetitive values (-75°, 165°), the dihedral angle of the peptidic bond is always 
in cis.  
 
 
Figure II-6 : Different perspectives of PPI helix 
 
Anyway this succession of cis peptide bonds are quite unfavourable energetically especially 
in water, so that this kind of helices is poorly populated in nature. 
 
II-3.1.1.2 Polyproline II(PPII) 
 
PPII consist in an extended structure with three proline residues per turns (31 helix) in which 
Φ and Ψ angles adopt -75° and + 145° values. The major difference between both PPI and 
PPII structure is that PPII adopt a left handed helicoidal structure with the amide bond 
between two proline residues in trans. 
 
   
Figure II-7 : Different perspectives of PPII helix 
Unlike PPI, PPII helices occur quite often in nature. It has an important role in several 
biological functions, as signal transduction, cell motility, and immune response19. As 
described in the precedent section, the polyproline II is also component of structural proteins 
like collagen, and it is believed to be the dominant conformation in proline rich sequences.  
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II-3.1.2  α-helices 
 
Proline amino acids are mostly known for having a disrupting effect on helices, nevertheless 
numerous proline residues are found in transmembranar helicoidal segments of proteins acting 
as receptors  subunits or transporters20. Indeed, the wide family of protein G coupled receptors 
possess transmembrane helicoidal units containing numerous proline residues. Mutagenesis 
studies demonstrated that these residues play a key role in receptor activation, and ligand 
binding. These experiments led to the hypothesis that the cis/trans isomerisation properties of 
proline could be at the origin of conformational changes in proteins necessary for the 
regulation of a transport channel. In addition, presence of intrahelical proline residues favours 
the exposure of the previous amino acid carbonyl groups outside of the helix tube. In this 
way, the CO of the previous residues have the possibility to bind other ligands such as metal 
cations (Na+ or Ca2+). Transmembranes helices containing proline could thus play a role in 
ionic pumps. 
 
II-3.2 Proline in turns 
 
Turns in peptides and proteins are important structural and biological features. It is widely 
present in the extremity of proteins, and have proved to participate in protein-protein 
interactions and recognition phenomena. Because the pyrrolidine ring of the Proline residue 
forces the Φ angle to be centred on the -60° (+/- 15°), proline presents a ready opportunity to 
change the direction of the polypeptide chain. It is now widely known that proline serves as 
turn inducer in natural peptides and proteins. 
II-3.2.1 Proline in Type II β-turns 
 
Proline is often present at the i+1 position of β II- turns (Figure II-8). This turn is widely 
found in peptides and proteins since it is connectings anti parallel β- strands.21 
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FigureII-8 : β- turn containig proline in the i+1 position 
 
 
 
II-3.2.2 Proline in VI β- turns: cis proline turns 
 
Although if this this kind of turn is less common in proteins it seems to play an important role 
in protein folding, it has been found in the terminal part of a helical segments22,23and it appear 
to be important in protein ligand recognition phenomenon.24 This motif is constituted of 4 
amino acids like the II β-turn above but in this secondary structure the proline occupies the 
i+2 position. Another particularity of this secondary structure is that the proline preceding 
amino acid and proline it self are linked trough a cis peptide bond.  
 
II-3.2.3 Proline in new foldamers 
 
Recently, proline has been used for the design and synthesis of new foldamers. Baruah & al. 
in 2007,25 reported the synthesis of a new hybrid peptide (Figure II-9) that adopt a compact 
three dimensional structure that display periodic γ-turn. 
 
FigureII-9 (reproduced with the agreement of ACS publisher) 
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Srinivas et al.26 at the same period described another hybrid foldamer repeating the Aib-Pro-
Adb (3-amino 4,6-dimethoxy benzoic acid) sequence that was folding alterning β-turns motifs 
(Figure II-10). 
 
Figure II-10 (reproduced with the agreement of ACS publisher) 
 
 
These two new peptidomimetics highlights that the importance of this natural amino acid is 
not limited to natural proteins but also as synthetic tool for scientist to expand the 
conformational space available for foldamer design. 
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III- CYCLIC α-AMINO ACIDS CONTAINING A NITROGEN 
ATOM IN THE RING: TOOLS FOR THE DESIGN OF 
PROLINE MIMICS  
 
 
Peptides are bioactive compounds involved in numerous biological pathways in nature. They 
are thus attractive targets for the design of new drugs. Unfortunatly, they are not suitable for 
the development of pharmacologically active compounds, since they are highly exposed to 
proteolytic degradation. The great properties of proline provided the scientists a starting point 
for the development of new synthetic tools that would mimic and improve on its own 
properties. Actually the design and synthesis of new conformationally restrained tools, such 
as Cyclic Amino-Acids (CAA) as well as their incorporation in peptides and proteins, would 
give the opportunity to acquire a better understanding of protein folding phenomenon as well 
as protein biological behaviour. In addition, the non proteinogenic character of CAA amino 
acids would be an asset for the development of new peptide-like drugs. Actually, the presence 
of a non natural amino acid-like molecule in a peptidic segment could reduce the sensitivity of 
peptides toward enzymes, and thus overcome the problem of bioavailability of peptide-based 
drugs. Another advantage of cyclic amino acids containing peptides is the structural control 
they confer to peptidomimetics, and this could also augment the selectivity for specific 
receptors. 
 
Thanks to proline, Cyclic Amino Acids have become molecules of increasing interest in both 
fields of synthetic and medicinal chemistry. Cyclic secondary amino acids have been applied 
to several biological issues, and their incorporation into bioactive peptides has been reported 
over the past years.27 
CAA synthesis has been already well commented in a previous review,28 I will here report 
some of the major synthetic pathways described in the literature focussing in particular on 6-
membered ring cyclic amino acids in which we were interested for the present work. 
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III-1  C3 Aziridin-2- carboxylic acids and derivatives 
 
Aziridines rings are versatile and powerful building blocks in organic synthesis due to their 
high reactivity. Synthetic aziridines exhibit multiple biological properties, such as enzyme 
inhibition29 and DNA alkylation. Their susceptibility to regio- and stereoselective ring 
opening,30 renders these compounds useful precursors for the synthesis of various  nitrogen 
containing compounds, notably chiral amino acids.31 In particular, the aziridine-2 carboxylic 
acids could be important components for the preparation of a variety of conformationally 
constrained peptidomimetics building block. 
 
III-1.1 Synthetic routes 
 
In 1996, Goodman and coworkers,32 proposed a three step procedure providing the mono 
substituted aziridine carboxylic derivative 4 in good yields and as an optically pure material. 
Coming from the corresponding allylic alcohol via Sharpless asymmetric epoxidation, R-2-
methylglycidol 1, was oxidized to its carboxylic acid derivative. The acid was then protected 
by a benzyl group, and subsequent ring opening was performed with NaN3 to form the azido 
alcohol 3. Refluxing the azide derivative with triphenyl phosphine provided the 
enantiomerically pure aziridine carboxybenzyl 4 (Scheme III-3).  
 
Scheme III-3 
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Boukris et al. in 200333 described a two step synthesis of tri-substituted aziridine 
carboxyester. In a first step the halohydrins 5 prepared from the corresponding epoxy esters, 
were treated with hydroxylamine derivative to give the cyclisation precursor 6. In a second 
step, the N-protected β-halo α-aminoesters were converted into the corresponding aziridine 
carboxylic ester 7 in good yields (Scheme III-4).  
 
Scheme III-4 
 
Diaper et al. in 2005,34 introduced the Aziridine-2-carboxylic acid motif in analogues of the 
antibiotic diaminopemilic acid (DAP). Reaction of phosphonate ester XcCOCH2PO(OEt)2 
with N,N-di-Boc glutamate semi aldehyde using a Horner-Wadsworth-Emmons type coupling 
gives exclusively the trans alkene. Removal of one of the Boc groups generated the 
aziridination precursor 9. Subsequent aziridination performed in presence of 3-Amino-2-
ethyl-3,4-dihydroquinozolinone, led to the Aziridine derivative as a diastereoisomeric mixture 
(9:1). The major diastereoisomer was then purified by recristallisation and deprotected to 
afford the desired molecule with the aziridine-2-carboxylic moiety 11 as an optically pure 
compound.  
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Scheme III-5 
 
More recently, Minijew & al. in 200635 developed two different diastereoselective procedures 
based on the cyclisation of selanyl esters. First of all, a chiral center was introduced to induce 
diastereoselective reactions. Addition of a chiral lithium amide to α,β-unsaturated esters 
afforded the product 14 as only one diastereoisomer. Then, the debenzylation with CAN 
selectively provided the corresponding amine 15. Then deprotonation by LDA followed by 
addition of benzene selenienyl bromide afforded β-amino α-selanylesters, that was obtained 
as two diastereoisomers 16 and 16’. The two diastereoisomers were separated by 
chromatography, and each pure diastereoisomer was cyclised after activation of selanyl amino 
esters with Meeerwein salt or NBS providing the trans aziridine compound 17 and 
17’.
 
Scheme III-6 
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III-1.2 In the field of peptide and petido mimetics 
 
Aziridine 2-carboxylic acid is a useful tool in peptide chemistry. Its introduction in the 
backbone or in the lateral chain of peptides, afford reactive electrophilic site for further 
modifications (conjugation of glucide moieties, introduction of modified lateral chains). 
Anyway, this great reactivity toward nucleophiles creates difficulties in maintaining the ring 
integrity during peptide coupling synthesis. Therefore only few methodologies are at the 
moment available to build this kind of peptidomimetics containing Aziridine carboxylic acid 
motif. 
 
Danica et al. in 2005, reported a strategy to incorporate the azyridine carboxylic acid motif in 
peptides (Scheme III-7). 
 
 
 
Scheme III-7 
 
 
Tripeptides containing a central Aziridine moiety 22, were prepared by initial coupling of N-
Trityl protected serine 18 with alanine benzyl ester. The resulting dipeptide, was reacted with 
methanesulfonyl chloride and subsequently treated with triethylamine in THF to afford the 
corresponding N-tritylaziridine-containing dipetide. Further deprotection of the trityl group 
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followed by acylation of the free azyridine with various Boc protected amino acids led to the 
generation of tripeptides that possess a central aziridine moiety 22.  
 
Another synthesis of azirididine containing peptides has been reported by Fioravanti et al in 
200836. In this case the aziridine ring was introduced by reacting (E)-acrylonitrile with Nosyl-
oxycarbamate (Nosyl=Ns=4-NO2C6H4SO2) in the presence of CaO as a base (Scheme III-8). 
During this reaction, the E configuration of the double bond was conserved. Subsequent 
deprotection of the aziridine nitrogen, followed by coupling of a third aminoacid (under mild 
conditions), afforded a library of aziridyl-tripeptide sequences. These kind of procedure 
allowed the creation of libraries of di- to tetrapeptides containing aziridines, but longer 
peptides containing aziridine-2-carboxylic acid is still a challenging field. 
 
 
Scheme III-8 
 
 
 
Regarding foldamers synthesis, Takashi et al. reported the synthesis of a β-sheet mimic, 
where the two arms were linked through an aziridine motif (figure III-11). But no 
conformational studies  were reported on this structure.37-39 
 
 
 
Figure III-11 
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III-2  C4 Azetidine-carboxylic acids and derivatives 
 
 
Azetidine-2-carboxylic acid (L-Aze), has first been discovered and isolated from convallaria 
majalis by Fowden in 195540. Later it appeared to be a constituent of several natural products 
like mugineic acid41 or nicotiamine 42. It has also been recently incorporated in the 
pharmacologically active molecules Melagatran or Extenta that act as Thrombin inhibitors43. 
 
 
 
 
Figure III-12 
III-2.1 Synthesis 
 
Because of its numerous possibility of functionalisation and its conformational restriction 
properties, this 4-membered-ring heterocycle has become a convenient building bloc in 
organic synthesis. Its preparation has been reviewed in 2002 by Kurth et a.l 44, and more 
recently by Cordero & al.,45 so I will report here only some examples of synthetic strategies 
providing the “chimera” amino acid enantiomerically pure.  
 
 
Chromatographic separation of diastereoisomers : 
 
Ma et al.25 developed a synthetic procedure to obtain both enantiomers of the L-Aze 24 and 
24’, (Scheme III-9). This route involve Methyl 2, 4-dibromobutanoate, dihalogenated 
compound that will react with (R)-phenylethylamine an inexpensive source of chirality. The 
base-promoted cyclisation led to a diastereoisomeric mixture of the N-protected azetidine-2-
carboxylic acid 23 and 23’. Diastereoisomers were then separated by chromatography and 
further deprotection gave both enantiomers of the desired optically pure free amino acid in 
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good yields. Similar strategy had been developed previously by Couty & al46 and Futamura et 
al47 . 
 
 
Scheme III-9 
 
 
Procedure using chiral auxiliaries: 
 
Hanessian et al.48 (Scheme III-10) described a selective synthesis of L-Aze using the 
Oppolzer sultam derivative of glyoxylic acid oxime and allyl bromide to form allyl glycine 
25, and thus introducing the stereocenter. The chiral auxiliary was then removed, and the 
carboxylic and amino groups were orthogonally protected. Ozonolysis of the double bond 
followed by reduction of the new formed aldehyde function gave the alcohol derivative that 
was then transformed into the corresponding mesyl group 28. Finally deprotection of the 
amino group and cyclisation afforded the desired azetidine carboxylic skeleton 27 which was 
involved in the final steps of deprotection and DOWEX purification to give pure L-Aze 28.  
23 
23’ 
24 24’ 
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Scheme III-10 
 
 
Sterically directed cyclisation : 
 
An efficient and unexpected cyclisation leading to the formation of an azetidine-2-carboxylic 
acid derivative was described by Sardina et al.49 In this route protected 
2S,3S-hydroxyaspartate was converted in two steps in its dimesylate derivative 29, which was 
cyclised under basic condition to afford the Trans-substituted azetidine 30 as unique product 
(Scheme III-9). The epimeric 2S,3R-derivative, under the same conditions, led to the 
formation of the aziridine derivative as a major product. 
 
 
Scheme III-11 
 
25 
 
 
26 
27 28 
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Rearrangement of already existing cycles : 
More recently, anti-aziridino amino esters were thermally rearranged upon treatment with 
Et3N to trans-N-protected alkyl-3-aminoazetidine-2-carboxylic esters 31 (Scheme III-12)50 
 
 
Scheme III-12 
 
 
III. 2. 2 Peptidomimetics 
 
L-Aze as proline surrogate: 
 
L-Aze and L-proline adopt similar conformation in peptides since they are both constraining 
the conformational space of the previous residue by steric interaction with the ring. Therefore 
Aze has been early incorporated in vivo and in vitro into cellular proteins using the cellular 
protein synthesis machinery.51,52 Anyway some differences are detected: particularly in 
dihedral angles and bond distances. Comparative calculations on both rings have shown that, 
L-Aze in dipeptides  is presenting more energetic minima than proline, meaning that it could 
introduce more flexibility in polypeptides. L-Aze, has earlier been incorporated in 
collagen-like polytripeptide molecules instead of proline.53-55 It has been reported that 
collagen containing L-Aze , present modified biological and physiological properties. It is 
mainly retained in the cell so that the extrusion to form intercellular matrix is reduced 
preventing the incorporation into tissues. It seems that this is due this enhanced flexibility 
induced by L-Aze thus destabilizing the triple helix of collagen. 
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In a more recent paper the effect of proline substitution by L-Aze was studied in the 
polypetides [(AlaGly)ProGluGly]16. The interesting outcome of this investigations is that 
proline containing peptides were disordered, whereas L-Aze containing sequences promoted 
the formation of β-structures.56 This tendency was confirmed by Ogoshi & al37 who 
performed comparative conformational studies on tetrapeptides containing L-Aze. Finally 
Baeza & al57,58, demonstrated recently the propensity of L-Aze to induce γ-turns in short 
peptides (Figure III-13). 
 
Figure III-13 Conformational preferences of proline and azetidine dipeptides 
(reproduced with the agreement of ACS publisher) 
 
 
III-3  C5 Decorated pyrrolidine rings, a route to modified proline 
 
In term of mimics, what more than a five membered heterocyclic ring could mimic proline ? 
Actually, nature has already produced a plethora of modified prolines in which the most 
famous one is hydroxy proline where the presence of the hydroxyl substituent on the 
pyrrolidine ring is stabilizing the collagen triple helix59. Subtituted proline mimic have been 
used in particular to study stabilization mechanism of hydroxyproline replacing the hydroxyl 
substituent by different functional groups. Substituted proline, have been found in biologically 
active molecules, anticancer agents (Figure III-14): are also convenient scaffolds for the 
development of new pharmacogically active molecules. 
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Figure III-14 : 3-substituted proline in anti proliferative agent, polyoxypeptin 
 
 
Various approaches are now available to build substituted proline derivatives. And it has been 
reviewed in 2004 by Karoyan et al.60 and I will repport some synthesis examples as well as 
structural preferences of this constrained amino acids. 
 
III-3.1 Synthesis 
 
III-3.1.1    2-subsituted prolines  
 
Asymmetric synthetic procedures for the preparation of the so called quaternary prolines have 
been recently reviewed by Calaza & al, 61 so I will report here only some recent examples.  
Scheme III-13 reports the different strategies elaborated to perform the synthesis of these 
highly constrained compounds. 
 
Scheme III-13 
 
α-functionalization of L-proline (Route1,Scheme III-13 ) 
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The challenging parameter of this reaction is to maintain the optical purity of the previous 
proline compound. Therefore  Seebach et al. in 198362 provided a methodology to perform 
alpha alkylation of proline, inventing the concept of self-reproduction of chirality. In this 
procedure (Scheme III-14) L- proline was condensed with piruvalaldehyde to afford a single 
conformer of 2-tert-butyl-1-Aza-3-Oxabicyclo[3.3.0]octane-4-one 31. Subsequent 
deprotonation with LDA gave then a non racemic enolate intermediary which was combined 
with alkyl halides to provide the α-alkylated proline skeleton 32 with complete 
diastereoselection. The oxazolidinone ring was then opened under hydrolytic conditions 
providing the desired alkylated  proline 33 with good enantioselectivity. 
 
 
 
Scheme III-14 
 
 
 
 
Synthesis with the formation of the pyrrolidine ring (routes 2, 3 and 4 ) 
1, 3 dipolar addition cycloaddition: Azomethine ylides (route 3, Scheme III-13). 
1,3- dipolar cycloadditions of azomethine ylides and alkenes is a powerful method to afford 
the stereocontrolled formation of polysubstituted pyrrolidine rings. These kind of reactions 
involves 2 partners Scheme III-13: An alkene bearing an electron withdrawing group (EWG) 
although usually called dipolarophile, and an ylide. The stereocontrol of the reaction can be 
induced either by the presence of stereocenters on one of the partner by a chiral auxiliary, or 
by employing chiral catalysts. The example chosen here show the [3+2] cycloaddition 
between a chiral E-nitroalkene 34 and an imine 35 (Scheme III-15) that afford polysubstituted 
 
 
31 
33 
 
32 
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prolines, that belong to a new family of inhibitors of α4β1-integrin-mediated-hepatic 
melanoma metastasis63.  
 
Scheme III-15 
 
C-N bond formation by intramolecular cyclisation of α-amino acid derivatives (Route 
2, Scheme III-13 ) 
Another methodology achieving the formation of α-alkyl prolines, propose the closure of the 
ring, by intramolecular cyclisation of a geminally disubstituted glycine equivalent with an 
appropriate leaving group on the side chain. As an example, Snider et al.64 used this strategy 
to synthesise of a (-)- 2,5-dimethylproline ethyl ester 42, a key intermediate in the synthesis of 
(+)NP-25302 acting as cell-cell adhesion inhibitor. This procedure starts with an 
enantioselective Michael addition between the ethyl 2-nitropropionate 37 and a methyl vinyl 
ketone 38 in the presence of the hydroquinone catalyst 43. The produced disubstituted glycine 
derivative 39, was then cyclised under reductive hydrogenation conditions, using H2 and Pd/C 
in ethanol to give the nitro compound 40. And the desired quaternary proline 42 was obtained 
“pushing” the conditions to 3,3 atmosphere of H2 in the presence of HCl, (Scheme III-16). 
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Scheme III-16 
 
C-C bond formation involving memory of Chirality (Route 4, Scheme III-13) 
 
 
Scheme III-17 
 
Starting from readily available α-amino acids a recent cyclization method via “memory of 
chirality” has been developed to provide at room temperature without the aid of external 
chiral sources cyclic amino acid with a tetrasubstituted stereocenter in alpha. 65-67. In this case 
the treatment of N-ω-bromoalkyl-N-terbutoxycarbonyl α-aminoacids 44 derivatives with 
KOH powdered in DMF at 20°C provided 4, 5 and 6 membered ring cyclic amino acids with 
excellent yields and enantioselectivity. 
 
Key features of this method are the preservation of the chirality of the starting material due to 
the high reactivity of axial enolate intermediary A (Scheme III-17). As an example, The 
 
44 
 40 
cyclisation of the N-ω-bromoalkyl-N-terbutoxycarbonyl phenylalanine derivative 45 afforded 
the corresponding substituted proline 46 in excellent yields and enantiomerically pure 
(Scheme III-18). 
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Scheme III-18 
 
 
III-3.1.2    3-substituted proline 
: 
Synthesis with the formation of the pyrrolidine ring 
 
Mothes et al. in 200868 developed a convenient synthetic procedure to obtain in three steps 
and good yields 3-substituted proline- homotriptophane. This method is based on the amino-
zinc-ene-enolate cyclization(AZEE). In a first step, the zinc intermediate 48 was generated 
starting from the commercially available olefin 47. Carbocyclization was performed by the 
deprotonnation/transmetallation sequence using LDA and ZnBr2. The strereochemistry of the 
two stereocenters (cis in this case) created during the cyclistion, was directed by the chiral 
auxiliary initially on the molecule(S-α-methylbenzylamide). Finally Neigishi cross-coupling 
of the zinc intermediate with indole rings, was achieved using Pd and Fu’s catalyst (Fu’s 
catalyst= [t-Bu3PH)]-BF4). And the orthogonally protected proline homotriptophane 49 was 
obtained optically pure (Scheme III-19). Following similar procedures, the same group, used 
similar methodology, to build 3-substituted prolino dervatives, bearing polar,69 and  alkyl 70 
side chains of natural amino acids. 
 
 
 
Scheme III-19 
47 
48 
49 
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III-3.1.3    4-substituted proline 
 
In the case of 4-substituted proline the commercial availability of the starting reagent trans-4- 
hydroxyproline made of it a reagent of choice towards the synthesis of 4- substituted proline. 
Actually the cis 4- substituted proline can be in this case easily obtained by SN2 diplacing the 
Tosylate or Mesylate derivative of trans -4 hydroxyproline (Scheme III-20, route 1),71 and 
Mitsunobu reactions (Scheme III-18 route 2),72 replacing the alcohol by different functional 
groups. 
 
Scheme III-20 
 
III-3.1.4    5-substituted proline 
 
Intramolecular cyclisation  
Lubell and coworkers reported in 1993 the synthesis of the 5-substituted n-butyl proline 
starting from the conveniently protected glutamate derivative. In a first step, the enolate 
formation followed by the acylation with valeryl chloride of the glutamate derivative led to 
compound 51. Then the intramolecular imine formation followed by a selective reduction of 
the imine intermediate led to the 5-substituted proline enantiomerically pure. SchemeIII-21.73  
 
Scheme III-21 
 
 
 
Route 1 Route 2 
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III-3.2 Structural features 
 
Substitution of the pyrrolidine ring induces changes in the conformation of the proline cycle, 
and thus can influence the conformation of peptides. Depending on the substitution position, 
these amino acids chimeras are attractive tools to modulate secondary structure formation in 
peptides. 
 
Studies on Ac-L-2-MePro-NHMe model peptide74 showed that α-methyl proline has a 
tendency to form γ-turn in non polar solvents as well as destabilization the cis preceeding 
amide bond. In biologically active peptides, β-I turns were stabilized by introduction of α-
methylproline derivatives in Tyr-Pro-Tyr-Asp,75,76 an antigene peptide and in tandemly 
repeated sequences Asn-Pro-Asn-Ala motifs respectively.52 Examples of peptidomimetics 
containing α-substituted proline have been used to mimic β-turns. One of the widely studied 
motif used as β−ΙΙ-turn mimic are spirolactam-derivatives. Different bi or tricyclic 
77,78structures containing a spirolactam at the (i+1) position have been designed and 
synthetized over the past years (Scheme III-22), folding each time as efficient β-II turns 
mimics. 
 
 
 
 
Scheme III-22 (reproduced with the agreement of ACS publisher) 
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Benefitting from the decrease of the number of degree of freedom due to the presence the 
spirolactam introduced in the α-position of proline 78, these kind of bicyclic proline could act 
as β-II turn nucleator. Actually the spirolactam is rigifying the Ψ-angle of the proline natural 
amino acid, meaning that in this compound both dihedral angles are constrained. So that, the 
pyrrolidine ring will restrict the conformational space of its N-terminal neighbour, and the 
spirolactam ring will reduce the conformational space of its C-terminal neighbour amino acid. 
In this case conformational analyses based on Variable Temperature (VT) NMR analysis, as 
well as IR analyses both confirmed the existence of an H-bond between the C-terminal Boc-
carbonyl, and the NH hydrogen of the Methyl amide. These observations together with 
additional computational calculations are in agreement with the presence of a type β-II 
structure.  
 
Gramberg et al in 199479, designed and synthetized a spirolactam bicyclic proline linking this 
time the α-position of the proline to the α-position of the N-terminal amino acid. Thus the 
Xaa proline peptide bond was constrained to a cis-conformation forming a β-VI turn mimic.  
 
 
Substituents in position 3 have shown different structural feature depending on the length and 
bulkyness of the substituted chain and on the stereochemistry of the trisubstituted carbon. It 
seems like cis 3- substituted prolines stongly destabilize γ-turn conformations because of 
disfavouring interactions with the carboxamide group, whereas the γ-turn conformation 
predominates in trans 3substituted prolines.74  
4-Substituted prolines: as it as been reported before, substitution in position 4 is famous for 
directing the folding of collagen through a PPII helix. Studies of fluorosubstituted proline 
derivatives have shownn enhancement of the PPII structure stabilisation. 
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It has been shown that the introduction of substituents in position 5 of proline strongly 
destabilized the the trans conformation of the preceding peptide bond. So that this kind of 
modification, tends to stabilize type IV β-turn structures.80  
III.4.  C-6, 6-membered ring cyclic α-amino acids 
 
III-4.1 Synthesis 
 
III-4 1 1 Pipecolic acids and derivatives 
 
The natural non proteinogenic pipecolic acid (also called homoproline) is an attractive 
synthetic target because it is a key constituent of many natural and synthetic molecules. For 
instance, biologically important natural products such as immunosuppressant FK50681, 
anticancer agent VX71082, antitumour antibiotic sandramycin83, histone deacylase inhibitor 
apicidin84 contain a pipecolic acid moiety. Research in the area of 4-substituted pipecolic 
acids alone has resulted in novel therapeutically relevant agents in areas such as  HIV-1 
protease inhibition (Palivavir),N methyl-D-aspartic acid receptor antagonism (Selfotel), and 
thrombin inhibition (Argatroban) See scheme III-23 .85 
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Scheme III-23 
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Furthermore it is a interesting tool for building of new petidomimetics.86,87 
The synthesis of pipecolic acid and derivatives has thus received a huge attention in the last 
20 years. Synthetic routes have been already extensively reviewed by Park et al. in 200228 and 
by Kadouri-Pouchot et al. in 2005,88 so I will repport here only on more recent synthetic 
pathways.  
 
In 2005 Watanabe et al.89 proposed a simple and efficient route to access both enantiomers of 
pipecolic acid. Refluxing dibromoethane with diethyl Boc-aminomalonate 53, in basic 
conditions led to the monoacid monoester derivative, decarboxylation at high temperature 
afforded then the cyclisation precursor 54 as a racemic mixture. Resolution using subtilisin 
Carlsberg from bascillus licheniformis afforded both pure enantiomers 55b and 54a. The ethyl 
ester of Boc-D-amino-6-bromohexanoic acid 54a was then removed, and deprotection of the 
Boc group followed by an intramolecular cyclisation in presence of triethyl amine, afforded 
both enantiomers of pipecolic acid 56a and 56b in 27% overall yield (Scheme III-24).  
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Asymetric catalysis has also proven to be a valuable method to produce the piperidine ring. 
Ginestra et al. in 200290 reported the synthesis of pipecolic acid involving a cyclisation via 
ring closing metathesis (RCM). From the known enriched epoxyalcohol 58 synthesised from 
the allylic alcohol 57 via Sharpless epoxydation, nucleophilic ring opening of the epoxide 
using allyl amine was followed by the protection of the amino group with Boc2O. The key 
intermediate 61 was obtained by ring closure metathesis catalyzed by the Grubb’s reagent 60, 
of the doubly unsaturated amine 24 with 72% yield. Further hydrogenation and oxidation led 
to N-Boc pipecolic acid 62 in 99% ee after recrystallisation (Scheme III-25).  
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Increasing the ring of the cycle of cyclic amino acids, offers larger possibilities of 
substitutions, and as we can see on the represented compounds in the scheme III-21, 4-
substituted pipecolic acid have shown high pharmacollgical activity. Increasing efforts has 
been developed by synthetic chemists to provide also routes to these 4-substituted 
compounds. The same method as described before involving RCM has been recently applied 
to afford the trans-4 methyl pipecolic acid.91 
Another widely used component of therapeutics is the cis-3-hydroxy pipecolic acid, that is 
included in the antitumor antibiotic tetrazomine (Figure III-15).  
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Figure III-15 
 
 
 
Recently Pham et al.92 reported a new synthesis to access this type of compounds. Starting 
from the ozonolysis of oxazoline 63, the subsequent addition of trimethyl phosphonoacetate to 
the resulting aldehyde yield α-β unsaturated methyl ester 64. Reduction of 64 with L-
selectride and subsequent hydrogenolysis provided, by intramolecular cyclisation, the desired 
piperidine skeleton 66. The carbonyl group was then reduced with borane methyl sulphide 
complex to give 67 in good yields. The dihydroxyl monosilyl compound was then submitted 
to several steps of protection deprotection steps to afford the free primary alcohol. And finally 
oxidation with RuCl3 and NaIO4 led to the corresponding cis hydroxyl pipecolic acid 68 
(scheme III-26). 
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Scheme III-26 
 
 
 
 
III-4.1.2 Piperazines carboxylic acids 
 
The piperazine ring is a favored structural element in medicinal chemistry, and is often 
encountered in the structure of enzymes inhibitors, and clinical therapeutics. Piperazine-2-
carboxylic acid, has been employed to form biologically active peptidomimetic anti HIV 
protease inhibitor indinavir (Figure III-16). 93 This useful synthetic building block and related 
hydroxymethyl derivatives have since been employed in the preparation of a variety of 
biologically active compounds, antibacterial, antineoplasic , antinociceptive agents.  
 
 
Figure III-16 
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This skeleton is traditionally prepared from pyrazine carboxylic acid by hydrogenation to 
produce the racemate. The racemate is then resolved by fractional crystallization of 
diastereomeric salt as camphor sulphonic acid salt.94 This methodology has been used more 
recently to provide the piperazine-2,3-dicarboxylic acid 69 that is a precursor of NMDA (N-
Methyl D-Aspartate receptor) antagonist (scheme III-27).95  
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Scheme III-27 
 
 
Enzymatic methods resolution of the corresponding carboxamide precursor using 
stereoselective amidases led to both S and R pure enantiomers of the piperazine carboxylic 
acid but a disadvantage of these enzymatic methods is the low amount of product available. 96  
 
In 2005, Palucki et al. reported a synthesis of 5-substituted piperazine, as a precursor of 
melanocortin receptor agonist. The 5-alkylated piperazine compounds were prepared in a 
linear fashion illustrated in Scheme III-28. Starting with commercially available methyl N-β-
Boc-L-α,β-diaminopropionate hydrochloride 75, conversion to diamine 76 was achieved via 
alkylation with various substituted α-bromoketones. Removal of the Boc group followed by 
reductive amination provided the optically pure piperazine 77.97 
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Scheme  III- 28 
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III-4.1.3 Piperazic acid 
 
Piperazic carboxylic acid, is also found is several biologically active compounds, the L- 
enantiomer residue, for example is present within the bicycle ring system of many bioactive 
synthetic product like cilazapril which is a drug for the treatment of hypertension98(Figure III-
17) and pranalcazan, an antinflamatory.99 
 
 
Figure III-17 : Cilazapril 
 
 
This building block has also shown interesting structural properties in peptides.100 Its 
synthesis has been reviewed in1998 by Ciufolini et al.101 and I will report here a recent 
synthesis from Hanachi et al. 102 in 2004 who described an efficient synthesis of piperazic 
acids of different ring sizes. the hydrazino acid precursor 80 was previously obtained from 
electrophilic amination of the benzyl protected amino acids 78 with oxaziridine 79. Then 
diazomethane esterification followed by mild oxidation and TFA treatment lead to the 
unsaturated compound 81 in 76% yield. Finally the piperazic acid 82 was obtained by 
reduction of the hydrazone function with NaBH3CN. The present compound was unstable and 
was thus Fmoc protected affording finally the desired orthogonally protected piperazic 
derivative 83 (Scheme III-29). 
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Scheme III-29 
 
 
 
 
III-4.1 4 Morpholine-3-carboxylic acid 
 
This scaffold has been used to build several bioactive molecules, such as TACE103, MMP and 
TNF-α inhibitors,104 and a potent orally active VL-4 antagonist.105 The first synthesis of 
morpholine-3-carboxylic acid was reported in 1981 by Anteunis et al.106 providing the 
racemate. This firs attempt was followed by the synthesis proposed by Brown et al. in 1985, 
describing the preparation of the amino acid as the N-benzyl ethyl ester derivative from serine 
in 6% overall yield. In the same years, Kogami and Ogawa reported the most convenient 
synthesis of morpholine-3-carboxylic acid wich employed chiral benzyl N-Cbz-2-aziridine 
carboxylate derived from serine, to give the title amino acid after three steps in 66% yields.107 
And recently an enzymatic synthesis has been proposed.108 
 
Guarna et al in 2007, proposed a really convenient synthesis starting from serine methyl ester 
84, and giving in five steps the corresponding morpholine carboxylic acid Fmoc protected 89 
in good yields. Reductive amination of dimethoxy acetaldehyde with L-serine methyl ester 
hydrochloride was carried out under one hydrogen atmosphere in the presence of catalytic 
amounts of Pd/C and triethyl amine, giving the compound 85. Subsequent Fmoc protection, 
afforded the cyclisation precursor 86. The cyclisation was then conducted in acid conditions 
via acetalization, and in situ elimination of the methoxy group was achieved by adding 
catalytic amounts of p-toluene sulfonic acid and refluxing. Hydrogenation of the double bond 
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and final deprotection of the methyl ester give the corresponding morpholine derivative 89 
conveniently protected for petide synthesis (Scheme III-30).  
 
 
Scheme III-30 
 
 
III- 4. 2 Structural features 
 
 
As it has been shown during this report, all these six membered ring amino acids have been 
developed for medicinal chemistry needs, and have shown efficiency especially in structure 
activity researches, for the discovery of new bioactive compounds.  
Their conformational behaviour as inducer of secondary structure has retained less attention. 
Nonetheless it has been shown that in spite of their higher flexibily because of their larger 
ring size in respect to proline, they are interesting tools as folding nucleators. Pipecolic acids 
seems to be less efficient as proline because of its flexibility109 but Piperazic acid and the D 
enantiomer of morpholine carboxylic acid110 have shown propensities to form different turn 
sructures.111 
 
5-Oxo-piperazine-2-carboxylic acid (Pca), has received much less attention, and only few 
reports deal with its synthesis, structural and biological properties. 112-114 
Herein we report a practical synthesis of N-Boc-5-Oxo-piperazine-2-carboxylic acid 
derivatives, their introduction into peptidomimetic structures by a solution-phase peptide-
synthesis strategy, and a conformational analysis of tetrapeptide mimics incoroporating a 
PCA residue. 
84 85 
87
86 
88 89 
 53 
IV – DISCUSSION 
 
IV-1 Synthesis of the 5-Oxo-piperazin-2-carboxylic acid 
 
In the frame of our studies directed towards the synthesis of peptidomimetics with 
well defined conformational properties, we became interested in the synthesis of 5-Oxo-
piperazinone-2-carboxylic acid, and its introduction into peptide sequences as inducer of  
peptide’s secondary structures. 
A synthetic plan was envisaged starting from L- or D- serine, requiring the replacement of the 
hydroxyl by an amino group (possibly via an azide intermediate), acylation with a 
chloroacetyl derivative and, eventually, cyclization to the piperazinone ring (Scheme IV-1). 
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L-Serine was protected both at the nitrogen and carboxylic groups. The α-nitrogen 
position was protected with a Boc group and the carboxylic acid function was transformed in 
the methyl ester by reaction with methanol in the presence of acetylchloride 
(2.7equivalents).115 The acetylchloride reacts with methanol forming methylacetate and 
releasing a known amount of gaseous HCl in the methanol, which acts as an acidic catalyst for 
the esterification reaction. N-Boc-serine methyl ester was thus ready for the introduction of 
the nitrogen functionality. It was reported in the literature that this transformation could be 
achieved by activation of the OH of serine either as sulfonate ester116 or via a Mitsunobu type 
reaction.117,118 Unfortunately, the formation of sulfonate esters of serine, in our hands, gave 
only the elimination product, i.e. methyl α-tert-butyl-carbamoylacrylate. The Mitsunobu 
reaction required the use of a titrated solution of hydrazoic acid in a hydrocarbon solvent 
(originally benzene but toluene was used instead) which was obtained by reaction of sodium 
azide and concentrated sulfuric acid, followed by extraction of the resulting hydrazoic acid 
into the organic phase.119 
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The subsequent Mitsunobu reaction was then conducted in toluene and other solvent 
mixtures in order to determine if any solvent effect would be operating. The best experimental 
conditions involved running the reaction in toluene at room temperature; in this way excellent 
yields of the azide derivative 1a were obtained (Scheme IV-2). 
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Scheme IV-32 
 
The azide 1a was then converted in the primary amine via a catalytic hydrogenation using 
Pd/C and the cyclisation precursor was subsequently obtained by coupling the amine with 
chloracetyl chloride (Scheme IV-3). The subsequent cyclization reaction was then done 
utilizing two diverse strategies: a) deprotection of the α-nitrogen and further cyclisation under 
basic conditions, or, b) α-nitrogen deprotonation and further closure of the ring via 
intramolecular nucleophile substitution of the chlore atom (Scheme IV-3). 
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Scheme IV-33 
 
In case a) we could not isolate any cyclised product, and in the second case b) the cyclisation 
occurred in low yields (about 30%). We related this failure to the presence in the cyclisation 
precursor of two conformers in a cis/trans equilibrium (Scheme IV-4). 
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Scheme IV-34 
 
Indeed the cis-trans equilibrium in amide bonds is well known in particular in polypeptides, 
where it is mainly present under its trans configuration. It has been reported that the presence 
of cis isomers in polypeptides containing natural amino acids (proline excluded) is around 
0,06%.4 No cis peptide bonds are detected in X-Ray structures of proteins except when the 
nitrogen is tertiary in proline residues. Some well-established features for the peptide bond are 
the coplanarity of the group attached to it, its partial double bond character that is reflected in 
shortened C-N distances and moderate free energy barriers (∆G≠=16-22 kcal.mol-1) (Scheme 
IV-5).120 
The energetic difference (∆G°) between both cis and trans isomers is described to be around 
2,5 kcal/mol-1 for secondary amides.121 This barrier is sufficiently strong that no more than a 
few per cent of the cis form is detected in experimental studies of secondary amides. One 
explanation for the low occurrence of cis conformers in nature is the steric hindrance between 
R1 and R2 when they are on the same side of the double bound (Scheme IV-5). 
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Scheme IV-35 
 
To circumvent the failure due to the trans preferred conformation of the amide bond in our 
acylated derivative, an alternative synthetic way was proposed. To favour the presence of the 
convenient cis conformer and thus the closure of the ring, it was decided to introduce before 
the acylation step, a new bulky substituent on the amino group. In this way a tertiary amide 
would be obtained after introduction of the chloracetyl residue and this would favour ring 
closure by increasing the population of the cis-rotamer. We first thought to introduce a benzyl 
group on the amine position, which would be easily removable at the end of the synthesis. 
Therefore we proceed to the reduction of the azide group using standard hydrogenation 
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conditions to obtain the corresponding primary amine. We performed the benzyl substitution 
by reductive alkylation, using benzaldehyde and a reducing agent (scheme IV-6). 
Unfortunatly, it was not possible to avoid completely the formation of the dibenzylated 
byproduct, even by the use of stoichiometric amounts of benzaldehyde. 
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Scheme IV-36 
 
To avoid the dibenzylation of the primary amine we thought about another synthetic strategy 
starting from the azide, that could give us in “one pot” the monosubstituted compound. This 
new route is combining two new intermediates: in a first step the azide would be converted 
directly in an imminophosphorane derivative: “Staudinger intermediate”, and the following 
addition of benzaldehyde should give us the “Aza-Wittig product”: the benzyl imine. The 
imine would be then simply reduced to afford the desired monosubstituted product 
(SchemeIV- 6).  
In a Staudinger reaction122 the azide derivative is reacted with a phosphine to give the 
corresponding iminophosphorane intermediate and one diazote molecule is liberated (Scheme 
IV-7). This derivative reacts usually with the electrophile “H+” to give the primary amine.  
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Scheme IV-37 
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Of course other kinds of electrophiles can be used at this point of the reaction. These 
electrophiles can be aldehydes or halogenated alkyls (Aza-Witttig reaction),123 chloroformates 
(introduction of protective groups),124 anhydrides to afford rapidly substituted amine 
derivatives. In our case, the iminophosphorane was directly reacted with benzaldehyde in the 
same reaction medium to form the imine (Scheme IV-8).  
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Scheme IV-38 
 
With this methodology the dialkylation of the amine is not permitted since the alkylation of 
the iminophosphorane would lead to an unfavoured doubly charge salt (Scheme IV-9).125 
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Scheme IV-39 
 
To achieve this step in “one pot” we first screened different conditions. We started our work 
on this reaction using triphenyl phosphine126 but the formation of the iminophosphorane was 
slow, and the removal of the triphenyl phosphine oxide was difficult. So we rapidly switched 
to the much more reactive trimethyl phosphine, which is also producing a water soluble 
phosphine oxide. This new reagent gave us the corresponding iminophosphorane in 30 
minutes.127 The following addition of benzaldehyde in quasi stoichiometric amounts was 
directly poured in the reaction medium, and the imine formation occurred in one hour. 
Finally, we pitched on the in situ reduction of the imine, using NaBH4 as reducing agent and 
methanol as cosolvent,123 with this route we obtained the secondary amine in 55% yield. A 
better yield was then obtained removing completely the solvent and dissolving the crude 
mixture in methanol. In this way the mono-benzylated amine was obtained in a three-step-
one-pot procedure with an overall yield of 69% Scheme IV-10. 
. 
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Scheme IV-40 
 
The cyclisation precursor was then formed by addition of chloracetyl chloride in a two phase 
medium composed of a saturated solution of sodium bicorbonate and ethyl acetate in 95% 
yields.128 Thus the following base promoted ring closure using cesium carbonate to enhance 
the nucleophilicity of the Boc protected nitrogen in DMF at 65°C129 occurred successfully in a 
75% yield (Scheme IV-11). 
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Scheme IV-41 
 
Following the presently described synthesis we were able to obtain our scaffold in good 
amount. To obtain now the non proteinogenic amino acid in a suitable form to be incorporated 
in peptides sequences, we had to deprotect the methyl ester to provide the corresponding 
carboxylic acid. The methyl ester protecting group is widely used in organic synthesis and 
there are many way to cleave it. One of the most used, involves basic conditions using small 
amount of aqueous bases NaOH or LiOH. Although rather mild, these conditions are still 
basic, and could cause epimerization of the stereocenter in the α-position of the ester, prior to 
hydrolyis. In order to decrease the basicity of this method we prepared and used LiOOH, 
which is milder as it is less basic and more nucleophilic(Scheme IV-12).130 
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Scheme IV-42 
 
With our scaffold, 5-Oxo-piperazine-2-carboxylic acid, in hand we tried then to check its 
compatibility with peptide synthesis. Therefore we coupled L-alanine benzyl amide to the 5-
Oxo-piperazine-2-carboxylic acid, using HOBt and EDC as coupling reagent, DIPEA as a 
base and DMF as solvent.131 The product was obtained in good yields, but, unfortunately, we 
could detect by NMR the presence of two different signals for the methyl group of the alanine 
in the dipeptide. To exclude that the splitting of the signal could be due to the presence of 
rotamers at both Boc and benzyl groups, the NMR analyses on this Boc protected dipeptide 
were performed at higher temperature, but no significant difference was noticed. (Scheme IV-
13).  
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Scheme IV-43 
 
The evidences for the presence of the two isomers finally came from further analyses 
performed on the correspondent deprotected dipeptide. The removal of the Boc was 
performed using a mixture of TFA in DCM, and the free amine was isolated after 
neutralization of the TFA salt using aqueous NaHCO3 (Scheme IV-14). At this point of the 
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synthesis we were able to see two close spots on TLC plates and we could isolate both 
isomers by flash chromatography.  
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Scheme IV-44 
 
We first related this epimerization problem to the acidity of the α-proton of the scaffold 
during the base-promoted cyclisation. We therefore performed different cyclisation tests using 
different bases and solvent conditions (table IV-1). NaH conditions in DMF/THF have been 
reported for previous ring closure of piperazinone rings.132 The NaH assisted intramolecular 
cyclisation occurred rapidly, but the obtained product was a mixture of starting material, 
cyclised compound and saponified one. Cs2CO3 at high temperature in DMF that had been 
also reported for the cyclisation of piperazinone rings gave us the better results in term of 
yields but in term of enantiomeric excess K2CO3 in Acetonitrile at 80°C133,134 was more 
efficient. We chose this K2CO3 procedure as it had been reported for the N-methylation of α 
amino acids with no traces of epimerisation.21 Such differences in the enantiopurity with so 
similar bases let us notice the influence of the solvent. It has been previously reported that the 
use of DMF and Acetonitrile in base assisted intramolecular alkylation of nitrogen group, 
could influence the enantioselectivity.135  
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Base Solvents  T (°C) Yields D. R.* 
Cs2CO3 (2eq)
 
 DMF 65°C 75 % 1/1 
Cs2CO3 (1eq) DMF RT 44% 1/1 
NaH(3eq) DMF/THF (1/1) RT 55 % 1/1 
NaH(1eq) DMF/THF (1/1) RT 33 % 3/1 
K
2
CO
3
(2eq)
 
 Acetonitrile 80°C 70 % 3/1 
K
2
CO
3
(1eq)
 
 Acetonitrile 80°C 38 % 3/1 
tBuOK(1eq) THF RT 64 % 3/1 
* The diastereoisomeric ratio D. R. was calculated by 1H-NMR after coupling with L-alanine benzyl amide: i.e. 
on the product: Boc-Pca-Ala-Bn  
Table IV-1 
 
tBuOK was also tried as the base in this cyclisation procedure to test the effect of a bulky 
base, but, again, the enantiomeric excess remained the same.  
Despite our numerous trials with various basic conditions we were not able to produce the 
enantiomerically pure scaffold, following this synthetic scheme. 
To avoid this problem we decided then, to change protecting group. Consequently, we applied 
the same synthetic route to the Boc L-Serine tert-butyl ester. Since this protecting group is 
more bulky and electron donating, it could have been suitable to prevent the epimerization 
phenomena from our previous synthetic pathway. This route produced the cyclisation 
precursor, starting from the serine protected as Boc and tert-butyl ester, with enhanced yields 
for each synthetic step (see tables IV-2 and IV-3). 
 
Steps Methyl ester  Tert-butyl ester 
Mitsunobu rection 
Azide synthesis
 
 
81% 93% 
Aza-Wittig  
Substitution of the 
α-amine 
68% 83% 
Acylation 92% 96% 
 
Table IV-2 
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The cyclisation reaction was then performed using the same basic condition described above 
for the methyl ester derivative scheme (table IV-3). The corresponding piperazinone 
derivative was then deprotected at the same moment in its amino part and in its carboxylic 
part mediating a reaction with trifluoroacetic acid. The ecxess of TFA was removed and the 
nitrogen atom was directly reprotected using Boc-anhydride. Thus we could avoid the use of 
basic conditions for the deprotection(SchemeIV-15). 
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Scheme IV-45 
 
The peptide coupling to the L-Alanine benzyl amide gave us a better diastreoisomeric ratio 
(table IV-3), but the closure of the ring was anyway not giving us the scaffold with satisfying 
optical purity.  
* The diastereoisomeric ratio was calculated by 1H-NMR after coupling with alanine benzyl amide: i.e. on the product:  
Boc-Pca-Ala-Bn  
Table IV-3 
 
To further decrease the lability of the α-proton in the cyclisation step, we decided to deprotect 
the Boc-amino group of the cyclization precursor. In this way the cyclization would occur on 
the free amine which is definitely less acidic at the α-position that the Boc-derivative. A base 
was then used in the ring closure step to quench the TFA salt and control the formation of 
HCl.136,137 
 
  Bases Solvent  T (°C) Yields D. R. 
Cs2CO3(2eq)
 
 DMF 65°C 97 % 1/1 
K2CO3(1eq) Acetonitrile 80°C 52 % 3/1 
tBuOK(1eq) THF RT 93 % 3/1 
NaOHaq DCM RT N.R. N.R. 
Basic 
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Scheme IV-46 
 
Unfortunately, this method was not suitable in terms of yield, since we recovered substantial 
amount of the amine uncyclised.  
The cyclisation of a completely deprotected scaffold (both at the carboxylic and amino-group) 
was then envisaged. To this purpose the precursor 3b was deprotected with TFA and 
dissolved in a NaOHaq solution (in variable quantities). The cyclisation occurred in this basic 
aqueous medium. Subsequent addition of Boc-anhydride and dioxane provided the desired 
cyclic compound in good yields and conveniently protected for peptide coupling reactions.  
 
 
Scheme IV-47 
 
At this point of our investigations we set up chiral HPLC conditions,138,139 using the column  
CHIRALCEL OD-H and a mixture of hexane/ isopropanol: 9:1 and 0.1% of TFA140 (figure 
IV-1, Scheme IV-18). 
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Figure IV-18 
 
 
 
 
Scheme IV-48 
 
 
The cyclisation reaction has a crucial influence on the enantiomeric excess, and we screened 
this time again different conditions utilizing from 5 to 3 equivalents of NaOH or even 
buffered solutions to control precisely the pH of the solution. These different cyclisation 
conditions gave various results in term of yields and enantiomeric excess. Unfortunately, we 
noticed that these results were not always reproducible, and in some cases the enantiomeric 
excess was not in agreement with the strength of the base used. We attributed this erratic 
behaviour of the cyclization reactions to a different optical purity of the starting material 
depending on the different batches and this observation prompted us to reconsider carefully 
each step of the synthesis and check the enantiomeric purity of each intermediate of our 
synthetic sequence.  
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First of all we checked the enantiopurity of the azide obtained from the serine Boc tert-Butyl 
ester from the Mitsunobu reaction. Therefore we coupled the azide with the L-alanine benzyl 
amide, using classical conditions Scheme IV-19. 
 
 
N3
HN
Boc
COOtBu
HO
HN
Boc
COOtBu
HN3, DIAD, PPH3
Toluene
   81%
N3
HN
Boc
CONHAlaNHBn
1) TFA in DCM
2) Boc2O 
dioxane/water
3) HOAt, EDC, 
DIPEA, 
H2NAlaNHBn 
in DMF
 
Scheme IV-49 
 
 
 
After NMR analysis on the coupling product we could see only one diastereoisomer, thus 
confirming the enantiopurity of the previous protected azide.  
 
Following the synthetic procedure we then controlled the acylation step that required the use 
of basic conditions. In this case two different reaction conditions were compared: on the one 
hand the benzyl amine was submitted to the same conditions developed before, using 
chloracetylchloride in a biphasic medium (ethyl acetate - saturated solution of sodium 
bicarbonate) (A). On the other hand the benzylated compound was coupled to chloracetic acid 
mediating DCC and avoiding indeed the use of a base (B)141. Going ahead in the synthetic 
route, both carboxylic acids were obtained with no significative changes in the enantiomeric 
excess (Scheme IV-20). These results exclude the acylation step for being responsible of the 
epimerisation; nevertheless we chose the conditions involving DCC and chloracetic acid to 
proceed with the synthesis since it was giving us the desired acylated product in good yields 
without base. 
 
 
 66 
 
Scheme IV-50 
 
 
To finish with these controls we evaluated the Aza-Wittig step. Actually, the use of NaBH4 in 
methanol could lead to the formation of sodium methylate that could be responsible of 
undesired removal of the α-proton of the imine. To avoid this situation, milder conditions 
using catalytic hydrogenation were choosen to reduce the imine. This last modification gave 
us better yields and after all the analysis of the corresponding carboxylic acid by HPLC, gave 
us the evidence that we had synthetized only one enantiomer( see figure IV-2). 
 
 
S)-Boc-PCA registrato a 254 nm. 
 
(S)-Boc-PCA registrato a 230 nm. 
 
 
 
 
Figure IV-19 
 
 
In summary, we developed an efficient (yields of each steps > 85%) and simple synthesis to 
produce the N-Boc-5-Oxo-piperazine-2-carboxylic acid. The final synthetic scheme is 
described below (Scheme IV-21):  
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Scheme IV-51 
 
IV-2 Coupling studies on the 5-oxopiperazine-2-carboxylic acid  
 
Having now our 5-oxopiperazine-2-carboxylic acid enantiomerically pure in hands, we 
wanted to test its compatibility with peptide synthesis, in order to build new peptidomimetics 
incorporating our non proteinogenic aminoacid in natural amino acid sequences. In order to 
study the reactivity of our piperazinone toward peptide coupling reactions and determine its 
stability to epimerization.  
We begun our investigations, synthetizing a dipeptide containing our scaffold and a natural 
amino acid with an alkyl chain. We choosed the alanine for its commodity of detection in 
NMR spectra. The alanine was first benzylated to protect its carboxylic part and the BOC was 
removed under acidic conditions using TFA and DCM. 
N
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N Ph
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5 68
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Scheme IV-52 
 
 
 68 
The dipeptide was then formed using 3 different procedures: 
 
• Method A: DIPEA, HOAt, EDC in DMF. 
• Method B: DIPEA, HOBt, EDC in DMF. 
• Method C: DIPEA, HATU in DMF. 
 
The yield of the coupling step was always satisfying, but in all three cases we obtained a 
mixture of 2 diastereoisomers (Scheme IV-22). We could detect it by 1H NMR, where we 
could see some of the proton signals that were doubled 
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Scheme IV-53 
 
 
 
In order to exclude any doubts we decided to analyze directly the deprotected dipeptide to 
avoid the confusion due to the presence of the two rotamers of the Boc group. The dipeptide 
was deprotected under acidic conditions using TFA, and the TFA salt was neutralized using 
NaHCO3 (see scheme IV-14). The further analysis of the 1H NMR spectra confirmed us that 
we had two sets of signals belonging to two different products. Actually the racemization 
phenomenon during peptide coupling reactions, is known and described in the literature. 142In 
the course of a coupling reaction, racemisation can occur especially at the C-terminal 
aminoacid residue through the ionisation of the α-hydrogen and the formation of an 
oxazolone intermediate (Scheme IV-24). This ease of racemisation is emphased in the case of 
disubstituded amino acids, this problem is attributed to the absence of an acidic amide or 
urethane proton that would normally ionize first and suppress the α-deprotonation.143 
 
 69 
 
 
Scheme IV-54: Racemisation through oxazolone formation. 
 
We begun thus, coupling studies to elucidate which are, in our case, the causes of the 
epimerisation of the (Bn)-Pca during peptide synthesis. Different parameters are recognized to 
influence the amino acid behaviour towards epimerisation in peptide synthesis: Actually, 
coupling reagents like HOBt have shown a limited efficiency in cases of racemisation issues. 
Due to the presence of a pyrimidic nitrogen, HOAt and its uronium salt derivative 
HATU,131,144,145 have shown to be superior in term of yields and toward the reduction of 
racemisation (Scheme VI-25) 
 
                          
Scheme IV-55 common coupling reagents for peptide synthesis, HOBt, HOAt, HATU 
.  
But in our case the change of coupling reagent did not lead to better results. We decided thus 
to screen different coupling conditions, basing our studies on different parameters: basic 
conditions, coupling reagent, solvent and structure of our molecule. A parameter that is often 
cited in the literature, as responsible for epimerization phenomenon is the basic conditions 
used to promote coupling reactions; so in this case we choose different amines with lower 
pKa than the classical DIPEA (Scheme IV-26). It is to note, that the use of TMP in 
association with HATU have been widely used to decrease epimerization in both solution and 
solid state peptide synthesis.146 To set up the conditions of our study, we based our work on 
coupling reaction performed by Di Fenza et al.147 who reported a screening of different 
coupling reagents and bases conditions to avoid epimerization of serine residues in solid state.  
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Scheme V-56 
 
 
These studies were carried out synthesising dipeptides containing the Boc-(S)-Pca 5 and the 
Alanine benzylamide 8 (Scheme IV-22). As a comparison point, we synthesized at the same 
time, using the same procedures dipeptides containing the L-serine. In fact, the serine has 
been described to be sensitive to epimerisation during coupling procedures.147 As it is shown 
in (Table IV-4), independently on the coupling conditions the analyses of the dipeptide 
afforded us the product with a diastereisomeric ratio of 8 to 2 (Table IV-4).  
 
 
 Method A Method B Method C Method D Method E Method F 
PCA  1 eq 1 eq 1 eq 1 eq 1 eq 1 eq 
TFA salt 
AlaNHBn 
1.1 eq 1.1 eq 1.1 eq 1.1 eq 1.1 eq 1.1 eq 
Coupling  
reagent 
HATU 
1.1 eq 
HATU 
1.1 eq 
HBTU 
1.1 eq 
HBTU 
1.1 eq 
HATU 
1.1 eq 
 
HBTU 
1.1 eq 
Base DIPEA 
3 eq 
TMP 
3 eq  
DIPEA 
3 eq 
TMP 
3 eq 
DIPEA 
3 eq  
DIPEA 
3 eq 
Solvent DMF 
 
DMF 
 
DMF 
 
DMF 
 
THF 
 
THF 
Diasteroisomeric 
ratio 
D/L 
 
8/2 
 
8/2 
 
8/2 
 
8/2 
 
8/2 
 
8/2 
TableIV-4 Coupling conditions for the formation of dipeptide 6 
 
 
Coupling procedures involving the serine instead of (Bn)-Pca led respectively to the optically 
pure dipeptide (Table IV-5). 
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Scheme IV-57 
 
 
 
 
Method A Method B 
 
Method C Method D 
NH-Boc(L)Ser 1 eq 1 eq 1 eq 1 eq 
TFA Salt 1.1 eq 1.1 eq 1.1 eq 1.1 eq 
Coupling reagent HATU 
1.1 eq 
 
HATU 
1.1 eq 
 
HBTU 
1.1 eq 
 
HBTU 
1.1 eq 
 
Base DIPEA 
3 eq 
TMP 
3 eq  
DIPEA 
3 eq 
TMP 
3 eq 
Diastereoisomeric 
ratio 
(L)/(D) 
 
10/0 
 
10/0 
 
10/0 
 
10/0 
Table IV-5 Coupling conditions for the formation of dipeptide 9a 
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Scheme IV-58 
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To confirm these last analyses on the serine, and validate our analytical method, we 
synthesised the other diastereoisomer 9b (Scheme IV-28) containing the D-Serine this time. 
The corresponding dipeptide was analysed by HPLC, and afforded us only one peak with a 
different retention time. Further co-injection of the two diastereoisomers provided us the 
definitive proof that the serine in these cases was not submitted to epimerization. 
 
 
• Dipeptide (L)Ser(L)Ala 9a, obtained with the method A Tr = 8-8.31 min. 
 
 
 
 
 
 
• Dipeptide (D)Ser(L)Ala 9b, obtained with the method A, Tr = 9.08 min. 
 
 
 
 
 
 
 
 
 
 
 
Finally to exclude also an epimerization coming from the alanine benzyl amide 8 we changed 
the coupling partner, switching to a chiral amine: The (S)-α-methyl benzylamine was coupled 
to the piperazinone scaffold mediating HBTU, HOBt, and DIPEA. 
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Scheme IV-59 
 
In this case again the dipeptide was analysed by reverse phase HPLC, after deprotection of the 
Boc , and revealed the formation of two diastereoisomers, The diastereoisomeric excess was 
calculated from the HPLC trace (registered at 220nm) giving, in a 7 to 3 proportions, both 
diastereoisomers. 
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Figure IV-20 
 
 
 
(L)PCA (S)-α-methyl benzylamide Tr= 28.68 min. 
 
(D)PCA (S)-α-methyl benzylamide Tr=28.11 min. 
 
To conclude, these coupling studies reveal that our compound (Bn)-PCA is really sensitive to 
racemisation during peptide coupling reactions. Unfortunately, none of our coupling assays 
afforded us the diastereoisomerically pure compound. And what is really unusual, the 
diastereoisomeric excess of our coupled derivatives was always the same.  
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IV-3 Building of the piperazinone ring without the Benzyl 
substituent: 
 
IV-3.1 removal of the Bn or PMB group: 
 
To achieve our initial aim and prepare the piperazinone ring carboxylic acid as proline 
mimic the final step of the synthesis would have been the removal of the benzyl group. To 
perform this deprotection, we tried different methodologies based on hydrogenolysis. 
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Scheme IV-60 
 
We tested several conditions, including classical hydrogenolysis using from 1 to 3 
atmospheres of hydrogen, and Pd/C but all these failed in removing the benzyl substituent. It 
is known from literature that benzyl group is a  suitable protecting group in organic chemistry 
especially because of its clean deprotection conditions. However whith benzyl amide, 
classical deprotection condition are sometimes not suitable.148 Other methods are known to 
deprotect an amidic benzyl group but it involves drastically basic149 or acidic conditions.150 
On the one hand, the use of acidic conditions151 could be problematic in our case because it 
could contemporaneously deprotect the Boc group which is sensitive to acidic medium, and 
on the other hand basic conditions would be problematic in our synthesis because of risks 
towards loss of chirality that we already reported (part IV). The most convenient alternative to 
solve this issue appeared to be a change of protecting group. In this case we opted for the 
para-methoxy benzylgroup, that can be removed under milder oxidative conditions using 
CAN (cerium ammonium nitrate).152,153 Following this idea we applied the same synthesis 
described in section IV.1 (scheme IV-31) with the PMB in the amide position. 
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Scheme IV-61 
 
The PMB was introduced in the molecule during the Aza-Wittig reaction using para-
methoxybenzaldehyde in place of benzaldehyde. All the subsequent reactions were run 
uneventfully and in comparable yields and the para-methoxybenzyl-5-oxo-2-
piperazinonecarboxylic acid was thus obtained. 
The deprotection of the para-methoxybenzyl was then tested in several conditions using ceric 
ammonium nitrate in acetonitrile in the presence of water, but unfortunately only 
decomposition products were found, probably arising from deprotectionof both the PMB and 
Boc groups. Actually these two protecting groups should be orthogonal, but the pH of the 
solution at the end of the reaction was very acidic (pH < 1) and therefore we suspect that this 
caused deprotection of the Boc group as well. An in situ re-protection of the secondary amine 
was tried by neutralization and addition Boc2O goup, but without results  
 
 
 
SchemeVI-62 
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Using this synthetic pathway we were not able to product the unsubstituted scaffold 11. 
IV-3.2 Alternative synthesis: 
 
As described in our previous chapter III reviewing synthetic strategies for the elaboration of 
cyclic amino acids, there are several widely used methods to form this kind of heterocyclic 
compounds. Most of the described reactions involve the intramolecular C-N bond formation 
(Scheme IV-33).154  
 
 
Scheme IV-63 
 
 
In parallel to our investigations on the deprotection of the amide benzylated compound, we 
thought about another synthetic strategy, to close the ketopiperazine ring in a different way. 
One of the most used methods to access to ketopiperazines rings involves an intramolecular 
addition of an amine to an acid or ester to form the N1-C2 bond (procedure B scheme VI-2). 
The construction of the cyclisation precursor can then occur in different way. As an example, 
Cignarella and coworkers155 in 1979, reported a convenient procedure starting from the 1,2-
diaminoethane. Alkylation of the 1,2-diaminopropane 1,2-propane 13 provided the ester 14 
which was heated at 210° to afford the piperazinone ring 15 with loss of ethanol.(scheme IV-
34) 
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Scheme IV-64 
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More recently Goodmann’s synthesis156 of the constrained Leu–enkephaline analogue 18, 
consist in opening the ring of the Vederas lactone with the amino ester 16 and further 
coupling of the free amino acid with a dipeptide. Catalytic hydrogenation promoted then the 
cyclisation that occurred in mild conditions and high yield (scheme IV-35). 
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Scheme VI-65 
 
 
Inspired by these examples we decided to build our scaffold starting from the L-serine which 
was transformed into the corresponding methylester. Thus the carboxyester segment was 
added by reductive amination using ethyl glyoxalate giving the corresponding diester 
derivative 19 in 43% to 68% yield. Actually, the yield of the reaction is rather low, and this 
was attributed to the possible polymerisation of the ethyl glyoxalate, which could decrease the 
availability of the reagent. Thus, heating ethyl glyoxalate in toluene at reflux for 30 min 
depolymeriztion took place and ethyl glyoxalate was obtained as a pure monomer. This was 
directly added to the reaction medium, and in this way the compound was obtained in a 68% 
yield. We tried then to study the reaction controlling the formation of the imine, sampling 
aliquots of the reaction medium and measuring an NMR spectrum, after 30 minutes, we could 
see the complete disappearance of the aldehyde peak at 9,5 ppm, after 30 minutes, and the 
formation of a peak at 8.2 ppm corresponding to the formation of the imine. At this point, the 
reduction of the imine was performed under 1 atmosphere of hydrogen with Pd/C in catalytic 
amounts but, independently from the reaction time, we were not able to increase the yield. To 
generate our cyclisation precursor 20 we introduced via a Mitsunobu reaction the second 
amino group as an azide. Therefore we used the previously described conditions (Scheme IV-
2) and here again the azide was obtained in good yields. Finally, the transformation of the 
azide 20 into its corresponding amine derivative occurred under catalytic hydrogenation 
conditions, promoting at the same time the cyclisation reaction in excellent yields. Following 
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this new procedure we manage to build the unsubstituted piperazinone ring 21 in few steps 
and good yields. 
 
Scheme IV-66 
 
 
To go ahead with this scaffold in peptide synthesis, we introduced a Boc protecting group in 
the amino position by two different procedures. In the first case, using Boc2O in a mixture of 
water and dioxane with K2CO3 as base. This method afforded the corresponding compound 
protected both at the amino and carboxylic part 23. In a second procedure, the replacement of 
K2CO3 by the more basic NaOH, afforded at the same time protection of the amino group and 
hydrolysis of the methyl ester and formation of the free carboxylic group (Scheme IV-37) 
with no detectable changes in the optical purity.  
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Scheme VI-67 
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Having this scaffold in hands we first tried to control that no loss of chirality had occurred 
during the synthetic procedure. Therefore we synthesised the other enantiomer starting from 
D-serine. Measuring the optical rotatory power of each synthetic intermediate and of the final 
carboxylic acids we could see that these showed an opposite [α]D value with respect to 
corresponding derivatives obtained with L-series (Scheme IV-38). 
 
 
Scheme VI-68 
 
 
With both enantiomers of Boc-Pca in hands, we decided to test the compatibility of our 
scaffold with peptide coupling procedure. Therefore, the carboxylic group of both 
enantiomers of Boc-Pca was coupled to (R)-1-phenylethylamine. The coupling was achieved 
using HOBt and EDC as coupling reagents and DIPEA as the tertiary amine base. The 
coupling procedure worked well and the desired substituted compound was obtained in 12 h 
and acceptable yields. The optical purity was checked by NMR, but no conclusion could be 
drawn with this analysis since two set of signals were obesrved for each compound, which 
were attributes to the rotation of the Boc group. We therefore proceeded to removal of the 
Boc group followed by a neutralization of the amino group (Scheme IV-39). This 
manipulation afforded the corresponding compounds with the free NH groups in quantitative 
yields. Their NMR proton spectra showed only one set of signals for both isomers.  
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Scheme IV-69 
 
 80 
 
The optical purity of these compounds was also assessed by HPLC anlyses, using the 
conditions previously developed for the benzylated compound. We used an analytical HPLC 
containing a C18 column in reverse phase with different solvent gradients. Our better results 
are presented in Figure 1. 
5% of Acetinitrile (0.01%TFA)in 5min 
5-40% of Acetonitrile (0.01%TFA)in 55min .  
Graph 1: Mixture of both diastereoisomers 
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Graph 2 : Diastereoisomer with the S scaffold 
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Graph 3 :Diastereoisomer with the R scaffold 
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Figure IV-21 
 
As we can see in the figure IV-4, the separation of the peaks was only partial as we could not 
recover the baseline between the two peaks, anyway it seems to us that both products show 
different retention time:  
(S)-Pca-α-Methylbenzylamide=22,4min 
(R)-Pca-α-Methylbenzylamide=21,4min 
From trace 2 we can detect a small peak at 21.5min that could be a small amount of the other 
diastereoisomer. Anyway such a small amount of the other diastereoisomer would be in 
agreement with 5% reported epimerisation during coupling procedures.157 
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With these positive results we wanted also to check the compatibility of our piperazinone ring 
with solid phase peptide synthesis. Therefore, we attempted to protect the amino group as 
fluorenylmethyl urethane, using Fmoc chloride in dioxane (scheme IV-40),158 the protection 
occurred in good yields and the product was crystallized in a mixture of ether and methanol. 
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Scheme VI-70 
 
 
 
 
Figure IV-22 Crystal structure of  the compound 22. 
 
The X-ray structure reveals that the piperazinone ring adopts a half chair conformation with 
the carboxymethyl group in a quasi-axial orientation, whereas the fluorenylmethoxycarbonyl 
group shows an almost equatorial disposition. The intracyclic amide group has a planar 
geometry with the N-H bond bisecting the angle of the vicinal CH2 group.  
 
Unfortunatly assays of deprotection of the methyl ester in acidic conditions failed, leading to 
the quasi complete recovery of the starting material. 
 
N
H
NO
COOMe
Fmoc
N
H
NO
COOH
Fmoc
HCl/Dioxane
Reflux
18h
22
 
Scheme IV-71 
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IV-4 Conformational studies on tetrapeptides containing Pca: 
 
As anticipated in chapter II, proline is the only cyclic proteinogenic amino acid that plays a 
significant role in the structural and conformational properties of petides and proteins.159 
Proline is quite often observed at the i+1 position of turn structures, and thus imposes changes 
in the direction of peptide chains. It has been shown that this structural feature is of particular 
interest to expose recognition site for the protein protein interaction at the surface of 
proteins.160 These kinds of turns in peptides and proteins can be of different types and proline 
can nucleate some of them. γ and β turns, may or may not be stabilized by intramolecular H-
bonds. In γ-turns, the CO of the first residue i may be H-bonded to the NH of the i+2 residue, 
giving rise to a 7-membered hydrogen bond ring. In β-turns, the CO of the first residue i may 
be hydrogen-bonded to NH of the fourth residue (i+3), forming thus a ten membered ring 
(FigureIV-6). 
 
Figure IV-23 
 
 
The further β- or γ-turn classes are based on the geometry of the peptide backbone. So that 
these different turns are described by the values of the characteristic backbone torsion angles 
φ and ψ in the residues i+1 and i+2 for β-turns or in residue i+1 in γ-turns (table). 
 
 
 
 
 
γ-turn 
β-turn 
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conformation Φi+1 Ψ i+1 Φi+2 Ψ i+2 
βI-turn -60° -30 -90 0 
βI’-turn 60 30 90 0 
βII-turn -60 120 80 0 
βΙI’-turn 60 -120 -80 0 
βVI-turn -60 120 -90 0 
βVI’-turn -120 120 -60 150 
γ-turn 70 to 85 -60 to -70   
γ’−turn -70 to -85 70 to 70   
Table IV-6 
 
β-hairpins are widely occurring β-structures, consisting of two adjacent strands of anti parallel 
β-sheet and a connecting loop. The shortest common loop involves two residues, in which 
case the loop and the two adjacent residues form a β-turn. A tetrapeptide can adopt a minimal 
β-haipin structure, defined by the presence of a 10 and a 14-membered ring N-H….C=O 
hydrogen bond. Turns that serve in minimal β-hairpins are called reverse turns and are noted 
βI’ or βII’-turns where the prime indicates that the φ and ψ torsion angles of the central 
residues are opposite to those in the common turn. The type VI turn is a unique member of the 
β-turn family because it is the only turn that incorporate a Cis-peptide bond. Natural type VI 
β-turns always contain a proline residue at the i+2 position (Figure IV-8), since this is the 
only one that can exist in the cis configuration. 
 
Figure IV-24 
 
It is therefore of great interest to create new templates to mimic those kinds of effective 
structures. In the literature, numerous compounds have been developed to stabilize β-turns in 
peptide chains. β- and γ-turns mimetics have been taken into account for peptidomimetics 
design, as they allow presenting in a stereocontrolled fashion 2 to 4 side chains of amido acids 
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involved in biological interactions. In particular, because of their similarity with proline cyclic 
amino acids have been introduced into tetrapeptides and evaluated as turn inducer.109,110,161 
Because of the low amount of suitable methods to produce this C6 cyclic amino acid, there 
were no studies available investigating the oxopiperazine ring with a carboxylic group in 
position 2 as proline mimic and thus as inducer of secondary structures in peptides.  
So we will present here our investigations to elucidate the preferred conformations in 
solution, of tetrapeptides containing our amino acid mimic in i+1 position. 
 
IV-4.1 Tetrapeptides containing the Bn-Pca: 
 
We decided to synthesize new tetrapeptides inserting both Pca derivatives with and without 
the Benzyl group in the i+1 position of tetrapeptides, in order to evaluate their properties as 
secondary structure inducer. In the case of the benzyl derivative we had to pay particular 
attention to the separation of the peptide chain containing the epimerized Pca since this 
problem was not solved. 
First of all we chose the sequence of natural aminoacids based on previous work of Prins et 
al,162 that had demonstrated that the incorporation of Proline in i+1 position followed by a D-
amino acid in the i+2 position could enhance the probability of turn formation. The terminal 
residues were chosen based on their tendencies in proteins to occupy the first and fourth 
positions of β-turns embedded in β-hairpin.21 So we begun our conformational investigation 
synthesising the tetrapeptide with the following sequence Ac-Val-(Bn)Pca-(D)Ala-LeuNHBu, 
(Figure IV-9). The synthesis was performed in solution using a Boc strategy, and we 
separated both diastereoisomers by flash column chromatography after the first coupling 
between the scaffold and the chain of natural amino acids. The difficulties encountered during 
the purification together with difficult coupling of the secondary amine of Bn-Pca afforded us 
the desired product in small amounts. Conformational analyses were performed using variable 
temperature NMR studies and bi-dimensional ROESY experiments at low concentration to 
avoid aggregation phenomenon and in a non polar solvent to decrease the interactions of the 
compound with its environment.  
NMR data afforded us some informations about the tetrapeptide conformational behaviour in 
solution. Two NOE contacts were detected, (Figure IV-8) one between the Valine α-H and H 
of the (Bn)-Pca cycle, which is described to be a typical signal for a trans amino acid amide 
bond. Another one was detected between α-H of Pca and the H amide of the D-Alanine which 
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is typical for β-turn conformations. These contacts are characteristic from turn structures but 
they are not sufficient to conclude for a specific type of turn structure.163  
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Figure IV-25: tetrapeptide Ac-Val-PCA-(D)Ala-LeuNHBu, violet arrows represent NOEs contacts. 
 
 
In addition, the informations coming out of the analysis of temperature dependence 
coefficients and 1H NMR spectrum were contradictory. Temperature coefficient ∆δNH/∆T of 
H2 was inferior (in absolute value) to ∆δNH/∆T H3 but on the contrary, H3 was appearing at 
higher chemical shifts than H2 so that we could not have any definitive conclusion about the 
secondary structure of our tetrapeptide. Based on these NMR data, we can put forward the 
hypothesis that there was in this peptide exist as an equilibrium between a γ and a β-turn in 
solution. 
 
 
N-H δ 
(ppm)[a] 
∆δNH/∆T 
(ppb/K)[b] 
H1 6.6 -6,00 
H2 6,78 -3.25 
H3 7,47 -4,82 
H4 6,14 -7,18 
Table IV-7 [a] Complete proton resonance assignments were made with the aid of COSY experiments; [b] The 
temperature coefficients were determined between 238 and 298 K (where a linear dependence was 
observed);.and at a concentration of 2mM (no significant aggregation). 
 
 
Having a look again in the literature we decided to follow then the Gellman et al, paper of 
1996 164 for the design of our new tetrapeptide. Gellman has demonstrated the efficiency of 
the Proline i+1 and Glycine i+2 for the stabilization of minimal β-hairpin structures. So we 
decided to incorporate our scaffold in the following sequence Ac-Val-(Bn)Pca-Gly-Leu-
NHBu. 
25 a 
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Figure IV-26 
 
 
The tetrapeptide was synthesized as described above and analysed by NMR studies in CDCl3. 
First of all dilution studies afforded the evidence that there was no significant change in the 
chemical shift of amide protons in the considered range of concentration (1-10mM), 
indicating the absence of intermolecular interaction. Then variable temperature studies at low 
concentration (5mM) were perforemed in a range of temperature between 238 and 298K to 
study the resonance sensitivity of amide protons towards temperature. 
 
N-H δ 
(ppm)[a] 
∆δNH/∆T 
(ppb/K)[b] 
H1 6.08 -6,00 
H2 6,78 -2.90 
H3 7,80 -4,60 
H4 6,50 -3.40 
Table IV-8 [a] Complete proton resonance assignments were made with the aid of COSY experiments; [b] The 
temperature coefficients were determined between 238 and 298 K (where a linear dependence was 
observed);.and at a concentration of 2mM (no significant aggregation). 
 
 
Here again the informations collected out of the analysis of temperature dependence 
coefficients and 1H NMR spectrum were not conclusive. Temperature coefficient ∆δNH/∆T of 
H2 was lower (in absolute value) to ∆δNH/∆T H3 but at the same time, H3 was appearing at 
higher chemical shifts than H2 so that we do not have any definitive conclusion about the 
secondary structure of our tetrapeptide.  
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To get further informations on the possible conformations of our tetrapeptide, molecular 
dynamics in vacuo were performed at the University of Chateney Malabry by Cyril Bauvais. 
In these complementary studies, molecular dynamics experiments were performed at to 
different temperatures revealing here again two possible structures for this tetrapeptide. 
Analyses of the conformer of lower energy at 300K showed a preferred β-turn structure 
whereas at high temperature, 700K, the conformer of lower energy showed a preferred γ-turn 
structure. 
 
 
MD studies at 300 K: MD studies at 700 K: 
 
 
β-turn γ-turn 
Figure IV-27: molecular dynamics calculations were performed at two different temperatures in vacuo with the 
Tripos force field 
 
 
These conformationnal studies based essentially on NMR experiments afforded us some 
evidences on the propensity of our scaffold to initiate turn secondary structures, unfortunately 
racemisation problems of our scaffold during peptide coupling studies led to complicated 
separation of diastereoisomers that gave us both studied compounds in mg scale and did not 
allow us to perform complete conformational studies. Nevertheless, analyses of both 
synthesized oligopeptides seemed to show that Bn-Pca has a role on tetrapeptides folding, but 
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we are until now not able to conclude for the most populated γ- or β-turn conformation 
adopted in the case of our benzyl substituted Pca (Figure.IV-11). 
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Figure IV-28 
 
 
 
IV-4.2 Tetrapeptides containing non substituted Pca: 
 
As we mentioned above, we also prepared both enantiomers of the oxopiperazinone 
carboxylic acid without the benzyl group onto the intracyclic amide nitrogen and, for still not 
completely understood reasons, this compound was not suffering from the epimerization 
problems we encountered with the N-benzyl derivative. Both enantiomers of the Pca were 
introduced in the same tetrapeptide sequence described above. Thus Boc-Val-(R)Pca-Gly-
LeuCOOMe 26 and Boc-Val-(S)Pca-Gly-LeuCOOMe 27 were synthesized and 
conformational studies are now in course in our laboratory in Como. But first NMR studies 
showed already structural features about these two compounds. 
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Figure IV-29 
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The tetrapeptide containing the (L) piperazinone ring showed the presence of two conformers 
in solution, by NMR studies in CDCL3, whereas a single conformer was detectable in the case 
of the tetrapeptide containing the (D) scaffold. This preliminary results could be convenient 
with the presence of a stable turn structure induced by our (D)scaffold, and structural 
investigation are still in course in our laboratory to determine the structural preference of the 
ketopiperazine ring. 
 
Conclusions 
To conclude with these work performed in two years in Como and followed the third one in 
Regensburg, we manage to set up the reaction conditions for the synthesis of two oxo-
piperazine carboxylic acid derivatives. The first one substituted in its amide position by a 
benzyl group showed a high tendency to racemisation during peptide formation, in spite of 
our numerous studies to understand this phenomenon we were not able to set up suitable 
coupling conditions for its insertion in peptides. Nevertheless, the studies of purified 
tetrapeptides containing this scaffold was performed showing a certain tendency for turn 
shape. 
The second synthetic route afforded us the unsubstituted Pca in few steps and good yields. In 
addition, this scaffold did not demonstrate any issues toward racemisation, neither during the 
synthesis, nor during the coupling procedure. And it seems from last studies currently 
performed in our laboratory that this scaffold could act as a turn nucleator. 
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V - EXPERIMENTAL DATA: 
 
V-1 Materials and methods:  
 
All manipulations requiring anhydrous conditions were carried out inflame-dried glassware, 
with magnetic stirring and under a nitrogen atmosphere. All commercially available reagents 
were used as received. Anhydrous solvents were purchased from commercial sources and 
withdrawn from the container by syringe, under a slight positive pressure of nitrogen. 
Reactions were monitored by analytical thin layer chromatography using 0.25 mm pre-coated 
silica gel glass plates (DURASIL-25 UV254) and compounds visualized using UV 
fluorescence, aqueous potassium permanganate or ninhydrin. Flash column chromatography 
was performed according to the method of Still and co-workers165 using Chromagel 60 ACC 
(40-63 µm) silica gel. 
Melting points were obtained in an open capillary apparatus and are uncorrected. Proton 
NMR spectra were recorded on a spectrometer operating at 400.16 MHz. Proton chemical 
shifts are reported in ppm (δ) with the solvent reference relative to tetramethylsilane (TMS) 
employed as the internal standard. The following abbreviations are used to describe spin 
multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad signal, 
dd = doublet of doublet. Carbon NMR spectra were recorded on a spectrometer operating at 
100.63 MHz, with complete proton decoupling. Carbon chemical shifts are reported in ppm 
(δ) relative to TMS with the respective solvent resonance as the internal standard. Infrared 
spectra were recorded on a standard FT-IR and peaks are reported in cm-1. Optical rotation 
values were measured on an automatic polarimeter with a 1 dm cell at the sodium D line and 
are given in units of 10-1 deg.cm2.g-1. Elemental analyses were performed using a Perkin 
Elmer 2400 Series II CHNS/O Analyzer. High resolution mass spectra (HRMS) were 
performed on a hybrid quadrupole time of flight mass spectrometer equipped with an ESI ion 
source. A Reserpine solution 100 pg/ml (about 100 count/s), 0.1% HCOOH/CH3CN 1:1 was 
used as reference compound (Lock Mass). FAB mass spectra were recorded using a glycerol 
matrix. HPLC analytic analyses were performed in direct or reverse phase on a Shimadzu 
instrument equipped with a UV detector. 
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V-2 Synthesis of (Bn)-Pca derivatives: 
 
 
General procedure for the Mitsunobu reaction: 
 
Under nitrogen and at room temperature a stirred solution of protected L-serine in toluene 
(10mL per mmol), was treated with PPh3 (1.4 equiv.) and HN3 (2 equiv.). 
After complete dissolution of the reagents, the solution was cooled at 0°C and DIAD (1.4 
equiv.) was added. After 2h stirring under 10°C the reaction medium was poured in the 
column and the product was purified by flash chromatography, giving the desired azide. 
 
 
 
 
 
3-Azido-2-tert-butoxycarbonylamino-propionic acid methyl ester 1a: 
Compound 1a was prepared from the Boc (L) serine Methyl ester (333mg, 1,52mmol) and 
purified by flash column chromatography (PE/EA, 8/2) to give the corresponding azide as a 
transparent oil (285mg, 81%), Rf = 0,45 ( PE/EA, 8/2). [α]20D = 43.32 (c=1, CHCl3). 1H NMR 
(400MHz, CDCl3): δ=5.36 (br, 1H), 4.49(br, 1H), 3,82 (s, 3H), 3,74 (d, J=2.92 Hz, 2H), 1.48 
(s, 9H) ppm. 13C NMR (400MHz, CDCl3): δ=170.6, 155.4, 80.8, 53.9, 53.2, 53.0, 28.6 ppm. 
IR in CHCl3: 3366, 2109, 1749, 1716. MS (ESI+): m/z= 267,0 [MH+] 
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3-Azido-2-tert-butoxycarbonylamino-propionic acid tertbutyl ester  (1b): 
The compound 1b was prepared from the L serine Boc and tBu (1g, 3,83mmol)and purified 
by flash column chromatography (PE/EA, 85/15) to give a transparent oil (1.06g, 97%), Rf = 
0,41 ( PE/EA, 8/2). [α]20D = 18,01 (c=0,99, CHCl3). 1H NMR ( 400MHz, CDCl3): δ=5.37 (d, 
J=5.52 Hz, 1H), 4.34(t, J=3.19 Hz, 1H), 3,71 (dd, J=12.48 Hz, J=2.65 Hz 1H) ), 3,66 (dd, 
J=12.29 Hz, J=3.44 Hz 1H), 1.49 (s, 9H) ), 1.46 (s, 9H) ppm. 13C NMR (400MHz, CDCl3): 
δ=169.1, 155.4, 83.5, 80.5, 54.5, 53.4, 28.6, 28.3 ppm. IR in CHCl3: 3368, 2098, 1728, 
2523.C12H22N4O2 (286.33): MS (ESI+): m/z= 309,15 [MH+] 
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(S)-3-azido-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester (3b) 
 
1H 
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General procedure for the Aza-Wittig reaction: 
 
Under nitrogen and at room temperature a stirred solution of azide 1 in dichloromethane (5mL 
per mmol), was treated with a solution of PMe3 1M in THF (2 equiv). After 45 min stirring, 
freshly distilled benzaldehyde (1.1 equiv) was added and the solution was stirred 1h more. 
The solvent was then removed using an aqueous pump and a intermediary Dewar. 
 
Reduction of the imine: 
 
Procedure A: 
The obtained yellow paste was then dissolved in methanol (5mL per mmol). To this new 
medium NaBH4 (O,5 equiv) was slowly added over a period of 30min. The reaction was 
quenched with a saturated solution of NaHCO3 and extracted with DCM 5 times. The organic 
phase was then evaporated and dried over Na2SO4 before purification by flash column 
chromatography. 
 
 
Procedure B: 
The obtained yellow paste was then dissolved in methanol (5mL per mmol), Pd/C (10%, 
100mg per mmol) was added and the solution was stirred overnight under one atmosphere of 
H2. Pd/C was removed by filtration over celite and the pure product was obtained after 
purification by flash column chromatography. 
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3-Benzylamino-2-tert-butoxycarbonyl amino-propionic acid methyl ester 2a: 
This compound was prepared from the azide 1a (174mg, 0.71mmol) following procedure A 
and purified by flash column chromatography (PE/EA, 6/4) to give a transparent oil (151mg, 
68%), Rf =0.46 ( PE/EA, 6/4). 1H NMR ( 400MHz, CDCl3): δ=7.34-7,23 (m, 5H), 5.48(br, 
1H), 4.41 (br, 1H), 3.78 (m, 1H), 3.74 (s, 3H), 2.98 (dd, J=13.36 Hz, 2H), 1.46 (s, 9H), ppm. 
13C NMR (400MHz, CDCl3): δ=172.7, 155.9, 140.1, 128.8, 128.5, 127.6, 80.3, 53.9, 53.7, 
52.7, 50.3, 28.7 ppm. IR in CHCl3: 3348, 2978, 1730, 1714. 
 
 
 
3-Benzylamino-2-tert-butoxycarbonyl amino-propionic acid tert-butyl ester 2b : 
This compound was prepared from the azide 1b (1.06g, 3.71mmol) following procedure B 
and purified by flash column chromatography (PE/EA, 85/15) to give 2b as a transparent oil 
(1.29g, 99% over two steps), Rf =0.38 ( nHex/EA, 7/3). [α]20D = 8.82 (c=0.46, CHCl3). 1H 
NMR ( 400MHz, CDCl3): δ=7.35-7,25 (m, 5H), 5.39(d, J=5.60 Hz, 1H), 4,31 (br, 1H), 3,86 
(d(AB), J=13.30 Hz, 1H), 3,77 (d, J=13.22 Hz, 1H), 2.98 (d, J=4.42, 2H) ), 1.47 (s, 9H), 1.46 
(s, 9H) ppm. 13C NMR (400MHz, CDCl3): δ=171.3, 155.9, 140.3,128.7, 128.4, 127.4, 82.3, 
80.0, 54.5, 53.8, 50.8, 28.7, 28.4 ppm. C19H30N2O4 (350.46): calcd. C 65.12, H 8.63, N 7.99, 
O 18.26; found C, 65.29, H 8.68, N 7.67. IR in CHCl3: 3348, 2978, 2932, 1716. 
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(S)-3-benzylamino-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester (2b) 
 
1H 
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HN
HN
Boc
COOtBu
MeO
2c
 
 
(S)p-metoxy-3-benzylamino-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester 
(2c). Azide (595 mg, 2,08 mmol) was dissolved in dichloromethane (9 mL), under nitrogen 
atmosphere and at room temperature, and treated with PMe3 (4,16 mL of 1 M solution in 
THF, 4,16 mmol, 2 equiv). The resulting mixture was stirred at room temperature for 45 min 
and freshly distilled p-anisaldehyde (3.90mL, 3.71 mmol, 1.1 equiv) was added and the 
resulting solution was stirred for additional 60 min. The solvent was then removed under 
reduced pressure, and the residue was dissolved in methanol (18,5 mL). Palladium on 
charkoal (10% Pd/C, 100 mg) was then added and the resulting solution was filled with H2 by 
three vacuum/H2 cycles. The reaction mixture was then stirred under a hydrogen atmosphere 
overnight. Pd was removed by filtration over a pad of celite and the filtrate evaporated under 
reduced pressure. The residue was purified by flash chromatography (Pet. Ether/EtOAc, 6:4) 
to give 2c as a transparent oil (500 mg 63% over two steps). Rf =0.46 (Pet. Et./EtOAc, 6/4). R 
(CHCl3): 2926, 1718, 1460, 1367,1155,1037 .C20H32N2O5 (350.46): calcd. C 63.14, H 8.48, N 
7.36; found C 63.98, H 7.22, N 6.69 . 1H NMR ( 400MHz, CDCl3): δ=7.2 (d, J=8 Hz, 2H), 
δ=6.83 (d, J=8 Hz, 2H) , 5.44 (br, 1H), 4.27 (br, 1H), 3.77 (s, 3H), 3.74 (d, J=13.2 Hz 1H), 
3.66 (d, J=13.2 Hz, 1H), 2.91 (d, J=3.6 Hz, 2H), 1.44 (s, 9H), ppm. 13C NMR (400MHz, 
CDCl3): δ=171.4, 159.0, 156.0, 132.6, 129.7, 128.7, 114.0, 82.1, 80.1, 65.0, 55.7, 54.5, 53.2, 
50.7, 28.7, 28.3ppm.  
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(S)p-metoxy-3-benzylamino-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester (2c). 
 
1H 
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Acylation procedures: 
 
Procedure A: 
 
At room temperature the benzylated derivative  was diluted in a 1 to 1 mixture of ethyl acetate 
(2mL per mmol) and a saturated solution of NaHCO3 (2mL per mmol) and stirred for 24h at 
room temperature. The two phases were then separated and the aqueous phase was extracted 
with ethyl acetate 5 times. The combined organic phases were dried over Na2SO4, and 
concentrated in vacuo, to give the desired product without further purification. 
 
 
Procedure B: 
 
Chloroacetic acid 2eq, and DCC 2eq, were stirred for 1h in DCM (2,5mL per mmol). To these 
solution the benzyl derivative was added, and these final mixture was reacted overnight.  
The solvent was then removed under reduced pressure, and the pure product was obtained 
after flash column chromatography. 
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3-[Benzyl-(2-chloro-acetyl)-amino]-2-tert-butoxycarbonylamino-propionic acid methyl 
ester (3a) : 
This compound was prepared from the benzylated derivative (336mg, 1,1mmol) following the 
procedure A and purified by flash column chromatography (PE/EA, 7/3) to give a transparent 
oil (388mg, 92%), Rf =0,49( PE/EA, 7/3). NMR analysis gave us evidence of the presence of 
the product in a two rotamers form A: major rotamer, B minor rotamer. 1H NMR ( 400MHz, 
CDCl3): δ=7.40-7.18(m, 5H), 5.48(d, J=7.17 Hz, 1HA),5.30 (br, 1HB), 4.67 (m, 2HA), 4.55 (m, 
2HB), 4.22 (s, 2HB), 4.07 (s, 2HA), 3.97 (m,1 HA), 3.78 (s, 3HB), 3.76( s, 3HA), 3.69(dd, 2HB), 
3,58 (dd, J=4.72Hz, J=14.20 1HA), 1.59 (s, 9H), 1.45 (s, 9H) ppm. 13C NMR (400MHz, 
CDCl3): δ=171.3, 168.7, 135.8, 129.6, 129.1, 128.5, 128.3, 128.1, 126.7, 116.5, 53.3 53.1, 
52.6, 52.2, 48.9, 47.9, 41.5, 41.3, 30.028.6 ppm.  
IR in CH2Cl2: 3342, 3032, 2978, 1749, 1712, 1657 
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3-[Benzyl-(2-chloro-acetyl)-amino]-2-tert-butoxycarbonylamino-propionic acid tertbutyl 
ester (3b): 
This compound was prepared from benzyl derivative 2a (1,512g, 4,32mmol) following 
procedure B and purified by flash column chromatography (PE/EA, 7/3) to give 3a as a white 
solid (1,7g, 92%), Rf =0.31( nHex/EA, 8/2). mp= 110-112°C [α]20D =4.7 (c=0.83, CHCl3). 
NMR analysis gave us evidence of the presence of the product in a two rotamers form A, B in 
a 3 to 1 proportion.1H NMR ( 400MHz, CDCl3): A(67%) and B(33%) δ=7.40-7.19(m, 5H), 
5.41(d, J=7.68 Hz, 1HA),5.20 (bs, 1HB), 4.73-4.62 (m, 2HA&B), 4.43 (d, J=3.7Hz, 2HA&B), 
4.22 (s, 2HB) 4.07 (s, 2HA), 3.97 (dd, J= 10.1Hz J= 13.5, 2HB), 3.59 (dd, J= 14.3Hz, J= 
5.7Hz  1HA), 3.49 (dd, J=14,0Hz, J=3.8Hz 1HA), 1.47 (s, 9H), 1.45 (s 1.45) ppm. 13C NMR 
(400MHz, CDCl3): δ=169.9, 168.4 (CA), 167.6 (CB), 156.0, 136.6 (CB), 135.9 (CA), 129.5, 
129.1, 128.5, 128.4, 128.0, 126.8, 34.0, 83.0, 80.2, 53.3, 51.9, 49.1 (CB), 48.8 (CA), 47.8, 
41.8(CA), 41.5 (CB), 28.7, 28.3 ppm. C12H22N4O2 (426.94): calcd. C 59.08, H 7.32, N 6.56, O 
18.74; found C59,12, H7,24, N6,49. 
IR (CHCl3):3395, 2924, 2854, 1711, 1655 
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3-[Benzyl-(2-chloro-acetyl)-amino]-2-tert-butoxycarbonylamino-propionic acid tertbutyl ester (3b). 
 
1H 
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3-[p-metoxy-benzyl-(2-chloro-acetyl)-amino]-2-tert-butoxycarbonylamino-propionic 
acid tertbutyl ester (3c): 
DCC (372mg, 1.409mmol, 1.2equiv) and chloroacetic acid (220mg, 2.34mmol, 2equiv) where 
dissolved in dichloromethane (5 mL) and stirred for 1h at room temperature. To this solution 
Boc-(L)-serine amino p-metoxy-benzyl tert-butyl ester (447mg, 1.175mmol) previously 
dissolved in dichloromethane (5mL), was added. The corresponding solution was reacted 
overnight, the solvent was then removed under reduced pressure and the obtained residue was 
purified by flash chromatography (petroleum ether/EtOAc, 7:3) to give 3c as a white solid 
(480mg, 93%), Rf =0.31( nHex/EA, 8/2). mp= 123-125°C [α]20D =7.75 (c=0.57, CHCl3).  
C12H22N4O2 (426.94): calcd. C 57.07, H 6.84, N 6.34; found C 57.63, H 7.41, N 5.78. 1H 
NMR ( 400MHz, CDCl3):A(67%) and B(33%) δ=7.12 (d, J=8 Hz, 2 H), 6.85(d, J= 8, 2H), 
5.41(d, J=7.68 Hz, 1HA),5.20 (br, 1HB), 4.73-4.62 (m, 2HA&B), 4.43 (d, J=3.7Hz, 2HA&B), 
4.22 (s, 2HB) 4.07 (s, 2HA), 3.97 (dd, J= 10.1Hz J= 13.5, 2HB), 3.80 (d, J= 14.2 Hz , 3H), 
3.59 (dd, J= 14.3Hz, J= 5.7Hz 1HA), 3.49 (dd, J=14,0Hz, J=3.8Hz 1HA), 1.47 (s, 9H), 1.45 (s 
1.45) ppm. 13C NMR (400MHz, CDCl3): δ= 169.9, 168.3, 129.9, 128.3, 127.6, 55.5, 53.1, 
51.8, 48.1, 47.4, 41.5, 28.6 ppm. C12H22N4O2 (426.94): calcd. C 59.08, H 7.32, N 6.56, O 
18.74; found C59,12, H7,24, N6,49. 
IR (CHCl3) :3350, 2974, 1658, 1460, 1249, 1155, 1033 
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3-[p-metoxy-benzyl-(2-chloro-acetyl)-amino]-2-tert-butoxycarbonylamino-propionic acid tertbutyl 
ester (3c) 
 
1H 
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Cyclisation procedures: 
 
 
 
 
4-Benzyl-5-oxo-piperazine-1,2-dicarboxylic 1-tert-butyl ester 2-methyl ester 4a : 
To a stirred solution of the acylated derivative 3a (380mg, 0.98mmol) in DMF (4,9mL), 
Cs2CO3 (638.60mg, 1.96mmol) was added at 0°C. The solution was stirred over night at room 
temperature, the solution was then diluted with ethyl acetate 10ml and washed twice with 
5mL of a 1M solution of KHSO4 in water and brine. The solvent was then dried over Na2SO4 
and removed under reduced pressure to give a 4a white solid (235mg, 69%),mp= 126°C, Rf = 
0,42 ( nHex/EA, 7/3). [α]20D =0 (c=1, CHCl3). 1H NMR ( 400MHz, DMSO, 60°C): δ=7.36-
7.21(m, 5H), 4.72(d, J=14.7 Hz, 1H),4.7 (s, 1H), 4.29 (d, J=14.7 Hz, 1H), 4.08 (d, J=17.38 
Hz, 1H), 3.95 (d, J=17.38 Hz 1H), 3.74 (dd, J1=13,24 Hz, J2=4,63, 1H), 3.54 (dd, J1=13,19 
Hz, J2=2,67, 1H), 3.51(s, 3H), 1.42 (s, 9H) ppm. 13C NMR (400MHz, CDCl3): δ=170.1, 
165.6, 154.8, 136.2, 129.1, 128.8, 128.3, 82.0, 53.9, 52.9, 52.3, 50.1, 47.0, 46.9, 46.4, 28.6 
ppm. C18H24N2O5 (348.40): calcd. C 62.05%, H 6.94%, N 8.04%; found C61,81%, H6,93%, 
N7,86%. 
IR =2978, 1747, 1703, 1660 
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4-Benzyl-5-oxo-piperazine-1,2-dicarboxylic di-tert-butyl ester 4b : 
To a solution of the 3b derivative (90mg, 0.21mmol) in dry THF (3mL), tBuOK in solution in 
THF (21OµL, 0,21mmol) was added at 0°C under nitrogen. The reaction was carried out for 
2h at room temperature, and quenched with an aqueous solution 1M KHSO4. The solvent was 
evaporated under reduced pressure, and the residue was partitioned between dichloromethane 
20mL and aqueous solution of KHSO4 2mL. The organic layer was separated and washed 
twice with water, and dried over Na2SO4. The solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography (PE/EA, 7/3) to give a 
white solid (80mg, 97%), Rf =0,53 (PE/EA, 6/4).mp:102°C NMR analysis gave us evidence of 
the presence of the product in a two rotamers form A 66%, B 34%1H NMR (600MHz, 
CDCl3):A(%) δ=7.30-7.24(m, 5H), 4.78(d, J=3Hz, 1HA), 4.66 (d, J=14.4Hz, 1HA), 4.60 (d, 
J=15.0Hz 1HB), 4.56 (br, 1HB), 4.55 (d, J=14.4Hz 1HB), 4.47 (d, J=14.4Hz, 1HA), 4.25 (d, 
J=18.6Hz 1HA), 4.22 (d, J=19.8Hz, 1HB), 4.08 (d, J=18.0Hz 1HA), .08 (d, J=18.6Hz 1HB), 
3.65 ( d, J=11.4Hz 1HA), 3,59 (d, J=12.6Hz 1HB), 3,54 (m, 1HB, 1HA), 3.52 (dd, J= 4.5Hz, 
J=12.0 Hz 1HA), 1.47 (s, 9HA), 1.43 (s, 9HB), 1.35 (s, 9HB), 1.32 (s, 9HA) ppm. 13C NMR 
(600MHz, CDCl3): δ=168.5, 168.1, 165.6, 165.2, 154.4, 135.9, 135.8, 128.7, 128.5, 128.4, 
128.1, 127.8, 82.86, 82.81, 81.2, 81.07, 53.9, 52.3, 50.0, 49.9, 46.8, 46.7, 46.5, 46.0, 28.2, 
27.7ppm. EI-MS (C21H30N2O5) 390.2155 (calcd) 390,2152. (obsd) 
IR=2973, 2932, 1733, 1696, 1655cm-1 
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4-Benzyl-5-oxo-piperazine-1,2-dicarboxylic acid 1-tertbuthyl ester (5) : 
A solution of 3b (422mg, 0.98mmol) in dichloromethane (3mL) and TFA (3mL) was stirred 
for 2.5h at RT. The solvent was then evaporated, methanol (5mL) was added and evaporated 
twice, to remove the excess of TFA, ether (5mL) was added and evaporated to give the 
unprotected intermediate under its TFA salt’s form in quantitative yield. This salt was then 
dissolved in water (2mL) and an aqueous solution of NaOH 1M (2.94mmol, 2.94mL) and 
stirred over night at room temperature. Dioxane (4.94mL) was then added to the reaction 
medium followed by the addition of Boc anhydride (1.97mmol, 432mg) at O°C, this solution 
was stirred for 24 hours. The reaction was then diluted in water (10mL) and washed twice 
with ethyl acetate (5ml). The aqueous layer was cooled at 0°C, acidified to pH= 3 with a 
solution of KHSO4 (1M), and extracted with ethyl acetate 5 times (5mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo to afford the desired Boc 
protected piperazinone (209mg, 64%) as a white solid. 
Rf = 0.2 (DCM/MeOH 9/1) [α]20D = -11.07(c=0.84, CHCl3). m.p.174-176°C. 
1H NMR ( 400MHz, CDCl3, 50°C): δ=7.35-7.25(m, 5H), 4.86(br, 1H), 4.72 (d, J=14.54 Hz, 
1H), 4.73 (d, J=14.57 Hz, 1HB), 4.55 (d, J=14.54 Hz 1HA), 4.48 (d, J=14,77 Hz, 1HB), 4.31 
(d, J=18.34 Hz, 1H), 4.19(d, J=18.24 Hz, 1H), 3.71 (d, J=14.50Hz, 1H), 3.60 (dd, 
J1=12.86Hz, J2=4.48Hz 1H),1.50 (s, 9HA), 1,46 (s, 9HB) ppm. 13C NMR (100MHz, CDCl3): 
δ=173.3, 166.2, 154.9, 135.7, 129.1, 128.8, 128.4, 82.4, 82.1,.53.5, 52.1, 50.9, 47.1, 46.9, 28.6 
ppm. C12H22N4O2 (334.38): calcd. (+ 0.25%H2O) C 60.25, H 6.71, N 8.27 found C60.52%, 
H6.85%, N7.98%. IR (CH2Cl2) =3343, 2924, 2854, 1462, 1377 
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4-Benzyl-5-oxo-piperazine-1,2-dicarboxylic acid 1-tertbuthyl ester (5a) : 
1H
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HPLC Analyses:  
 
The optical purity of the compound 5, was then confirmed by chiral HPLC with Chiracel OD-
H column (25cm × 0.46cm ) and Isopropanol/ hexane (9/1) in isocratic conditions 1mL.min-1. 
 
HPLC trace for the product 5 registered at 230 nm. 
 
 
HPLC trace for the product 5 registered at 230 nm. 
 
 
 
For comparison, HPLC trace of the same cyclic product obtained with an ee% of 57% 
registered at 254 nm. In this figure we can note the retention times of both enantiomers. 
(S)-Boc-PCA- 13.5 min. 
(R)-Boc-PCA- 11.2 min 
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4-p-methoxy-benzyl-5-oxo-piperazine-1,2-dicarboxylic acid 1-tertbuthyl ester  5b: 
To a solution of the acyl derivative 3c (400mg, 0.905mmol) in dichloromethane (3mL), TFA 
(3mL) was added and the resulting mixture was stirred for 2.5h at RT. The solvent was then 
evaporated, methanol (5mL) was added and evaporated twice, to remove the excess of TFA, 
ether (5mL) was added and evaporated to give the unprotected intermediate under its TFA 
salt’s form in quantitative yield. This salt was then dissolved in water (10.86mL) and an 
aqueous solution of NaOH 1M (2.72mmol, 2.72mL) and stirred over night at room 
temperature. Dioxane (10.8mL) was then added to the medium followed by the addition of 
Boc anhydride (590mg, 2.72mmol, 3equiv) at O°C, this solution was stirred for 24 hours. The 
reaction was then diluted in water (10mL) and washed twice with ethyl acetate (5ml). The 
aqueous layer was cooled at 0°C, acidified to pH= 3 with a 1M solution of KHSO4 , and 
extracted with ethyl acetate 5 times (25mL). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo to afford the desired Boc protected piperazinone 5b 
(190mg, 58%) as a white solid. 
Rf = 0.2(DCM/MeOH 9/1) m.p. 240-242°C. 
1H NMR ( 400MHz, CDCl3, 50°C): δ 7.16(d, J= 8 HZ, 2 H), 6.85 (d, J= 8.2 Hz, 2H),  5.45 
( d, J= 8 Hz, 1H), 4.72 (d, J=14.54 Hz, 1H), 4.73 (d, J=14.57 Hz, 1HB), 4.55 (d, J=14.54 
Hz 1HA), 4.48 (d, J=14,77 Hz, 1HB), 4.31 (d, J=18.34 Hz, 1H), 4.19(d, J=18.24 Hz, 1H), 
3.80 (d, J=14 Hz, 3H), 3.71 (d, J=14.50Hz, 1H), 3.60 (dd, J1=12.86Hz, J2=4.48Hz 
1H),1.50 (s, 9HA), 1,46 (s, 9HB) ppm. 13C NMR (400MHz, CDCl3): δ=173.1, 166.5, 
159.5,154.9, 130.3, 114.5, 55.6, 50.1, 46.8, 42.4,28.7 ppm. 
IR in CH2Cl2=2922, 1460, 1377,723. 
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4-p-methoxy-benzyl-5-oxo-piperazine-1,2-dicarboxylic acid 1-tertbuthyl ester  5b 
 
1H 
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V-3 Coupling studies on the (Bn)5-oxopiperazine-2-carboxylic acid  
 
N
H
H
N
O
O
O
 
Boc-Alanine benzylamide: 
L-Boc-Ala (255 mg,1.32 mmol) was first dissolved in anhydrous DMF (13.2 ml). Under 
nitrogen, the benzyl amine (139 µl,1.32 mmol,1eq) was added, followed by the addition of the 
coupling reagent HOBt (217 mg,1.452 mmol,1.1 eq). 
The solution was then cooled at 0°C with an ice bath, and the EDC (253 µl,1.452 mmol,1.1 
eq) was added dropwise. The obtained mixture was then reacted for 2h at 0°C and then at 
room temperature for 22h.  
The DMF solution was then diluted with 5 mL of DCM and washed twice with 2mL of 
KHSO4 (1M), twice with 2mL of NaHCO3sat, and once with brine. The solution was then 
dried over dried Na2SO4 and the solvent was removed under reduced pressure to give the Boc 
protected compound as a white solid (349mg, 95%).  
mp= 96-98°C. 
1H NMR ( 400MHz, CDCl3): 
δ=7.36-7.26(m,5H), 6.67 (s,1H), 5.10(s,1H), 4.44(d,J=5.3 Hz,2H), 4.21(m,1H), 1.46(s,9H), 
1,40(d,J=7.06 Hz,3H) ppm.13C NMR (100MHz, CDCl3):δ=172.98, 138.49, 129.06, 127.85, 
43.79, 28.68, 18.7 ppm. C15H22N2O3 (278.35): calcd. C 64.73%, H 7.97%, N 10.06%; found 
C 64.16%, H 8.00%, N 9.32%.  
IR (CH2Cl2): 2926, 1377, 1298, 723. 
 
H3N
H
N Ph
OTFA-
8
 
The Boc-Ala-benzyl amine (40 mg, 0.143mmol) was dissolved in DCM (0.8 ml). To this 
solution, TFA (0.8mL, 8.6mmol)was added, and the mixture was stirred for 2h at ambient 
temperature. The obtained solution is then diluted with MeOH, and evaporated 3 times to 
eliminate the excess of TFA, and finally the TFA salt is precipitated in diethyl ether and dried 
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under vacuo. The corresponding salt 8 was obtained in quantitative yields and used with out 
further characterisation, in coupling studies. 
 
N
N
H
N
O
O
N
H
O
6
Boc
 
 
Boc-PCA-(L)Ala-benzylamide (6): 
To a solution of 5 (25mg, 0.075mmol) in 1 mL of DMF, HOAt (11mg, 0.082mmol), the 
alanine benzylamide under it’s TFA salt form (24mg, 0.082mmol), and DIPEA 
(35µL,0.224mmol) were added. The solution was cooled in an ice bath and treated with EDC 
(15µL,0.082mmol). The mixture was stirred for 1h at 0°C and at room temperature overnight. 
The DMF solution was then diluted with 5 mL ethyl acetate and washed twice with 2mL of 
KHSO4 (1M), twice with 2mL of NaHCO3sat, and once with brine. The solution was then 
dried over dried Na2SO4 and the solvent was removed under reduced pressure to give the 
crude product. Further purification by flash column chromatography (DCM/MeOH:95/5) 
gave us the desired product (6) in a 70% yield, as a mixture of two diastereoisomers (26mg, 
0.05mmol). 
Rf = 0.42(DCM/MeOH 9/1), mp= 68-72°C. 
1H NMR ( 400MHz, CDCl3, 45°C): δ=7.32-7.24(m, 10H), 6.74(m, 1HDIA1&DIA2), 6.45 (br, 
1H), 4.85 (m, 1HDIA1&DIA2), 4.46-4.24 (m, 5HDIA1&2), 4.04 (dd, J=6,47 Hz, J=17,50 Hz  1H), 
3.70 (2dd, 1HDIA1&DIA2), 3.45(2dd, J=18.24 Hz, 1H), 3.71 (d, J=14.50Hz, 1HDIA1&DIA2), 1.48, 
1.45 (2s, 9HDIA1&DIA2),1.36 (2d, 3HA), 1,46 (s, 3HDIA1&DIA2) ppm. 13C NMR (100MHz, 
CDCl3): δ=171.7, 169.2, 165.9, 138.2, 136.2, 129.1, 128.77, 128.73, 128.2, 128.0, 127.9, 
82.9, 56.6, 50.6, 50.5, 49.5, 47.1, 46.2, 43.9, 28.5ppm. C27H34N4O5 (494.60): calcd. C 
65.57%, H 6.93%, N 11.33%; found C 62.18%, H 7.57%, N 8.73%. IR (CH2Cl2):2854, 2725, 
2361, 1462, 1377, 802, 723, 422. 
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Boc-PCA-(L)Ala-benzylamide (6) 
 
1H 
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N
H
N
H
N
O
O
N
H
O
7a
 
 
 
4-Benzyl-5-oxo-piperazine-2-carboxylic acid (1-benzylcarbamoyl-ethyl)-amide (7a): 
Deprotection of the dipeptide was carried out in a 50% TFA solution in DCM for 2 hours, 
following evaporations with methanol and ether were done to remove the excess of acid. 
Subsequent neutralization using NaHCO3 and extractions with ethyl acetate 5 times gave us 
the mixture of the two diastereoisomers without Boc. 
They were then separated by flash chromatography 97/3 DCM/ MEOH 
To afford us both pure desired compounds in mg scale. 
Major diastereoisomer 7a 
Rf= 0.58 (DCM/MeOH: 96/4) 
1H NMR ( 400MHz, CDCl3): δ=7.61 (d, J= 7.61Hz, 1H), 7.33-7.21 (m, 5H), 6.59 (br, 1H), 
4.65 (d, J= 14.61Hz 1H), 4.48 (d, J=14,48Hz, 1H), 4.31 (d, J=18.34 Hz, 1H), 4.19(d, J=18.24 
Hz, 1H), 3.71 (d, J=14.50Hz, 1H), 3.60 (dd, J1=12.86Hz, J2=4.48Hz 1H),1.50 (s, 9HA), 1,46 
(s, 9HB) ppm. 13C NMR (400MHz, CDCl3): δ=173.3, 166.2, 154.9, 135.7, 129.1, 128.8, 
128.4, 82.4, 82.1,.53.5, 52.1, 50.9, 47.1, 46.9, 28.6 ppm. 
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H-PCA-(L)Ala-benzylamide (7a) 
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Minor diastereoisomer (7b)  
Rf= 0.55 (DCM/MeOH: 96/4) 
1H NMR ( 400MHz, CDCl3): δ=7.61 (d, J= 7.64Hz, 1H), 7.34-7.20 (m, 5H), 6.84 (br, 1H), 
4.65 (d, J= 14.52Hz 1H), 4.48 (d, J=14,08Hz, 1H), 4.31 (d, J=18.34 Hz, 1H), 4.19(d, J=18.24 
Hz, 1H), 3.71 (d, J=14.50Hz, 1H), 3.60 (dd, J1=12.86Hz, J2=4.48Hz 1H),1.50 (s, 9HA), 1,46 
(s, 9HB) ppm. 13C NMR (400MHz, CDCl3): δ=173.3, 166.2, 154.9, 135.7, 129.1, 128.8, 
128.4, 82.4, 82.1,.53.5, 52.1, 50.9, 47.1, 46.9, 28.6 ppm.  
 
H-PCA-(L)Ala-benzylamide dia (7b) 
 
1H 
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HPLC Analyses: 
 
For the need of coupling studies, the purity of product 7a and 7b was evaluated by HPLC 
analyses, in reverse phase conditions with the column C-18 (5 cm × 0.46 cm, 5µm), with a 
constant flux: 1mL.min-1 
 
 
Solutions 
A = H2O + 0.1% TFA 
B = CH3CN + 0.1% TFA 
 
 
Gradient:  
• A: 0-40% in 40 min 
• B: 100% for 10 min. 
 
 
 
The spectrum was registered at 230nm  
Retention times: 
7a: Dipeptide (L)PCA(L)Ala Tr= 15.9 min. 
 
7b: Dipeptide (D)PCA(L)Ala Tr= 15.6min. 
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NH-Boc(L)Ser(L)Ala benzylamide (9a): 
 
To a solution of Boc-L-Serine (140 mg, 0.683mmol) in anhydrous DMF (7mL), at 0°C, 
HATU (285mg, 0.75mmol), TFA salt of the Alanine benzylamide(219mg,0.75mmol) and 
TMP(270mL, 0.75mmol ) were added. After 1h stirring at 0°C, the mixture was stirred for 3h 
at ambient temperature. The solution was then diluted with ethyl acetate and washed 
subsequently with KHSO4, NaHCO3, and NaCl. The organic phase was then dried over 
Na2SO4, and the organic solvent was evaporated to afford the product 9a as a white solid 
(186mg, 77%). 
mp= 142-144°C. 
 
1H NMR ( 400MHz, CDCl3):δ=7.59 (d, J=7.2 Hz,1H), 7.53(d, J=7 Hz,1H),7.33-7.23 (m,5H) 
,5.78(d, J=5.77 Hz, 1H), 4.56 (t, 1H), 4.41(d, J=5.47Hz,2 H),4.19(m,1H),3.93(dd,J=3.8Hz, 
J=11.07 Hz,1H), 3.60(dd,J=7.16 Hz,J=14 Hz,1H),1.38(s,12H) ppm. 
13CNMR(100MHz,CDCl3):δ=172.83,171.71,138.11,128.07,127.9,63.31,55.91,49.81,44.03,2
8.65,18.32ppm. C18H27N3O5 (365.43): calcd. C 59.16%, H 7.45%, N 11.50%; found C 
58.25%, H 7.38%, N 10.55%. IR (CHCl3): 2924, 2854, 1462, 1377, 1091, 723. 
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NH-Boc(L)Ser(L)Ala benzylamide (9a): 
 
1H 
13C 
 121 
Starting from the D-Serine (110mg, 0.54mmol) the same dipeptide 9b was synthesized 
following the same procedure and afforded the corresponding dipeptide in a 90% yield 
(170mg)  
 
HPLC Analyses: 
 
For the need of coupling studies, the purity of product 9 was evaluated by HPLC analyses on 
its corresponding unprotected derivative under its TFA salt form. The analyses were carried 
out in reverse phase conditions with the column C-18 (5 cm × 0.46 cm, 5µm), with a constant 
flux: 1mL.min-1 
 
Solutions 
A = H2O + 0.1% TFA 
B = CH3CN + 0.1% TFA 
 
Gradient:  
• CH3CN da 0-10% in 15 min 
• CH3CN da 10-15% in 5 min 
• H2O 100% per 5 min. 
 
 
 
The corresponding TFA salts diluted in water were injected for HPLC characterisation. And 
HPLC traces were registered at 230nm. 
 
 
             (L)Ser(L)Ala Tr = 8-8.31 min.                                     (D)Ser(L)Ala, Tr = 9.08 min. 
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N-Boc(L)PCA-(S)-α-methyl benzylamide (10): 
To a solution of N-Boc-(S)-Pca 5 (30 mg, 0.083mmol) in anhydrous DMF (1mL), at 0°C, 
HBTU (40mg, 0.11mmol), HOBt (23mg, 0.11mmol), freshly distilled -(S)-α-metil 
benzylamide (12µL, 0.1mmol ) and DIPEA (46µL, 0.267mmol) were added. After 1h stirring 
at 0°C, the mixture was left stirring for 5h at ambient temperature. The solution was then 
diluted with ethyl acetate and washed subsequently with KHSO4, NaHCO3, and NaCl. The 
organic phase was then dried over Na2SO4, and the organic solvent was evaporated to afford 
the product 10 as a white solid(22.7mg, 58%), 
Rf=0.6 (DCM/MeOH=95/5) 
1H NMR (400MHz, CDCl3): δ=7.36-7.22(m,10H), 6.64(m,1H), 5.12(d,J=14.6 Hz,1H), 
5.06(m,1H), 4.66(m,1H), 4.28(d, J=14.6Hz,1H), 4.19(d,J=15.5 Hz,1H), 4.05(d,J=17.5Hz,1H), 
3.8(dd,J=13.7Hz,1H), 3.42(dd,J=12.1Hz,1H), 1.46(d,12H)ppm. 
13C NMR (100MHz, CDCl3): δ=136.4,129.15,128.76,128.22,127.93,126.38,126.2, 
82.73,50.88,49.53,46.91,28.55, 22.30ppm. 
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N-Boc(L)PCA-(S)-α-methyl benzylamide (10): 
1H 
13C 
 124 
N
N
H
Ph
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N
O
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Deprotection of the dipeptide 10 was carried out in a 50% TFA solution in DCM for 2 hours, 
following evaporations with methanol and ether were done to remove the excess of acid. 
Subsequent neutralization using NaHCO3 and extractions with ethyl acetate 5 times gave us 
the mixture of the two diastereoisomers without Boc  
 
HPLC Analyses: 
 
For the need of coupling studies, the purity of product 10 was evaluated by HPLC, on its 
corresponding unprotected derivative 11, in reverse phase conditions with the column C-18 (5 
cm × 0.46 cm, 5µm), with a constant flux: 1mL.min-1 
Solutions 
A = H2O + 0.1% TFA 
B = CH3CN + 0.1% TFA 
 
Gradient:  
• CH3CN da 0-10% in 15 min 
• CH3CN da 10-15% in 5 min 
• H2O 100% per 5 min. 
 
The product 11, diluted in H2O was then injected. 
And the analyses of the corresponding HPLC trace showed us a 3 to 7 diastereoisomeric ratio. 
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(L)PCA (S)-α-metil benzylamide Tr= 28.68 min. 
 
(D)PCA (S)-α-metil benzylamide Tr=28.11 min. 
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V-4 Synthesis of Pca: 
 
 
 
 
 
2-(Ethoxycarbonylmethyl-amino)-3-hydroxypropionic acid methyl ester (19): 
L-serine methyl ester hydrochloride (1g, 6.47mmol) was dissolved in methanol, then 
triethylamine (902µL, 6.47mmol), a 50% solution of ethyl glyoxalate in toluene, and 10% 
Pd/C (90mg), were successively added, and the resulting mixture was stirred overnight under 
a hydrogen atmosphere. Next the suspension was filtered over a pad of Celite, and the solvent 
was removed under reduced pressure. The crude product was purified by flash column 
chromatography (CH2Cl2/MeOH:98/2) to yield 19 as a color less oil (902mg, 68%) Rf= 
0.25(CH2Cl2/MeOH:95 /5) [α]20D =-27.8 (c=1, CHCl3). 
1H NMR (400MHz, CDCl3): δ=4.20-4.15 (q, J=8.74 Hz, 2H), 3.79 (dd, J1=11.16 Hz, 
J2=4.56Hz 1H), 3.74 (s, 3H), 3.69 (dd, J=5.86Hz, J =11.15 Hz 1H), 3.52 (d, J=17.4 Hz, 1H), 
3.40 (d, J=17.5 Hz, 1H), 2.76(br, 1H), 1.26 (t, J=7.14Hz, 3H), ppm. 13C NMR (400MHz, 
CDCl3): δ=173.1, 172.4, 62.8, 62.6, 61.2, 52.4, 49.2, 14.4 ppm. C8H15NO5 (205.21): calcd. C 
46.82%, H 7.37%, N 6.83%; found C46,74%, H7,32%, N6,46%. 
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2-(Ethoxycarbonylmethyl-amino)-3-hydroxypropionic acid methyl ester (19): 
1H 
13C 
 127 
 
 
 
3-Azido-2-(ethoxycarbonylmethyl-amino)-propionic acid methyl ester 20: 
Under nitrogen, to a solution of 19 (807mg, 3.93mmol) in dry toluene 30mL, 
triphenylphosphine (1.44g, 5.50mmol) was added. After complete dissolution of the 
phosphine, HN3(0.5M) (7,86mmol, 15.70mL) was added, followed by DIAD (5.50, 1.10mL). 
After 2 hours of reaction the mixture was directly poured into a column and purified by flash 
column chromatography (CH2Cl2/MeOH, 99/1) to give the azide as a transparent oil (796mg, 
88%). 
Rf=0.65(CH2Cl2/MeOH:95/5) [α]20D =-37.6 (c=0.5, CHCl3). 1H NMR ( 400MHz, CDCl3): 
δ=4.17(q, J=7.1 Hz, 2H), 3.75(s, 3H),3.53 (dd, J1=12,16 Hz, J2=5,25 Hz, 1H), 3.49 (dd, 
J1=12,16 Hz, J2=5,25 Hz, 1H), 4.08 (d, J=17.38 Hz, 1H), 3.95 (d, J=17.38 Hz 1H), 3.74 (dd, 
J1=12,16 Hz, J2=4,95Hz, 1H), 3.49 (d, J=17,30 Hz, 1H), 3.43(d, J=17,30 Hz, 1H), 1.25 (t, 
J=7,15Hz, 3H) ppm. 13C NMR (400MHz, CDCl3): δ=171.9, 171.5, 60.9, 60.2, 53.0, 52.3, 
49.0, 14.11 ppm. HRMS (ESI) m/z calcd for [C8H14N4NaO4]+ 253.O9073 [M+Na]+ found 
253.09097 
IR (CH2Cl2) =3352, 3063, 2108, 1744, 1445 
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3-Azido-2-(ethoxycarbonylmethyl-amino)-propionic acid methyl ester 20: 
1H 
13C 
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5-Oxo-piperazine-2-carboxylic acid methyl ester 21: 
To a solution of 20 (260mg, 1.12mmol) in MeOH (5mL) Pd/C (0.112 mmol 0.1eq) was 
added. The reaction was stirred overnight at RT under 1atm of H2. The solution medium was 
then filtrated through a pad of celite to remove the Pd/C, the solvent was evaporated under 
reduced pressure to obtain 21 (177 mg, 1.11 mmol, 99%) as a white paste. 
Rf= 0,3 (DCM/MeOH:92/8), [α]20D =-46.3 (c=1, CHCl3). 1H NMR ( 400MHz, CDCl3): δ= 
3.76(s, 3H),3.74 (dd, J1=8,06 Hz, J2=4,48 Hz, 1H), 3.66 (d, J=17.1 Hz, 1H), 3.61 (ddd, 
J1=11,84 Hz, J2=4,48 Hz, J3=3.13 Hz, 1H), 3.53 (d, J=17.44 Hz 1H), 3.52 (ddd, J1=11,85 Hz, 
J2=8,06, J3=1.84 Hz 1H) ppm. 13C NMR (400MHz, CDCl3): δ=171.4, 170.1, 54.2, 52.9, 48.2, 
44.1ppm. HRMS (EI-MS) m/z calcd for [C6H10N2O3] 158.06910 [M]+ found 158.06920 
IR (CH2Cl2) =3406, 3354, 3211, 1744, 1678 
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5-Oxo-piperazine-2-carboxylic acid methyl ester 21: 
1H 
13C 
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5-Oxo-piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester : 
To a solution of 21 (100mg, 0.63mmol )in Dioxane /1M solution of K2CO3 in water 
(3mL/3mL) mixture, at 0°C Boc anhydride was added. After 15min the ice bath was removed 
and the solution was stirred over night. Water 5mL was added and the solution was extracted 
with ethyl acetate. Solvents were removed under reduced pressure and the crude product was 
purified by flash column chromatography to afford the desired Boc protected compound 23 
(65mg, 40%)  
Rf=0.32(CH2Cl2/MeOH:97/3) [α]20D =-20.8 (c=1, CHCl3).mp= 85°C. 1H NMR ( 400MHz, 
CDCl3): δ= 6.65(bs, 1HB), 6.50(bs, 1HA), 4.99 (dd, J1=4,63Hz, J2=1,85Hz, 1HA),4.77 (br, 
1HB), 4.23 (d, J=18.49Hz, 1HA), 4.22 (d, J=18,62Hz, 1HB), 4.03 (d, J=18.49Hz 1HA), 4.00 (d, 
J1=18,62Hz, 1HB) 3.80 (ddd, J1=12.55Hz, J2=4.97Hz, J3=1.85Hz, 1HA), 3.78 (s, 3HA), 3.77(s, 
3HB), 3.66(dd, J1=12.55Hz, J2=4.63Hz, 1HB)ppm. 13C NMR (400MHz, CDCl3): δ=169.9, 
167.5, 81.6, 52.9, 51.4, 46.3, 42.3, 28.22ppm. C11H18N2O5+0.4H2O(258.27): calcd. C 49.76%, 
H 7.15%, N 10.55%; found C49,93%, H7,42%, N10,06%. 
IR (CH2Cl2) =3410, 2980,1749, 1693. 
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5-Oxo-piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester : 
1H 
13C 
 133 
 
 
 
 
 
 
5-Oxopiperazine-1,2-dicarboxylic acid 1-tert-butyl ester (12a) 
 
Procedure A from the Boc Methyl ester 23. 
 
A solution of 23 (65mg, 0.25mmol),in 3mL of THF was treated with a solution of LiOOH 
(3mL, 2.7M of LiOH in 30% H2O2) at 0°C. The reaction was stirred for 2h (25°C). 
The reaction mixture was acidified until pH=1 with saturated solution of KHSO4 and the 
aqueous phase was extracted with EtOAc (5X10mL). The Organic phase was then dried over 
Na2SO4 and Dried under vacuo to afford the corresponding acid as a white powder (53mg, 
87%) 
 
 
Procedure B starting from the compound 21 one pot Boc and Methylester deprotection: 
 
To a solution of 21 (120mg, 0.76mmol) in Dioxane 2mL/ NaOH(1M),1mL/water 1mL,at 
O°C, Boc2O (331mg, 1.52mmoles) was added. After 15minutes, the ice bath was removed 
and the reaction was stirred for 10 h. The reaction was quenched by addition of water 5ml, 
and the aqueous phase was washed 2 times with ethyl acetate 3mL. At O°C, then the aqueous 
solution was acidified until pH=3 mediating addition of a 1M solution of KHSO4. The acid 
phase was finally extracted 5 times with ethyl acetate 5mL, and dried over Na2SO4. 
Subsequent evaporation under reduced pressure of the solvent, afforded the pure product 11 
(135mg, 88%)as a thin white powder. 
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Rf=0.15(CH2Cl2/MeOH:97/3) [α]20D =-33,8 (c=0,5, CH3OH).mp= 103,5°C. 1H NMR ( 
400MHz, CDCl3): δ= 8.61 (d, J=3.21Hz, 1HB), 8.55 (d, J=4.33Hz, 1HA), 4.99(d, J=4,38Hz, 
1HA), 4.79 (d, J=2,98, 1HB), 4.23 (d, J=18.88Hz, 1HA&B), 4.07 (d, J=18,83Hz, 1HA), 4.07 (d, 
J=19.14Hz, 1HB), 3.88 (dd, J1=12,60Hz, J2=3.98Hz 1HA) 3.84 (dd, J1=17.32Hz, J2=4.10Hz, 
1HB), 3.65 (dd, J1=17.37Hz, J2=4.95Hz, 1HA&B), 1.50(s, 9HA), 1.48 (s, 9HB)ppm. 13C NMR 
(400MHz, CDCl3): δ=174.8CA, 174.6CB,171.1CA, 170.6CB, 154.8CA, 154.1CB, 82.3CA&B, 
73.7CA, 73.3CB, 52.9CA, 51.4CB, 46.2CA, 46.2CA, 45.6CB, 28.6CA&B ppm. HRMS (EI-MS) 
m/z calcd for [C10H16N2O5] 244.1059 [M] found 244.10602 
IR (CH2Cl2) =3408, 3230, 1707, 1647. 
5-Oxopiperazine-1,2-dicarboxylic acid 1-tert-butyl ester (12a) 
1H 
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 135 
 
 
 
5-Oxopiperazine-1,2-dicarboxylic acid 1-(fluoren-9-yl) ester 2-methyl ester 22. 
 
To a solution of 21 (128mg, 0.81mmol), in 2:1 water-dioxane (3mL) NaHCO3 (136mg, 
1.61mmol)was added. The mixture was cooled to 0°C with a ice bath, then a ,solution of 
Fmoc-Cl (209mg, 0.81mmol) in 1.5mL of dioxane was added dropwise over 15 min. The ice 
bath was removed and the reaction mixture was left stirring for 2.5h. Successively, the 
mixture was partitioned between EtOAc 14mL and water 7mL, and the organic phase was 
washed with with 1M HCl and brine, then dried over Na2SO4. The organic solvents were 
removed and the crude product was purified by flash column chromatography (DCM/MeOH: 
95/5) thus giving the pure fmoc protected compound 22 (258mg, 87%). 
Rf=0.45(CH2Cl2/MeOH:96/4) [α]20D =-11.9 (c=1, CHCl3).mp= 144°C. 1H NMR ( 400MHz, 
CDCl3): δ= 6.57(bs,1HB), 6,54(bs, 1HA), 5,04 (t, J=2Hz, 1HA), 4.61(bs, 1HB),4.60-4.49(m, 
2HA&B), 4.44 (dd, J1=7.2Hz,J2=3.6Hz, 1HA), 4.28-4.15 (m, 1HA+1HA&B), 4.12 (d, J=18Hz 
1HA), 4.03 (d, J=18.4Hz, 1HB) 3.84 (dd, J1=5.2Hz, J2=1.6Hz, 1HB), 3.81 (dd, J1=3.6Hz, 
J2=1.6Hz 1HB), 3.78(s, 3HA), 3.71(s, 3HB), 3.68(dd, J1=13.2Hz, J2=4.8Hz, 1HA), 3.57(dd, 
J1=12.8Hz, J2=4.4Hz, 1HA) ppm. 13C NMR (400MHz, CDCl3): δ=169.6(A), 169.5(B), 
167.4(B), 166.9(A), 155.2(A), 154.3(B), 143.5(A&B), 143.4(A&B), 141.3(A&B), 
141.3(A&B), 127.8(A), 127.7(B), 127.1(A), 127.1(B), 127.1(A&B), 124.9(A), 124.6(B),  
120.1(A), 120.0(B), 68.4(A), 67.8(B), 53.1(A&B), 52.5(B), 52.0(A), 47.1(A), 47.0(B), 
46.0(A&B), 42.2(A&B) ppm. C21H20N2O5+1.5H2O (380.40): calcd. C 61.90%, H 5.70%, N 
6.88%; found C61,95%, H5,31%, N6,69%. 
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5-Oxopiperazine-1,2-dicarboxylic acid 1-(fluoren-9-yl) ester 2-methyl ester (22). 
1H 
13C 
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X-Ray crystallographic data : C21 H20 N2 O5 ; MW=380.39g.mol-1; T= 123 K; λ(Mo 
Kα)=1.54184 A; Orthorhombic, space group P 21 21 21, a = 6.5176(2) A, b = 11.6690(5) A, 
c=23.9190(9) A, α = 90°,.β= 90°, γ = 90°.,V=;1819.13(12) A3, ρcalc=1.389 mg.m-3, Z=4; 
µ(Μο, Κα)= 0.828mm-1, R1 = 0.0283, wR2 = 0.0713, for 2679 unique data collected in the 
3.70-66.5° θ range. 
 
Selected bond distances and bond angles: 
Bond Distances Bond angles 
O(1)-C(14);1.453(2)  
O(1)-C(15);1.345(2)  
O(2)-C(15);1.2206(18)  
O(3)-C(17);1.227(2)  
O(4)-C(20);1.335(2)  
O(4)-C(21);1.449(2)  
O(5)-C(20);1.199(2)  
N(1)-C(15);1.353(2)  
N(1)-C(16);1.459(2)  
N(1)-C(19);1.451(2)  
N(2)-C(17);1.338(2)  
N(2)-C(18);1.457(2)  
N(2)-H(2A);0.8800  
C(1)-C(13);1.511(3)  
C(1)-C(6);1.401(3)  
C(16)-C(17);1.508(3)  
C(18)-C(19);1.515(3)  
C(19)-C(20);1.531(2)  
C(16)-H(16A);0.9900  
C(16)-H(16B);0.9900  
C(18)-H(18A);0.9900  
C(18)-H(18B);0.9900  
C(19)-H(19);1.0000  
C(21)-H(21A);0.9800  
C(21)-H(21B);0.9800  
C(21)-H(21C);0.9800  
C(14)-O(1)-C(15);115.07(12)  
C(20)-O(4)-C(21);115.75(14)  
C(15)-N(1)-C(16);117.02(13)  
C(15)-N(1)-C(19);125.58(13)  
C(16)-N(1)-C(19);116.18(13)  
C(17)-N(2)-C(18);124.93(15)  
C(17)-N(2)-H(2A);118.00  
C(18)-N(2)-H(2A);118.00  
O(2)-C(15)-N(1);123.20(15)  
O(1)-C(15)-N(1);112.43(13)  
O(1)-C(15)-O(2);124.37(14)  
N(1)-C(16)-C(17);114.02(15)  
N(2)-C(17)-C(16);119.06(15)  
O(3)-C(17)-N(2);121.64(17)  
O(3)-C(17)-C(16);119.30(17)  
N(2)-C(18)-C(19);109.62(15)  
N(1)-C(19)-C(20);112.09(15)  
C(18)-C(19)-C(20);110.91(14)  
N(1)-C(19)-C(18);108.29(13)  
O(5)-C(20)-C(19);124.22(17)  
O(4)-C(20)-O(5);124.18(16)  
O(4)-C(20)-C(19);111.59(15)  
N(1)-C(16)-H(16A);109.00  
N(1)-C(16)-H(16B);109.00  
C(17)-C(16)-H(16A);109.00  
C(17)-C(16)-H(16B);109.00  
H(16A)-C(16)-H(16B);108.00  
N(2)-C(18)-H(18A);110.00  
N(2)-C(18)-H(18B);110.00  
C(19)-C(18)-H(18A);110.00  
C(19)-C(18)-H(18B);110.00  
H(18A)-C(18)-H(18B);108.00  
N(1)-C(19)-H(19);108.00  
C(18)-C(19)-H(19);109.00  
C(20)-C(19)-H(19);109.00  
O(4)-C(21)-H(21A);109.00  
O(4)-C(21)-H(21B);109.00  
O(4)-C(21)-H(21C);109.00  
H(21A)-C(21)-H(21B);109.00  
H(21A)-C(21)-H(21C);109.00  
H(21B)-C(21)-H(21C);109.00 
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5-Oxo-piperazine-2-carboxylic acid (1-phenyl-1ethyl)-amide 24 : 
 
To a solution of 12a (30mg, 0.123mmol)in DMF(2mL), HOBt (21mg,0.135mmol), (R)α-
Methylbenzylamine (24µL,0.184mmol) and DIPEA(4.2µL, 0.246mmol) were added. The 
solution was cooled to 0°C with an ice bath and EDC.HCl (26mg, 0.135mmol) was added. 
The reaction mixture was stirred overnight letting the reaction medium rise at room 
temperature. 5mL of DCM were added to the medium, and the organic phase was washed 
sequentially with an acid solution of KHSO4 (2times, 3mL), with a saturated solution of 
NaHCO3 (2 times 3mL) and finally with brine (2 times 3mL). the Organic layer was then 
dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product 
was analysed by NMR, and directly diluted in a solution of DCM/TFA (1mL/1mL). The 
solution was stirred for 2 hours at room temperature. The excess of TFA was then removed 
under reduced pressure using several additions of methanol. The TFA salt was then diluted in 
water (2mL) and the solution was cooled at O°C with an ice bath. At this temperature, the 
solution was neutralized mediating a saturated solution of NaHCO3 until pH=7. And the 
neutral aqueous phase was extracted 5 times with 4mL of ethyl acetate. The combined organic 
phases were then dried over Na2SO4 and the solvent was removed under vacuo to give the 
desired unprotected product 24 in acceptable yield (22mg, 72%). 
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V-5 Tetrapeptides 
 
 
 
 
 
 
 AcVal-L-(Bn)Pca-D-Ala-LeuNBu (25 a) 
To a solution of Ac-L-Val (26 mg, 0.165 mmol) in dry DMF (200 µL) and collidine (22 µL, 
0.165mmol), under a nitrogen atmosphere and at 0°C, HATU (63 mg, 0.14 mmol) was added. 
After 1h a solution of H-Pca-Gly-L-Leu-NHBu (50 mg, 0.11 mmol) in dry DMF (300 µL) and 
DIPEA (28µL, 0.165 mmol) was slowly added and the reaction was stirred at 0°C for 10 
minutes and at RT for a week-end. The mixture was diluted with EtOAc (15 mL) and the 
organic phase was washed in order with: 1 M KHSO4 (2×10 mL), aqueous NaHCO3 (2×10 
mL) and brine (2×10 mL), dried over Na2SO4 and volatiles were removed under reduced 
pressure. The residue was purified by flash chromatography on silica gel (DCM/MeOH 94:6) 
several times to afford the desired product as a white solid in mg scale. 
1H NMR (400MHz, CDCl3): δ=7.53 (d, J=8Hz, 1H), 7 .48-7.24(m, 5H), 6.89 (d, J=8.28Hz, 
1H), 6.70 (br s, 1H), 6.59 (br s, 1H), 5.10(m, 2H), 4.66(d, J=16.78, 1H), 4.68-4.35(m,3H), 
4.20-4.16 (m,2H), 3.94 (dd, J =13.11 Hz, J=3.04Hz, 1H), 3.40 (dd, J =13.01 Hz, J=4.41Hz, 
1H), 3.20 (m, 2H), 2.10-2.02(m,4H), 1.80-1.77(m, 1H), 1.61-1.57(m, 2H), 1.54-1.43(m, 3H), 
1.40-1.27(m,4H), 1.08(d, J=6.64Hz, 3H), 1.00 (d, J=6.73, 3H), 0.9-0.8(m, 9H)ppm. 13C NMR 
(100MHz, CDCl3): δ=172.8, 172.4, 172.2, 168.2, 164.3, 135.9, 129.2, 128.6, 128.3, 56.8, 
53.3, 52.4, 50.9, 50.4, 48.3, 46.4, 40.9, 39.6, 31.9, 30.3, 25.3, 23.3,22.9, 22.2, 20.4, 19.9, 19.4, 
18.0, 14.16 ppm. 
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AcVal-L-(Bn)Pca-Gly-LeuNBu (25 b): 
To a solution of Ac-L-Val (23 mg, 0.14 mmol) in dry DMF (200 µL) and collidine (18.5 µL, 
0.14mmol ), under a nitrogen atmosphere and at 0°C, HATU (53 mg, 0.14 mmol) was added. 
After 1h a solution of Pca-Gly-L-Leu-OMe TFA salt (43 mg, 0.093 mmol) in dry DMF (300 
µL) and DIPEA (24 µL, 0.14 mmol) was slowly added and the reaction was stirred at 0°C for 
10 minutes and at RT for a week-end. The mixture was diluted with EtOAc (15 mL) and the 
organic phase was washed in order with: 1 M KHSO4 (2×10 mL), aqueous NaHCO3 (2×10 
mL) and brine (2×10 mL), dried over Na2SO4 and volatiles were removed under reduced 
pressure. The residue was purified by flash chromatography on silica gel several times 
(DCM/MeOH 94:6) to afford the desired product as a white solid in mg scale. 
 
1H NMR ( 400MHz, CDCl3):δ=7.49 (d, J=7.7 Hz,1H), 7.34(d, J=7.08 Hz, 2H), 7.26 (d, J=6.7 
Hz, 2H), 6.8 (d, J=8 Hz, 1H), 6.61 ( m, 1H), 6.29 (m, 1H), 5.1 (dd, J=10 Hz, J=4.47 Hz, 2H), 
4.65(d, J=16 Hz,1H), 4.38(m,2H), 4.34 (s,1H), 4.18 (m,1H), 
4.16(s,1H),3.96(dd,J=12Hz,1H),3.83(s,1H), 3.66 (s,1H), 3.40 (dd, J=4 Hz, J=12.7 Hz, 1H), 
3.22 (m, 2H), 2.06 (s, 3H), 1.17 (m, 2H), 1.6 (m, 2H), 1.47(m, 2H), 1.34 (m,2H), 1.27(s, 1H), 
1.1 (d, J=6.6 Hz, 3H), 1.01(d, J= 6.6 Hz, 3H), 0.96 (d, J=6 Hz, 3H), 0.92(d, J=7 Hz, 6H) 
ppm.13C NMR (400MHz, CDCl3): δ=172.72, 172.22, 169.53, 169.28, 164.64, 129.25, 
128.80, 128.53, 56.87, 54.79, 52.62, 50.89, 48.53, 46.13, 44.13, 40.68, 39.69, 31.76, 30.36, 
30.13, 25.28, 23.56, 22.86, 21.85, 20.39, 19.37, 14.18 ppm. 
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Boc-Val-Pca-Gly-Leu-COOMe 26, 27. 
 
To a solution of Boc-L-Val (15 mg, 0.07 mmol, 1.5 eq) in dry DMF (200 µL) and DIPEA (16 
µL, 0.094 mmol, 2.0 eq), under a nitrogen atmosphere and at 0°C, HATU (27 mg, 0.07 mmol, 
1.5 eq) was added. After 1h a solution of PCA-Gly-L-Leu-OMe TFA salt (20 mg, 0.047 
mmol) in dry DMF (300 µL) and DIPEA (24 µL, 0.14 mmol, 3.0 eq) was slowly added and 
the reaction was stirred at 0°C for 10 minutes and at RT for a week-end. The mixture was 
diluted with EtOAc (15 mL) and the organic phase was washed in order with: 1 M KHSO4 
(2×10 mL), aqueous NaHCO3 (2×10 mL) and brine (2×10 mL), dried over Na2SO4 and 
volatiles were removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel (DCM/MeOH 94:6) to afford the desired product as a white 
solid (15 mg, 68% (L-Pca); 14 mg, 64% (D-Pca) 
. 
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Boc-Val-(D)-Pca-Gly-Leu-COOMe 26 
 
1H NMR (400MHz, CDCl3): δ=7.80 (br s, 1H), 6.79(d, J=4.8Hz, 1H), 6.66 (d, J=8.4Hz, 1H), 
5.24 (d, J=5.2Hz 1H), 5.16 (br s, 1H), 4.65-4.64 (m, 2H), 4.25(dd, J=16.8Hz,  J=6.0Hz, 1H), 
4.11-3.90(m, 2H), 3.89 (d, J=5.6Hz, 2H), 3.71 (s, 3H), 3.53 (dd, J =12.80 Hz, J=3.6Hz, 1H), 
2.02 (m, 1H), 1.64 (m,2H), 1.40 (s, 9H), 1.06 (d, J=6.8Hz, 3H), 1.01 (d, J=6.8Hz, 3H) 0.9 (m, 
6H)ppm 
 
Boc-Val-(D)-Pca-Gly-Leu-COOMe 26 
 
1H 
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Boc-Val-(L)-Pca-Gly-Leu-COOMe 27 
 
Two conformers in proportions 2 (conformer a) to 1(conformer b) 1H NMR (400MHz, 
CDCl3): δ=8.16 (br s, 1Hb), 7.53(br s, 1Ha), 7.37(br s, 1Ha), 7.25 (d, J=8.4Hz 1Ha), 7.00 (d , 
, J=8Hz,1Hb), 6.89 (d, J=4.8Hz 1Hb), 5.51(d, J=8.0Hz, 1Ha), 5.33 (d, 1Hb), 4.91-4.88 (m, 
1Ha and 1Hb), 4.66-4.42 (m, 4Ha and b), 4.28-4.08 (m, 3Ha and b), 3.99-3.79 (m, 1Ha and 
b), 3.77-3.72 (m, 5Ha and b) 1.64-1.49 (m, 3Ha and b), 1.43(s, 9Ha) 1.40(s, 9Hb), 1.31-0.86 
(m,12 H)ppm.  
 
Boc-Val-L-Pca-Gly-Leu-COOMe 27 
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VII - δ-AMINO ACIDS AS INDUCER OF SECONDARY 
STRUCTURES: 
 
 
VII-1 δ-amino acids and folding properties: 
 
VII-1.1 α-Helix peptidomimetics containing δ-amino acids 
 
As mentioned before, in the past years, the interest in a rational design of amino acid and peptide 
mimetics has extensively grown due to the pharmacological limitation of bioactive peptides. 
Numerous example of unnatural oligomeric sequences have been found that fold into well 
defined conformations in solution.1,2 Although the oligomers of β- and γ-amino acids are more 
extensively studied, experimental hints were also obtained for the formation of ordered structures 
in oligomers of δ-amino acids. However detailed structure information is still missing. 
Members of the δ-peptide family are isosteric replacements of dipeptide units. As such, this is the 
first member of the peptidomimetics lineage in which a single unit represents two or more α-
peptide repeats. Thus, δ-amino acid monomers are able to adopt the secondary structures of α-
peptide sequences, particularly helices and β-turns.  
In 2004, Hofmann and co-workers described on the basis of theoretical studies all possible helix 
types in oligomers of δ-amino acids (δ-peptides) and their stabilities.3 
Thus far, the chemical literature has mostly involved carbopeptoid backbones. In fact, 
carbohydrate research produced interesting examples of new δ-amino acids as building blocks for 
peptidomimetic design. Sugar amino acids can adopt robust secondary turn or helical structures 
and they can be used as substitutes for single amino acids or dipeptide isosters 1 (Figure VII-1).  
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Figure VII-1 : Comparison between the α-peptide subunit and the furanose-based subunit as a dipeptide isoster 
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Carbopeptoids,4 homooligomers of sugar amino acids, have been prepared from both furanose5 
and pyranose6 residues. 
Motivated by the fact that O-glycoside oligomers of sialic acid were helical in solution,7 Gervay 
and co-workers reported in 1998 that (1→5) amide-linked sialooligomers 2 longer than the trimer 
formed ordered secondary structures in water8 (Figure VII-2). The conformational features 
apparently varied with chain length. After circular dichroism (CD) studies9 and in combination 
with molecular modelling, the hypothesis was that for the shorter oligomers, 16-membered 
hydrogen-bonded rings stabilized a helix involving three residues per turn while for the octamer 
22-membered hydrogen-bonding stabilized a helix involving four residues per turn. More 
recently, Gervay synthesized also new neuraminic acid analogues.10  
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FigureVII-2. Amide-linked β-O-methoxy neuraminic acid oligomer. 
  
 
 
In 2005, on the basis of their conformational investigations, Fleet and co-workers described an 
octameric chain of carbohydrate amino acids 3 that adopt in solution a left-handed helical 
secondary structure stabilized by 16-membered (i, i – 3) interresidue hydrogen bonds11 (Figure 
VII-3). 
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Figure VII-3. Octameric chain of C-glycosyl α-D-furanose configured tetrahydrofuran amino acids 8. 
 
 
Huc and co-workers reported on the stable helical conformation adopted by oligomers of a new 
quinoline-derived δ-amino acid 4 (Figure VII-4).12,13 This class of aromatics foldamers present 
the advantage that the quinoline amino acid monomers are easily accessible, functionalizable, and 
assembled into oligoamides. These oligomers adopt unusually stable helical conformations even 
in polar solvents at high temperature.  
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FigureVII-4. Structure of quinoline-derived oligoamide foldamers. 
 
VΙΙ.1.2 δ-Amino-acids in turns : 
 
As they did for helical structures, Hofmann & al.3 envisaged  also the β-turns motif as folding 
possibility. The typical β-turn in α-peptides consists of four consecutive α-aminoacids. The most 
frequent one is characterized by a hydrogen bond between the peptidic CO of the first and the 
peptidic NH bond of the fourth amino acid, thus forming a 10-membered ring pseudo cycle. 
Since the first and the fourth amino acids are involved in periodic structures, the induction of the 
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β-turn is controlled predominantly by the second and the third amino acid. So that, the 
replacement of this dipeptide unit by a δ-amino acid could be suitable for the induction of β-
folded structures. In this case the C(β)-C(γ) of the δ-amino acid would replace the peptide linkage 
of the previous dipeptide. Hoffman’s calculations, showed in a first time that δ-amino acids 
introduced in α-amino acid sequences were possible inducers of β-I/βI’ and βII/βII’turns (see 
figure VII-5). 
 
 
Figure VII-5. Comparison of the βI-and β-II-turns of α-peptides with the two turn conformers C10VII and C10VIII of a 
blocked δ-amino acid constituent. 
 
They described in a second time, that the incorporation of these non proteinogenic amino acids 
could generate new turn types that are not permitted in natural amino acids because of the rigidity 
of the peptide bond. Finally, they confirmed that replacing the C(β)−C(γ) flexible single bond of 
δ-amino acids by a double bond would be suitable for the stabilisation of β-I/II turn mimics. 
This last structural alternative remark, has already been investigated, and experimental data have 
been reported in the past years. 
VII-1.2.1 Isosteres containing a double bond in C(β)-C(γ) position: 
 
The precocious work of Hann et al. in 1980,14 investigated the replacement of a peptide bond by a 
trans double bond to form Leu-enkephalin analogues and increase their stability toward proteases. 
They reported that from a structural point of view both double bonds and amide bonds were 
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showing similar bond distances, and angles, so that they could direct subsequent attached peptidic 
strands in a similar way (Figure VII-6). 
 
Figure VII-6. Spatial disposition of amide and trans–olefin bonds (distances in angstroms) 
 
 
Based on the previous work of Hann, Wipf and coworkers, reported in 1998,15 the evaluation of 
δ-amino acids containing in the C(β)-C(γ) place a (E)-double bond. It was established by X-ray 
studies that methyl and trifluoromethyl substituted alkenes provided highly preorganized peptide 
mimetics. The D-L methyl-(E)-alkene isostere 5 sequence prefers an intramolecularly H-bonded 
type-II’ β-turn in the solid state, whereas the trifluoromethyl analogue 6 representing a D-L 
sequence showed a preference for a type II β-turn. 
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CONHMe
BocHN CONHMe
CF3
5 6
 
FigureVII-7. Chimical structure of  the D-L methyl-(E)-alkene isostere and its trifluoromethyl analogue. 
 
 
Gardner et al. in 1995,16 and then in 1999, 17 reported a trans-5-amino-3,4-dimethylpent-3-enoate 
residue (ADPA) glycyl-glycine mimic promoting β-hairpin formation in solution. It came out of 
this study, that ADPA tetrasubstituted (E)-alkenes favours adoption of folded conformation in the 
corresponding tetrapeptide mimic 7, whereas disubtituted alkene (APA), more flexible was not 
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efficient. In this case, it seems that allylic strains present in ADPA is introducing rigidity in the 
tetramer and thus blocking the conformation (Figure VII-8).  
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Figure VII-8. APA and ADPA dipeptide isosteres and β-hairpin mimic tripeptide containing ADPA. 
 
VII-1.2.2 Linear δ-amino acids: 
 
Balaram and coworkers, in 2006,18examined crystal structure of tripeptides comporting δ-
aminovaleric acid (δ-Ava) in the i+1 position. In this study, the sequence Piv-Pro-δ-Ava-OMe 
does not fold into a β-turn like structure, in comparison with the model Piv-Pro-Gly-OMe that 
provoke in solid state a quasi perfect β-II turn (Figure VII-9).  
H2N OH
O
δ-Ava
 
 
 
 
Figure VII-9. δ-aminovaleric acid, Piv-Pro-Gly-OMe turn Piv-Pro-δ-Ava-OMe extended structure. 
 
 
In 2007,19the same group focussed on longer peptides, bearing one residue δ-Ava. The 
octapeptide Boc-Leu-Val-Val-DPro-δ-Ava-Leu-Val-Val-OMe was first analysed by NMR that 
did not achieve complete resolution of the structure. However, these previous conformational 
analyses were consistent with further crystal structure data, gaving the evidence that this peptide 
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was folding through a β-hairpin structure. As it is shown in FigureVII-10, it folds in an anti 
parallel hairpin form that contains a central DPro-δ-Ava (α-δ hybrid turn) stabilized by a C13 
hydrogen bond between the Vall3 CO and Leu7 NH groups. In the crystal structure, the turn 
structure was visible showing the arrangement of the δ-Ava chain, in an extended loop that 
spread the continuing strand close to the pyrrolidine ring. Although if the strands part of the 
molecule have shown to be similar in both solid and liquid state, but it was not possible to get any 
informations concerning the the turn region in solution because of a lack of NMR data and in 
particular NOE contacts. 
 
 
 
Figure VII-10. Molecular conformation of the peptide Boc-Leu-Val-Val-DPro-δ-Ava-Leu-Val-Val-OMe. 
Intramolecular hydrogen bonds are shown as dotted lines. Right: Side view of the molecule showing the pleated 
sheet formation (top) and ribbon representation. 
 
 
Nowick & al. described in 2003,20 a new stable turn structure involving δ-aminoacid: Ornithine 
(δOrn) 8 for the stabilization of further β-hairpin structures 10. To establish this feature two 
models were chosen for comparison. The first one came from Gellman & al.21 that had previously 
described a suitable DPro-Gly motif 9 as turn inducer efficient for further hairpin stabilisation. 
The second β-hairpin model was formed by two complementary α-amino acid sequences locked 
at the extremity by two δ ornithine segment 11 (see FigureVII-11). 
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Figure VII-11. (Right) Acyclic and cyclic β-hairpin analogues containing one or two Ornitine dervatives.  
(Left) D-Pro-Gly turn mimic and dOrn turn mimic. 
 
This study allowed the assignation of the unlinked β-hairpin in which the δOrnitine that was 
evaluated to be as good as DPro-Gly of Gellman (Figure VII-11), as reverse turn inducer and the 
hairpin was as folded as the locked one. The properties of such compound were then used for the 
design and synthesis of extended molecules as mimic of protein quaternary structure.22  
VII-1.2.3. Bicyclic dipeptide isosteres: 
 
In the last years, Guarna & al.23 focused on the development of a new class of bicyclic molecular 
scaffolds. BTAa (Bicycles from Tartaric Acid and amino acids) having a 3-aza-6,8-dioxabicyclo 
[3.2.1] octane as core structure, and amino acid side chain functionalities. These molecules reveal 
to be a good template for reverse turn inducer. Their properties were first demonstrated in cyclic 
peptides. In 2001,24 Guarna et al synthetized a cyclic peptide mimic of the loop extremity of the 
BBI protein 12 (FigureVII-12) containing a BTAa motif.  
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Figure VII-12. Representation of the BBI sequence and in particular, the part of the loop involved in inhibition of 
proteases in red showing a β-turn structure 
 
The modified BBI peptide containing the 7-endo-BTAa motif (Figure VII-12) led to only one 
NMR visible conformer. NMR analysis showed also high vicinal coupling constant JNH-αH and 
strong sequential NOE correlations which is convenient with extended conformations. Molecular 
modelling calculations and superimposition of both natural and mimic structures showed the 
hight similarity between both peptides. These observation lead to conclusion that 7-endo BTAa 
could be suitable as turn inducer (Figure VII-13). 
 
 
Figure VII-13. Turn inducing property of 7-endo-BTAa 
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In linear peptides, scaffolds deriving from the combination of leucinol and meso-tartaric acid 
have been used to test the reverse turn propensity of linear hexapeptidic sequences. Petides 
containing a BTAa scaffold in the central part of the peptide (see figure VII-14) 7-endo-BTL 
(Bicycle from Tartaric acid and Leucine ), having a leucine side chain at the 4-exo position, 
showed a mixture of rotamers. One of the rotamer showed a better organized structure, this was 
supported by sequential NOE contacts between NH and α-H protons indicating a β-strand 
organisation of the N-terminal main chain. This was reinforced by a 14- membered ring hydrogen 
bonded structure typical of β-hairpin like structure. The lack of the 10 membered ring H-bond in 
this particular case indicate that the driving force for nucleation of β-structure is here related to 
the scaffold structure.  
 
Figure VII-14. Comparison between natural reverse turn and its mimic containing endo-BTL, substituting both 
positions i+1 and i+2. 
 
 
VII-1.2.4. Sugar-amino acids as β-turn mimics: 
 
Von Roedern & al.25 reported in 1994, and in 1996,26 the design and synthesis of new dipeptide 
isosteres based on the sugar monomer H-Gum-OH a glucose derivative 13 (Figure VII-15). The 
cyclic structure of H-Gum-OH fixes the ωI angle at 180°, which corresponds to a trans amide 
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bond. The ϕ+1 angle is also fixed in a 180° angles; this is often found in β-sheet structures. 
According to its structure the H-Gum-OH was used to replace two neighbour natural amino acids 
in cyclic hexapeptides 14, derivatives of cyclic somatostatin analogues. Conformational analysis 
by NMR in solution, and molecular dynamics, lead to the described structure Figure VII-15. The 
hexapeptide show a β-II’turn type conformation were the sugar residue occupies the i+1 and i+2 
positions. In this case the peptidic ring is distinctly bent because of the steric repulsion of the ring 
oxygen and the carbonyl of the neighbour amino acid. In contrast in “normal” hexapeptides the 
two β-turns are almost coplanar. 
 
 
Figure VII-15. (Right) : corespondance between H-Gum-OH skeleton and angles with classical peptide structure. 
(Left) Turn like structure in cyclic hexapeptide containing H-Gum-OH in i+1 and i+2 position (image from MD 
simulations)  
 
The same work was applied to linear peptides, but in this case peptides showed a non folded 
structure. 
In 2000, Chakraborky and coworkers27 reported the design and synthesis of new peptidic turn 
mimic using new furanoid sugar amino acids 15 and 16. Furanoids sugars were incorporated in 
Leu-enkephalin analogues 18 at the place of two neighbouring glycine residues (Figure VII-16). 
Conformational analysis using NMR, molecular dynamics and circular dichroism showed that 
two of these analogues (containing the sugar Gaa and Iaa) displayed an unusual β-turn structure 
involving a C9 membered ring hydrogen bond between NH-Leu and C3 OH of the sugar. 
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Figure VII-16. Furanoid sugar amino acids and their analogues. Gaa=6-amino-2,5anhydro-6-deoxy-D-gluconic acid, 
Iaa=6-amino-2,5anhydro-6-deoxy-D-Idonic acid. 
 
It came out of these studies that the driving force for the turn nucleator depends not only from the 
restriction caused by the ring but also from the substitution of the ring, since unsubstituted furane 
were not able to fold. 
In the course of this year, Fleet and co-worker described oxetane amino acids and oligomers 19 
obtained from it28 (Figure VII-17). These  δ-2,4-cis-oxetane amino acid oligomers adopt well-
defined secondary structure in solution in which the major conformation is dictated by internal 
10-membered H-bonded rings.29 This β-turn motif is repeated along both the tetramer and 
hexamer. 
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Figure VII-17. Structures of homo-oligomers of  δ-2,4-cis-oxetane amino acid.  
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VIII - NEW δ-AMINO ACIDS TOWARDS NEW FOLDAMERS 
 
VIII-1  INTRODUCTION 
   
 
The folding of polypeptide chains into secondary and eventually into a bewildering array of 
tertiary structures results in protein molecules that are responsible for most of the biological 
interactions and functions found in nature. Therefore, peptides and proteins are attractive targets 
for drug design. Poor bioavailability and metabolic stability of peptidic drugs, however, have 
resulted in significant limitations. A logical next step is to mimic nature and create 
nonbiologically derived molecules that either fold into well-defined secondary structures, or 
assemble into larger architectures. The pioneering studies of Gellman and Seebach on β-peptides, 
a class of unnatural peptidomimetic folding oligomers, have demonstrated the feasibility of 
folding unnatural oligomers into well-defined conformations. Extending the concept of β-
peptides has led to other peptidomimetic foldamers such γ-peptides30,31 and δ-peptides.8 
In the presented work we are interested in δ-amino acids towards new foldamers. 
As mentioned in the chapter VII, δ-amino acid residues 20 are isosteres of dipeptide elements in 
α-peptides 21 (Figure VIII-1). 
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Figure VIII-1. Comparison of δ-amino acid residues 20 with α-dipeptide elements 21. φ, ψ, θ, ζ, ρ, ω are the 
backbone torsion angles. 
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Therefore, δ-amino acids are potential surrogates for α-dipetides and can be useful to improve 
the resistance of natural peptide chains toward degradation by proteases. 
There are some examples of the incorporation of a single δ-amino acid into  longer natural amino 
acid sequences,32-34 but most of the cases deal with sequences based on repeating δ-amino acid 
units, particularly on sugar amino acids derived from furanose35 and pyranose.6 In fact, homo-
oligomers of sugar amino acids have been extensively studied and provide many examples of 
foldamers.6,11,29,36 
Oligomers of different types of amino acids are also important in conformational design and can 
be potentially useful to obtain new foldamers. Our approach presented in this chapter is based on 
the synthesis of peptides containing α- and δ-amino acids with different chain length and α-amino 
acid composition. 
 
 
VIII-2.   Model peptides containing δ-amino acid units 
 
VIII-2.1.   Previous work in the laboratory 
 
The application of unnatural building blocks to induce a predictable conformation requires the 
investigation of their conformational preferences. 
In our group we investigated the conformational preferences of peptide mimics containing the 
two enantiomers of a novel δ-sugar amino acid 22 and 23 (FigureVIII-2). The synthesis of both 
enantiomers was previously developed by M. Haque in our group.37  
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Figure VIII-2. (S,S)-22 and (R,R)-23 enantiomers of a novel δ-sugar amino acid. 
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The key intermediate 25 was obtained starting from inexpensive furan-2-carboxylic methyl ester 
24 in four steps by using a procedure that has been previously developed in our group.38 
Treatment of γ-butyrolactonaldehyde 25 with 4-methoxybenzylamine to form the corresponding 
imine, followed by reduction with NaBH4 provided the amine 2639 in 76% yield. N-Boc 
protection afforded the protected amine 27,40 in which the PMB group was removed with CAN to 
give the carbamate 2841 in 79% yield. Finally, ruthenium catalyzed oxidative cleavage of the 
allylic double bond with NaIO4 gave the δ-amino acid enantiomers 22 and 2342 in 86% yield 
(Scheme VIII-8).  
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Scheme VIII-8. Synthesis of compounds 22 and 23. Reagents and conditions: 
 
a) (i) Na2SO4, 4-methoxybenzylamine (1.1 equiv), CH2Cl2, 3 h; (ii) NaBH4 (2equiv), MeOH, H2O, 0 °C, 30 min, 76%;
b) (Boc)2O, dioxane-1M K2CO3 (1:1.2), r.t., overnight, 74%; c) CAN (4 equiv), CH3CN-H2O (1:3), 0 °C, 1 h and 
r.t., 2 h, 79%; d) RuCl3. 3 H20 (6 mol%), NaIO4 (4.0 equiv), CCl4-CH3CN-H2O (1 : 1 : 2), 0 °C, 1 h and r.t., 2 h, 86%.
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Delatouche and Bordessa synthesized two α-δ pentapeptides 29 and 30 (FigureVIII-3) using the 
scaffolds 22 and 23, respectively, which were alternated with the natural amino acid 
phenylalanine. In addition, Bordessa synthesized heptapeptide 31 using the R,R enantiomer and 
phenylalanine (FigureVIII-3). 
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Figure VIII-3. Pentapeptides containing α-δ amino acids 29 and 30 and heptapeptide 31. 
 
The aim of our work has been to investigate the conformational analyses of the two pentapeptides 
29 and 30, and of the heptapeptide 31, in order to determine their secondary structure preferences. 
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VIII-2.2.   Conformational investigations  
 
The conformation of peptides depends principally on their amino acidic composition and on the 
sequence of these amino acids. As the physical and biological properties of peptides are 
determined by their structure, the knowledge of the latter is essential to understand these 
properties. There are many techniques to investigate the three dimensional structure of peptides. 
FT-IR and CD spectroscopy are important tools to indicate the presence or absence of secondary 
structure elements, while NMR spectroscopy and X-ray crystallography allow a detailed 
description of the localization and spatial arrangement of such elements within the amino acid 
sequence. However, for the X-ray crystallography single crystals are needed, and there always 
exists the possibility of a difference in the conformation between the solid state and the one seen 
in solution. In the present work we employed NMR, CD, FT-IR spectroscopy, and molecular 
modelling to characterize the peptides synthesized.  
 
NMR investigation 
 
The most common and useful tool to investigate the secondary and tertiary structure of peptides 
and proteins in solution is the Nuclear Magnetic Resonance (NMR) spectroscopy.43NMR 
spectroscopy allows an investigation of the structure of biopolymers on an atomic level in 
solution. Moreover, NMR investigations can highlight the presence of conformational equilibria 
and the dynamics of the folding. Important structural information can be obtained from both 
mono- and bidimensional NMR spectra. 
 
Information from 1D-proton NMR spectra 
 
Even though the NMR-spectra of biopolymers are derived from the nuclear spins of the 
monomers thea are build up from, there is no straightforward correlation between the NMR 
spectra of the low molecular weight components and the three-dimensional strucutre of the whole 
polymer.43 A dispersion of nucleus’s chemical shift values is the first indication of the presence 
of spatial folding in a peptide chain. When a peptide has a defined conformation in solution, a 
proton in the sequence will have a different microenvironment compared to those in a random 
coil structure. It will also be different from the same proton contained in an identical residue type 
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at a different point in the sequence. This fact leads to different specific chemical shift values 
compared to those for an unfolded structure and to a good dispersion of the signals. 
The presence of a secondary structure in solution can lead to a slower exchange rate for labile 
protons, which can be measured by time dependent NMR-spectroscopy, while in small molecules 
proton exchange is too fast to be observed. Moreover the slower diffusional motions of the 
macromolecul in solution can substantially affect the spin relaxation and the Nuclear Overhauser 
Enhancement (NOE).43 The presence of hydrogen bonds can be detected from onedimensional 
NMR spectra. These techniques are based on the assumption that the NHs involved in a H-bond 
are less sensitive to perturbations such as changing of temperature, concentration or solvent, than 
the NHs that are exposed to the solvent. The determination of the temperature coefficients 
(∆δ/∆T) for the amide protons is based on the observation that, upon warming, NHs involved in 
hydrogen bonds display shifts at a smaller extent than the NHs that are exposed to the solvent. 
Generally, values of -∆δ/∆T > 3 ppb/K indicate amide protons in an equilibrium between a 
hydrogen-bonded and a non-hydrogen-bonded state, while values of -∆δ/∆T < 2.6 ppb/K are 
considered an indication of hydrogen-bonded NH protons or of NH protons locked in a 
hydrogen-bonded conformation.44  
The secondary structures of peptides are characterized by distinct torsion angles along the 
backbone. Since the size of the spin-spin coupling constant 3JHN-Hα depends on the torsion angle 
NH-CHα, on the basis of Karplus relationship, the measurement of 3JHN-Hα is useful for secondary 
structure determination, as it can be directly related to the backbone dihedral angle φ.43,45 
Generally, 3JHN-Hα values < 6 Hz indicate turn or helical conformations, whereas values higher 
than 6 Hz are referred to unordered structure or an extended conformation (Figure VIII-3).     
 
Figure VIII-3: Table of the 3JHN-Hα values in regular secondary structures43  (left side). Torsion angles φ and ψ 
present along the backbone of a α-peptide (right side).  
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Information from 2D-proton NMR spectra 
 
The most useful data relating to a peptide conformation is gained from 2D-NMR investigation. 
Of particular interest are the correlation spectroscopy (COSY), total correlation spectroscopy 
(TOCSY) and NOE spectroscopy/rotational frame NOE (NOESY/ROESY) experiments.  
The cross peaks observed in the COSY spectrum correspond to proton-proton correlations due to 
scalar (through-bond) couplings, though the respective protons may only be separated by a 
maximum of three covalent bonds. The TOCSY spectrum contains all correlations between 
protons of one spin system and in the case of peptides each amino acid has a particular spin-
system pattern that allows the identification of every residue type in the sequence. With the help 
of these two experiments, it is possible to assign completely all the chemical shifts of the protons 
in a peptide. Further, NOESY experiment displays cross peaks due to dipolar coupling resulting 
from through space interactions. NOESY cross peaks depend on the distance between two 
protons and occur between two nuclei that are close in the space up to 5 Å.A NOE cross peak 
indicates that two non-covalently bonded nuclei are close enough to interact or to exchange. NOE 
cross peaks are usually defined as sequential distances when they are between backbone protons, 
or between a backbone proton and a β proton of residues that are nearest neighbours in the 
sequence. Medium-range distances are all non-sequential signals between residues within a 
segment of five consecutive residues. Long-range distances are between the backbone protons of 
the residues that are at least six positions away in the sequence.43 Depending on the torsion angles 
that characterize the secondary structure of a peptide, sequential and medium-range proton-
proton distances will have different values.For instance the sequential NH-NH and CHα-NH 
contacts for a regular α-helix are about 2.8 and 3.5 Å, respectively. The CHβ-NH contacts, since 
they depend also on the torsion angle on the side chain χi, vary between 2.5 and 4.1 Å for a α-
helix.43 Medium-range contacts in helices are usually i,i+2, i,i+3, and i,i+4. In particular i,i+4 
contacts are especially useful since they are present in a regular α-helix and not in a 310-helix. 
Tight turns have close i,i+2 values. In the case of β-structure short medium-range distances are 
not observed, since the polypeptide segments are almost fully extended.43 Table VIII-1 lists short 
sequential and medium-range distances that are found in known α-peptide conformations. 
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Table VIII-1. Short sequential and medium-range 1H-1H distances in some common secondary structures in α-
peptides.43 
 
 
Circular dichroism 
 
Circular Dichroism (CD) spectroscopy is an important technique to investigate the secondary 
structure of proteins and peptides. It is based on the differential absorption of left and right 
circularly polarized light. To deliver a CD signal, a compound has to possess a chromophore, 
which is either inherent chiral or surrounded by a chiral environment and absorbs in the observed 
wavelength range. These prerequisites are met by the amide bond in peptides and proteins, 
rendering the CD spectroscopy a suitable methodology for the elucidation of their structural 
preferences. The observed bands in the CD spectra of peptides and proteins stem from the n → π*  
and the π → π*
 
transitions of the amide bonds.
 
Every secondary structure gives rise to a specific 
CD spectrum that represents a survey upon the averaged overall structure of a peptide or protein, 
while it is impossible to assign structural preferences to an individual residue (Figure VIII.4). 
However, algorithms based on protein and peptide reference data sets enable the calculation of 
the secondary structure elements composition of a peptide/protein from its CD spectrum.  
In addition to the far-UV region over the range 190-250 nm, also the near-UV region from 250 to 
320 nm can deliver useful information, as it shows the contribution of aromatic residues like 
tyrosine or tryptophan.46,47
  
 
Distance α-helix 310-helix      β-sheet 
dαN 3.5 3.4           2.2 
dαN(i,i+2) 4.4 3.8  
dαN(i,i+3) 3.4 3.3  
dαN(i,i+4) 4.2   
dNN 2.8 2.6  4.2-4.3 
dNN(i,i+2) 4.2 4.1  
dβN 2.5-4.1 2.9-4.4  3.2-4.7 
dαβ(i,i+3) 2.5-4.4 3.1-5.1  
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Figure VIII.4: CD spectra characteristic for common secondary structure elements (adapted from Greenfield).48 
 
 
The molar ellipticity [Θ]
λ 
at the wavelength λ is defined as follows (Equation 1):  
 
Θ Deg . cm2
   dmol
 100 . Ψ
  l . c
=λ
       Equation 1      
 
where Ψ is the deviance of left- and right-circularly polarized light in degree, l the cell length in 
cm and c the peptide concentration in M. To compare peptides with different chain lengths, the 
molar ellipticity per residue is used, which is obtained by dividing [Θ]
λ 
by the number of amino 
acids. The CD bands characteristic for helical peptides at 190, 208 and 222 nm stem from the π 
→ π* 
 
transition (190 nm and 208 nm are the components perpendicular and parallel to the helix 
axis, respectively) and n → π* transition (222 nm), with the latter being sensitive to hydrogen 
bond formation.49
 
The ratio R between the two minima at 222 and 208 nm can be used as an 
indicator for the presence of interacting helices, as the band at 208 nm, corresponding to the 
parallel component of the π → π*  transition, changes its energy upon an interhelical interaction. 
Ratios larger than 1 are commonly regarded as the result of interacting helices, as found in coiled 
coil structures, while ratios lower than 1 indicate the presence of non-interacting helices.50
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Conformational analysis  
 
In the presented work by using the Sybyl program (version 7.0) we carry out computer 
simulations in the hope of understanding the properties of assemblies of molecules in terms of 
their structure and the microscopic interactions between them. This serves as a complement to 
conventional experiments, enabling us to learn something new. Molecular structures generated in 
silico have to be geometry optimized to find the individual energy minimum state by applying a 
molecular mechanics method. This is a method employed to calculate molecular geometries and 
energies. In the framework of the molecular mechanics method the atoms in molecules are treated 
as rubber balls of different sizes (atom types) joined together by springs of varying length (bonds). 
For calculating the potential energy of the atomic ensemble Hooke’s law is used. In the course of 
a calculation the total energy is minimized with respect to atomic coordinates where: 
 
Etot = Estr + Ebend + Etors + Evdw + E elec 
 
where Etot is the total energy of the molecule, Estr is the bond-stretching energy term, Ebend is the 
angle-bending energy term, Etors is the torsional energy term, Evdw is the van der Waals energy 
term, and E elec is the electrostatic energy term. Molecular mechanics enables the calculation of 
the total steric energy of a molecule. The set of parameters consisting of equilibrium bond lengths, 
bond angles, partial charge values, force constants and van der Waals parameters is known as the 
force field. In our work was used the MMFF94 Force Field51 that was developed as a combined 
"organic/protein" force field, one which was equally applicable to small molecules as well as 
proteins and other systems of biological importance. 
The technique known as energy minimization is used by molecular mechanics only to find the 
local energy minimum but not implicitly the global energy minimum. Lower energy states are 
more stable and are commonly investigated because of their role in chemical and biological 
processes.  
Molecules can be modelled either in vacuum or in the presence of a solvent. Simulations of 
systems in vacuum are referred to as gas-phase simulations, while those that include the presence 
of solvent molecules are referred to as explicit solvent simulations. In another type of simulation, 
the effect of solvent is estimated using an empirical mathematical expression; these are known as 
implicit solvation simulations. In our work the molecular modelling was performed in vacuum.  
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As mentioned before, the use of theoretic methods to obtain models that allow predicting 
structures, properties and molecular interactions is known as “Molecular Modelling”. 
Molecular Modelling provides information that is not available directly from conventional 
experiments, thus it has a complementary role in the field of the experimental chemistry. 
There are several simulation technique methods: quantum chemistry, molecular mechanics, 
molecular dynamics (MD).  
It is known that the structures with lower energy states are more stable and take a part in 
chemical and biological processes. Molecular dynamics simulation offers an effective tool to 
detect the energetically most favored 3D structure of a system. 
 
In our work simulations incorporating NOE derived distance constraints as well as “free” 
dynamics were investigated in vacuum (gas-phase simulations). MD calculations were performed 
using Sybyl program (version 7.0) with MMFF94 force field. The temperature was increased 
progressively from 300 to 700 K and the time period of each simulation was 222 ps, where a 
molecule was extracted every 500 steps. Among the resulting structures those energetically 
favored were then minimized and analyzed. 
 
 
FT-IR spectroscopy 
 
Infrared light is energetic enough to excite molecular vibrations to higher energy levels. The main 
characteristic bands of the peptide group are called amide A, amide I and amide II. Evidence 
exists that the position of these bands is related to the conformation of the peptide.52 The amide A 
band is mainly due to the N−H stretching vibration. It is very sensitive to the strength of a 
hydrogen bond, thus providing an opportunity to gain information about any intra- or 
intermolecular hydrogen bond. Usually, in a non polar solvent, non hydrogen-bonded NHs adsorb 
above 3400 cm-1, while NHs that are involved in hydrogen-bonds absorb below 3400 cm-1.53 The 
amide I and II bands are related to the backbone conformation. The amide I is associated with the 
C=O stretching vibration, while the amide II results from the N–H bending and from C–N 
stretching vibrations. 
 
 174 
 
 
Table VIII.2. Frequencies (cm-1) of the amide I and amide II bands found for different α-peptide conformations. 
 
 
VIII-2.3.   Results on alternated α/δ amino acids  
 
The pentamer containing alternated (S,S)-δ-amino acid and phenylalanine was analyzed by NMR 
in both CDCl3 and methanol-d3 solvents. Comparing both analyses at different temperatures, the 
spectrum in CDCl3 seemed to be less comprehensible than the spectrum in methanol-d3, showing 
a lower dispersion of the NH signals, and higher temperature coefficients (-∆δ/∆T > 10ppb/K). 
We therefore present here only the analyses performed in methanol-d3. This choice was also 
supported by the CD experiment, where the CD curve appeared to be much more defined in 
methanol than in TFE. Thus, the synthesized α/δ-peptide 29 (Figure VIII.5) was dissolved in 
methanol-d3 and studied by NMR spectroscopy. 1D experiments were first acquired at five 
different temperatures (273, 278, 283, 293 and 303 K), and the one that gave the better resolved 
spectrum (283 K) was chosen to record the 2D experiments. The complete 1H-NMR resonance 
and sequence assignments were done by using the COSY, TOCSY and ROESY spectra. 
Sequential and interresidue NOE cross-peak intensities were classified as strong (1.8-2.7 Å), 
medium (1.8-3.3 Å) and weak (1.8-5 Å) based on the number of contours in the contour plot of 
the ROESY spectrum. The NOE contacts observed for this peptide are shown in Figure VIII.5.  
 
 
 
 
 
 
 
 175 
O
N
H
ONH
O
O
N
H
O
N
H
O
O
O
O
O
N
H
O
O
F1 X2 F3 X4 F5
29 S,S enantiomerδ-amino acid:
 
 
Figure VIII.5  Summary of the interresidue NOE contacts observed for the peptide 113 in methanol-d3 at 283 K 
(pink arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
The values of the 3JHN-Hα coupling constants were estimated in the 1D 1H-NMR spectrum and 
these vicinal coupling constants showed always values bigger than 6 Hz (Figure VIII.6).  
Amide protons showed high temperature coefficients (Figure VIII.6), suggesting a non-hydrogen-
bonded state. However, studies of deuterium exchange in methanol-d4 showed a slow 
disappearance of one or both amide protons of the lactone residues. The presence of the hydrogen 
bond possibility in this molecule was confirmed by IR experiments in CH2Cl2, which showed two 
bands in the amide region: a broad and intense band at 3311 cm-1 in the H-bonded region, and a 
weaker one at 3420 cm-1.  
 
 
 
 
Figure VIII.6: Variable temperature studies in methanol-d3 of peptide 29. 
 
 
 
-∆δ (ppb)/ 
∆T(K) 
3JHN-Hα (Hz) 
 
NHF1 10.3 7.2 
NHX2 7.1   
NHF3 8.3 6.9 
NHX4 7.1   
NHF5 8.1 8.2 
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Molecular modelling was performed using molecular dynamics experiments in vacuum. 
Introduction of four of the NOE contacts found in the ROESY spectrum as constraints in this 
experiment gave the structure shown in Figure VIII.7 as the conformational energetic minimum, 
which is characterized by a large loop locked at the extremities by two hydrogen bonds. 
 
 
 
 
Figure VIII.7: Structure of low-energy conformer calculated for peptide 29. Hydrogen bonds are indicated with 
dashed lines and all hydrogen atoms have been omitted for clarity. 
 
The CD spectrum in methanol at 0.1 mM showed two maxima at 200 and 219 nm that were not 
comparable with any data in the literature (Figure VIII.8). 
 
Figure VIII.8: CD spectrum of the pentapeptide 29 in methanol. 
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The pentamer containing alternated (R,R)-δ-amino acid and phenylalanine 30 (Figure VIII.9) was 
analyzed by NMR in both CDCl3 and methanol-d3 solvents. Due to  low solubility and low 
dispersion of the signals in methanol, we used only the analyses in CDCl3. The synthesized α/δ-
peptide 30 was thus dissolved in CDCl3 and studied by NMR spectroscopy. 1D experiments were 
first acquired at five different temperatures (278, 283, 288, 293, 298 and 303 K), and the one that 
gave the better resolved spectrum (288 K) was chosen to record the 2D experiments. The 
detected NOE contacts are shown in Figure VIII.9. 
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Figure VIII.9: Summary of the interresidue NOE contacts observed for the peptide 30 in methanol-d3 at 288 K (pink 
arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
In comparison with the pentamer containing the (S,S)-δ-amino acid, this oligomer had a better 
dispersion of the signals in the 1H spectrum with no overlapping of the NH amides, and the 
ROESY spectrum allowed us to find numerous NOE contacts that are reported in Figure VIII.9. 
In counterpart, we could see the presence of more than one conformer. We focused our study on 
the major conformer. NMR analyses showed amide protons at high ppm values (between 7.4 and 
8.4 ppm), which is characteristic of protons involved in hydrogen bonding. However, -∆δ/∆T 
were quite high, ranging between 6 and 10.4 ppb/K, and also the 3J coupling constants were 
higher than 6Hz (Figure VIII.10). 
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Figure VIII.10: Variable temperature studies in methanol-d3 of peptide 30. 
 
 
The CD spectrum was recorded in TFE (0.3 mM) and gave two maxima at 203 and 218 nm 
(Figure VIII.11). 
 
 
Figure VIII.11: CD spectrum of the pentapeptide 30 in methanol. 
 
Finally, molecular dynamics experiments, taking into account eleven NOE contacts, afforded the 
structure shown in Figure VIII.12 corresponding to the energetic minimum. 
 
 
 
−∆δ(ppb)/ 
∆T(K) 
3JHN-Hα (Hz) 
 
NHF1 2.0 7.2 
NHX2 8.8   
NHF3 10.4 6.9 
NHX4 6.0   
NHF5 8.8 8.2 
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Figure VIII.12: Structure of the low-energy conformer calculated for peptide 30. For clarity hydrogen bonds are 
omitted. 
 
The heptamer containing alternated (R,R)-δ-amino acid and phenylalanine was analyzed by 2D 
NMR only in CDCl3, since it was insoluble in methanol. In this solvent it showed a high 
dispersion of the signals, as well as numerous NOE contacts, among them long range ROE 
contacts were also detected. We can remark that the major part of the contacts were found in the 
N-terminal part of the molecule (Figure VIII.13): in particular, we detected contacts between two 
non neighbouring lactones, which gave indication about an eventual organisation of this part of 
the molecule. However, we could not see any repetitive contacts that would have been an 
evidence for the presence of a periodic structure.  
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Figure VIII.13: Summary of the interresidue NOE contacts observed for the peptide 31 in CDCl3 at 292 K (green 
arrows: medium NOEs; blue arrows: weak NOEs). 
 180 
Here again ∆δ/∆T coefficients adopt quite high absolute values between 7 and 8 ppb/K, excepted 
for the third lactone and the Boc terminal phenylalanine, and 3J coupling constants were also 
quite high, excepted for F5 that showed a 3J of 4.8 Hz (Figure VIII.14).  
 
 
 
 
Figure VIII.14: Variable temperature studies in CDCl3 of peptide 31. 
 
IR in solution was performed in CH2Cl2 at low concentration showing in this case again two 
bands, a weak one at 3420 cm-1 representing the non hydrogen-bonded amide, and an intense 
band at 3300 cm-1, reflecting the presence of amide protons involved in hydrogen bonds. To gain 
further information about the amide protons involved in hydrogen bonding, we tried for the 
penta- and heptapeptides containing the (R,R)-δ-amino acid to perform solvent competition 
experiments, by progressive addition of DMSO in the NMR tube and controlling the changing in 
the chemical shifts. Unfortunately, this experiment failed due to the fact that by adding DMSO 
we were not able anymore to assign the amide protons. Deuterium exchange experiments 
revealed to be unrealisable, since our compounds were precipitating upon addition of minimum 
amounts of methanol-d4. Molecular dynamics was performed including seventeen constraints 
taken from NOE contacts. Two pictures of the energetic minimum are represented below 
showing in the first segment, containing Boc-Phe-Lac-Phe-Lac-Phe, a folded part that describes a 
first loop of helix, while the folding in the C-terminal part seems to be disrupted from the last 
lactone. One reason for the loss of the folding properties in C-terminal part of the peptide could 
 
 
 
−∆δ(ppm)/ 
∆T(K) 
 
3
JHN-Hα (Hz) 
NHF1       0.7        9.6 
NHX2       7.8   
NHF3       7.7        8.4 
NHX4       7.3   
NHF5       7.8        4.8 
NHX6       3.9   
NHF7       7.2        7.2 
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be the high spatial freedom of the benzyl ester group that directs the C-head of the peptide in 
another direction. This is particularly evident in the second view of the structure, in which we can 
see the compact helical structure imposed by the two first lactones X2 and X4, followed by a 
reversal of the structure in the C-terminal part (Figure VIII.15). 
 
 
 
 
 
 
Figure VIII.15: Two views of the structure of low-energy conformer calculated for peptide 31. For clarity hydrogen 
bonds are omitted. 
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In contrast to the CD spectra of the pentamers, the CD spectrum of the heptamer in TFE at 0.5 
mM showed only the maximum at 218 nm, whereas the second maximum near 200 nm found for 
the pentamers disappeared (Figure VIII.16). This might be indicative of the presence of an 
ordered structure stabilized by the longer peptide chain.  
 
 
 
FigureVIII.16: CD spectrum of the heptapeptide 31 in TFE. 
 
The results presented above on the conformational analysis of three peptidomimetics containing  
aromatic α-amino acids alternated with polar δ-amino acids suggest that these δ-amino acids have 
the potential to induce structural motifs, which, however, differ from those typically adopted by 
α-peptides. Interestingly, peptides containing the (S,S)-δ-amino acid showed major solubility in 
methanol, also showing better folding properties in polar solvents. In contrast, peptides 
containing the (R,R)-δ-amino acid showed better folding properties in non polar solvents. 
According to the numerous NOE contacts found in the analysis of pentamer and heptamer 
containing the (R,R)-δ-amino acid, this enantiomer is likely to have better folding properties than 
the S,S enantiomer. Finally, increase in the length of the peptide sequence led to a stabilization of 
the secondary structure. 
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VIII-3  New peptides containing δ-amino acids: Objectives and design  
 
 
After the results obtained with peptides 29, 30, 31 (Figure VIII.3), we decided to synthesize 
further α/δ-peptides containing a variety of -amino acids ranging from apolar to charged residues. 
This should avoid the overlapping of the signals in NMR spectra  and lead to peptides with 
different properties. In the case of 32 (Figure VIII.16), we modified the sequence by increasing 
the number of positively charged residues. Thus, two lysines and one glutamine were alternated 
with δ-units. To investigate the effect of our scaffold on the secondary structure of longer 
peptides, we carried out the synthesis of peptides 33 and 34 (Figure VIII.16), which contain both 
apolar and polar α-amino acids. The synthesis and the results of the 2D-NMR, CD, FT-IR 
measurements and of the molecular modelling will be shown and discussed in the following 
paragraphs.  
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Figure VIII.16. Lactone containing peptides 32, 33 and 34 that have been synthesized and investigated in this work. 
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VIII.4   Synthesis of peptides 32-34 
 
The model peptides containing the enantiomers (S,S) or (R,R) of our lactone-scaffold that were 
synthesized and investigated in the course of this study are shown in Figure VIII.16.          
The synthesis of the building block, being suitably functionalized to be introduced in peptides, 
has been carried out as developed in our group from γ-butyrolactonaldehyde 25 in 
enantiomerically pure form (S,S)37-35 and (R,R)-36 (Figure VIII.17 ).  
 
NHFmoc
OO
O
OH
OO OH
O
NHFmoc
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CHO
24
35
36
(S,S) enantiomer
(R,R) enantiomer
 
 
Figure VIII.17. Pentalactone building blocks 35 and 36 for peptide synthesis. 
  
 
Synthesis of Fmoc protected δ-amino acid (R,R) 36. 
 
The synthesis of the Fmoc protected δ-amino acid (R,R)36 is described in Scheme VIII.9 36 was 
synthesized starting from (R,R) lactone 23 (Figure VIII.2), by cleavage of the Boc protecting 
group with TFA in dry CH2Cl2. The resulted product 37 was treated with Fmoc-OSu in dioxane-1 
M K2CO3 to afford the desired compound in  moderate yield (60%). 
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Scheme VIII.9.  Synthesis of  the Fmoc protected δ-amino acid 36. Reagents: 
a) TFA, dry CH2Cl2, 100%; b) FmocOSu, dioxane-1M K2CO3 ( 1 : 2), 60%.
 
 
 
Synthesis of alternated α/δ-unit peptides 
 
The peptides 32-34 were synthesized, as shown in Schemes VIII.10 and 11, using a solid phase 
protocol. The solid phase synthesis can be commonly performed by using two alternative 
protecting groups, tert-butyloxycarbonyl (Boc)54 and fluorenyl-9-methoxycarbonyl (Fmoc),55,56 to 
mask the α-amino group of the amino acid only temporarily to allow further chain elongation. 
Generally, the Fmoc strategy is more suitable for solid phase synthesis, as the Fmoc group is a 
base-labile protecting group which can be removed using secondary amines like piperidine and 
the cleavage of the peptide from the resin occurs under mild acidic conditions. Another very 
important advantage of the Fmoc group is its stability upon different conditions used to remove 
side-chain protecting groups, including strong acidic or reductive conditions. 
The products presented in this work were synthesized by manual coupling using Fmoc chemistry 
on Rink amide MBHA resin 38 (loading 0.6 mmol g-1) (Figure VIII.18). The resin was in the 
Fmoc-protected form and, for this reason, to obtain N-free linker, the resin was treated with 
piperidine in DMF/NMP (80:20 v/v).  
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Figure VIII.18. Rink amide MBHA resin 38.  
 
In the case of peptide 32 the synthesis is outlined in Scheme VIII.10, and was performed with 
(S,S)-δ-amino acid. The first amino acid (4 equiv.), lysine, was coupled activating in situ the 
carboxylic function with HBTU (3.9 equiv.), HOBt (4 equiv.) in DMF/NMP (80:20 v/v), in the 
presence of DIPEA (8 equiv.). Fmoc cleavage was accomplished by treating the peptidyl-resin 
with 20% piperidine in DMF/NMP (80:20 v/v). For the coupling of the second amino acid, 
Fmoc-δ-amino acid, 2.5 equiv. excesswere used, together with HBTU (2.4 equiv.), HOBt (2.5 
equiv.) in DMF/NMP (80:20 v/v), and DIPEA (5 equiv.). The following steps, the Fmoc 
deprotection and the coupling of glutamine, were done with the same conditions used for lysine. 
To monitor the progress of the synthesis, small scale cleavage was performed and the resulting 
sample was analyzed by MALDI-ToF-MS. To avoid a potential lactone ring opening, we decided 
to use milder conditions for the Fmoc deprotection (only 15% of piperidine in CH2Cl2 for 3 min. 
instead of 20% for 5 min. in DMF/NMP) and to change the coupling conditions for the second 
Fmoc-δ-amino acid: DIC (2.5 equiv.) and HOBt (2.5 equiv.) in CH2Cl2 without base. After the 
coupling of the second lysine and the Fmoc deprotection, the last step was the N-terminal 
acetylation using acetic anhydride (5 equiv.) and DIPEA (2.5 equiv.). Final cleavage of the 
peptide from the resin and simultaneous side-chain deprotection was achieved by treatment with 
a TFA/water/TIS mixture (90:5:5) for 2.5 hours. The peptide was then precipitated from ice-cold 
diethyl ether, centrifuged and subjected to three ether-washing/centrifugation cycles to remove 
the scavengers. The characterization was performed by HPLC and MALDI-ToF-MS.  
 188 
 
Fmoc-NH
NH2
Fmoc-Lys(Boc)
linker
Fmoc-Lys(Boc)-OH
HBTU, HOBt, DIPEA in DMF/NMP 8:2  
1) 20% piperidine in DMF/NMP 8:2
2) Fmoc-δ-amino acid-OH
    HBTU, HOBt, DIPEA in DMF/NMP 8:2
Fmoc-δ-amino acid-Lys(Boc)
1) 20% piperidine in DMF/NMP 8:2
2) Fmoc-Gln(Trt)-OH
    HBTU, HOBt, DIPEA in DMF/NMP 8:2
1) 15% piperidine in CH2Cl2
2) Fmoc-δ-amino acid-OH
    DIC, HOBt in CH2Cl2
Fmoc-Gln(Trt)-δ-amino acid-Lys(Boc)
Fmoc-δ-amino acid-Gln(Trt)-δ-amino acid-Lys(Boc)
1) 15% piperidine in CH2Cl2
2) Fmoc-Lys(Boc)-OH
    HBTU, HOBt, DIPEA in DMF/NMP 8:2
1) 15% piperidine in CH2Cl2
2) Ac2O, DIPEA
Ac-Lys-δ-amino acid-Gln-δ-amino acid-Lys-CONH2
TFA:H2O:TIS 90:5:5
Fmoc-Lys(Boc)-δ-amino acid-Gln(Trt)-δ-amino acid-Lys(Boc)
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Scheme VIII.10. Solid phase synthesis of 32 using the Fmoc chemistry. 
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In the case of peptides 33 and 34 containing (R,R)-δ-amino acid, the solid phase protocol used 
was the same as the one just described for 32, but this time only DMF was used as the reaction 
solvent. A different number of equivalents of the amino acids (Xaa 5 equiv.), coupling reagents 
(HOBt 5 equiv./HBTU 4.8 equiv./DIPEA 10 equiv.) and acetic anhydride/DIPEA (8 equiv./ 
7equiv.) were also used (Scheme VIII.11). 
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HBTU, HOBt, DIPEA in DMF
1) 20% piperidine in DMF
2) Fmoc-δ-amino acid-OH
    HBTU, HOBt, DIPEA in DMF
Fmoc-δ-amino acid-Xaa
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Ac-δ-amino acid-Xaa
Ac-δ-amino acid-Lys-δ-amino acid-Ala-δ-amino acid-Tyr-CONH2
and
Ac-Leu-δ-amino acid-Lys-δ-amino acid-Ala-δ-amino acid-Tyr-CONH2
 Fmoc-Tyr(tBu)-OH
 Fmoc-Ala-OH
 Fmoc-Lys(Boc)-OH  for hexapeptide
 Fmoc-Leu-OH          for heptapeptide
Xaa =
 
 
Scheme VIII.11.  Solid phase synthesis of 33 and 34 using the Fmoc chemistry.  
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VIII-5   Results and discussion 
 
VIII.5.1   Alternated α/(S,S)-δ-unit peptide 
 
The synthesized α/δ-pentapetide 32 was dissolved in methanol-d3 and studied by NMR 
spectroscopy. 1D experiments were first acquired at five different temperatures (283, 288, 293, 
298 and 303 K), and the one that gave the better resolved spectrum (303 K) was chosen to record 
the 2D experiments. The complete 1H-NMR resonance and sequence assignments were done by 
using the COSY, TOCSY and ROESY spectra. Unfortunately only, medium and weak contacts 
were found and only between one residue and its neighbour, or intralactone in one case (Figure 
VIII.19). 
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Figure VIII.19. Summary of the interresidue ROE constraints observed for the peptide 32 in methanol-d3 at 303 
K (green arrows: medium ROEs; blue arrows: weak ROEs). 
 
The values of the 3JHN-Hα coupling constants were estimated by using the amide region in the 1D-
NMR spectrum and the vicinal coupling constant value is always bigger than 6 Hz. No estimation 
was possible in the case of the two lactones. These values are typical of an extended or unordered 
structure (Figure VIII.20). 
The temperature coefficients (∆δ/∆T) for the pentapeptide 32 were also measured, which were in 
the range of -6.6/-8.0 ppb/K (Figure VIII.20). 
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-∆δ(ppm)/ 
∆T(K) 
 
 
3JHN-Hα (Hz) 
 
NHQ3 7.4 7.0 
NHX4 7.4   
NHX2 7.2   
NHK5 6.6 7.6 
NHK1 8.0 7.2 
                                                                                 
Figure VIII.20 Temperature coefficients for the NHs and vicinal coupling constants for HN-Hα in methanol-d3 for 
32. 
 
We used molecular modelling to investigate the possible structures that the peptide could adopt. 
After the construction of the molecule in silico the observed NMR contacts were introduced as 
constraints before carrying out an energy minimization and Molecular Dynamics. In our analysis 
we excluded the molecules in which there were violations of the NMR-derived constraints and 
we considered only the structures energetically favored. The lowest energy conformer of this set 
of molecules is shown in Figure VIII.21 Clearly the peptide forms a large loop, in which the two 
lactones are located opposite to each other, with the central residue glutamine acting as a pivot.  
 
 
Figure VIII.21 Structure of low-energy conformer calculated for compound 32. Hydrogen atoms are omitted for 
clarity. 
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The CD investigation was performed in methanol (5 mM) and the peptide 32 displayed only one 
negative band at 230 nm (Figure VIII.22). Unfortunately, no similar spectra have been reported 
either in the literature or in our previous work. 
 
 
. 
Figure VIII.22 CD spectra of compound 116 (5 mM in methanol). The data are normalized for peptide 
concentration and number of residues. 
 
 
VIII.5.2.   Alternated α/(R,R)-δ-unit peptides 
 
Two further peptides containing the (R,R)-δ-unit alternated with α-amino acids like lysine, 
alanine, tyrosine and leucine were prepared by solid phase methodology.The 1H NMR spectra of 
hexapeptide 33 were recorded at five different temperatures (280, 287, 296, 303 and 310 K), and 
the one at which the dispersion of the signals was reasonable (280 K) was chosen to record the 
2D experiments. Nevertheless, NMR characterization was complicated from the significant signal 
overlap in the spectrum. The ROESY spectrum in connection with COSY and TOCSY spectra 
revealed several contacts, including those between neighbour amino acids (Figure VIII.23). The 
central part of the peptide seemed to be more structured and the temperature coefficient of 
lactone X5 was relatively small (Figure VIII.23).  
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Figure VIII.23. Summary of the interresidue NOE constraints observed for the peptide 33 in methanol-d3 at 280 K 
(pink arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
 
 
 
 
 
 
 
Figure VIII.24 Temperature coefficients for the NHs and vicinal coupling constants for HN-Hα in methanol-d3 for 
33. 
 
Using several NOE contacts as constraints, MD simulations were carried out, but we could not 
see a periodic structure (Figure VIII.25). 
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3JHN-Hα (Hz) 
 
NHA4 7.6 6.4 
NHX5 4.0  
NHK2        7.9 
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Figure VIII.25 Structure of low-energy conformer calculated for compound 33. Hydrogen atoms are omitted for 
clarity 
 
We recorded the circular dichroism spectrum in methanol at concentration of 2 mM (Figure 
VIII.26), which exhibited a strong positive band at 238 nm. 
 
 
 
 
 
Figure VIII.26 CD spectra of compound 33 (2 mM in methanol). The data are normalized for peptide concentration 
and number of residues. 
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The heptapeptide 34 was obtained from 33 after elongation with an additional α-amino acid, 
leucine. The 2D NMR analyses at 303 K revealed only few and non-relevant NOE contacts 
(Figure VIII.27).  
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Figure VIII.27 Summary of the interresidue NOE constraints observed for the peptide 34 in methanol-d3 at 303 K 
(pink arrows: strong NOEs; green arrows: medium NOEs; blue arrows: weak NOEs). 
 
 
The temperature coefficients and coupling constants of 34 are reported in Figure VIII.28 It can be 
noted that the amide protons of the alanine-δ-lactone motif in 33 and 34 show comparable 
temperature coefficients.  
 
 
 
 
Figure 87. Temperature coefficient for the NHs and vicinal coupling 
constants for HN-Hα in methanol-d3 for 34. 
 
The CD spectrum of 34 at 2 mM in methanol was characterized 
by a weak positive band at 200 nm, followed by a broad 
positive band at 230 nm (Figure 88). 
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NHY7 7.4 8.4 
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Figure VIII.28 CD spectra of compound 34 (2 mM in methanol). The data are normalized for peptide concentration 
and number of residues. 
 
 
 
VIII.6   Monomer studies 
 
VIII.6.1   Previous work on the δ-butyrolactone amino acid  
 
In a previous work carried out by  M. Haque37 in our laboratory in Regensburg, the tetramer 39 
consisting of four (S,S)-δ-amino acid units was synthesized (Figure VIII.29). The NMR 
investigation was not possible due to signal overlapping especially in the NH region.  
 
O
O
NH
O
O
NH COOH
O
O
O
NH
O
O
O
NHBoc
O
39
 
 
Figure VIII.29. Tetramer 39. 
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Therefore CD analyses in different solvents were performed (Figure VIII.30). The CD spectra 
were recorded in the far UV region, at the concentration of 5 mM in TFE, methanol and 
methanol/water 60:40. In TFE the CD spectrum was characterised by a positive band at 191 nm, 
and by a broad negative band centred at 214 nm, with a crossover at 204nm. Changing TFE with 
methanol doubled the intensity of the negative band, while the shape and the bands position 
remained the same. The intensity of the negative band further increased in the mixture 
methanol/water, becoming more than two times higher than in methanol and more than four times 
higher than in TFE. Again, the shape of the band remained more or less constant, but a better-
defined minimum was present at 214 nm. The fact that the CD spectra were solvent dependent 
indicates that the conformational properties of the peptide are influenced by the environment. An 
increase in the intensity of CD bands suggests an improved structural stability. For the δ-
oligopeptide a stabilisation effect was observed in methanol rather than in TFE, and in the 
presence also of water rather than in 100% methanol. This behaviour is quite unusual, as the 
conformation of peptide mimics is normally destabilized by addition of water that is a strong 
donor and acceptor of H-bonds. In contrast, TFE is a well-known secondary structure stabilizer, 
being a strong H-bond donor but a weak H-bond acceptor.  
 
 
Figure VIII.30 Left: CD spectra in TFE (green), methanol (red) and water/methanol mixture (blue). Right: 
Hofmann’s calculations: a) in gas-phase, helix-like structure; b) in water, turn-like structure. 
Gas phase, 
helix-like 
structure 
Water phase, 
Turn-like 
structure 
 198 
 
To reinforce and illustrate these results, molecular modelling experiments were performed at the 
University of Leipzig by the Hofmann’s group and the results showed two families of structures. 
The first family in gas-phase had a helical tendency (Figure VIII.30 a), whereas the second one in 
water showed a succession of turn-like structures (Figure VIII.30 b). In both cases, the secondary 
structures seemed to be stabilized by H-bonds formed between the carbonyl and the NH of the 
same lactone residue (8-membered hydrogen-bonded ring). Another feature distinguishing both 
Hofmann’s structures is the conformation of the lactone. In the case of the calculations in gas-
phase both substituents on the cycle are occupying an axial position, whereas the calculations in 
water show the two “arms” of the lactone in an equatorial position. It was not possible to confirm 
by NMR and X-ray any of the information obtained from the computational and CD data. 
 
VIII.6.2.   New analyses on the monomer 
 
In order to gain further information about such structures in solutions, we decided to perform 
conformational studies on the monomer. First we wanted to control its ability to form an internal 
H-bond (8-membered H-bonded ring) that would confirm the possible stabilization of the 
structures described by Hofmann’s calculations and, secondly, we wanted to study the lactone 
ring conformation as it could play a crucial role in the structural behaviour of further lactone-
containing peptidomimetics. 
 
 
Design and synthesis 
 
This kind of conformational studies based on monomeric structures have been previously 
reported by Gellman and co-workers57 in their attempt to evaluate folding properties of β- and γ-
aminoacids. To study the particular H-bond preferred conformation of our lactone we needed two 
types of compounds. In the first one, only one hydrogen bond would be possible, and in the 
second one the monomer could adopt two hydrogen bond patterns. Thus, we synthesised 
compounds 41 and 42 as described in Scheme VIII.12 In the first step the Boc-protected lactone 
derivative 22 was coupled to a mono or dialkylated amine. The resulting compound 40 was Boc 
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deprotected by treating it with TFA in dry CH2Cl2, and finally the amino group was acetylated to 
afford our model compounds 41 and 42. 
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Scheme VIII.12  Synthesis of compounds 41 and 42. Reagents:  
a) NHEtR, EDC, HOBt, DMF, 42% when R=H and 65% when R=Et; b) (i) TFA, dry CH2Cl2 ; (ii) Ac2O, THF, 65% when R=H and 60% when R=Et.
 
 
Conformational analyses 
 
We studied both compounds first by NMR and, secondly, by IR in CH2Cl2 at low concentration 
(3 mM) and room temperature (Figure VIII.31).  
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Figure VIII.31 a) IR studies of 41; b) IR studies of 42. The possible hydrogen bonds are shown in magenta.  
 
 
In the IR spectra it is possible to observe two N−H stretch bands for amide protons: the highest 
one about 3400 cm-1 indicates an amide in a non-hydrogen-bonded state, whereas the lowest one 
appearing near 3300 cm-1 corresponds to an amide in hydrogen-bonded state.  
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The disubstituted amide in 41 presented two IR bands at 3347 and 3412 cm-1 with similar 
intensity (Figure VIII.31 a), whereas the monosubstituted compound 42 showed an intense band 
in the non-hydrogen-bonded NH region at 3441 cm-1 and a weaker band in the region of H-
bonded amides at 3331 cm-1 (Figure VIII.31 b). These data suggest that the intraresidue H-bond 
is favoured in the monomer 41 comporting only one H-bond possibility, whereas in the 
monosubstituted derivative 42 with more possible combinations, the non-H-bonded state is 
preferred. These analyses confirm that an intraresidue H-bond is possible in our structure, 
supporting indeed the H-bond pattern described in Hofmann’s structures. 
In NMR investigations two parameters were considered. On the one hand, variable temperature 
studies gave the temperature coefficients that in some cases can be correlated with the H-bonding 
state of amide protons. On the other hand, NOESY experiments gave insight about the distance 
between two protons in the space.  
In variable temperature studies the NH(7) of the disubstituted lactone 41 showed a high 
temperature coefficient (-9.2 ppb/K), typical value for non-hydrogen-bonded state, and NOESY 
spectra performed at room temperature did not show any intra-strand NOE contacts. In contrast, 
the monosubstituted lactone 42 appeared to adopt two distinct behaviours depending on the 
temperature in which it was studied, at room temperature and at 225 K. The temperature 
coefficient for the NH(7) (-8.9 ppb/K) was similar to the one in the disubstituted lactone, whereas 
the NH(12) showed a lower value of ∆δ/∆T = -6 ppb/K. For this compound NOESY experiments 
were performed at room temperature and at 225 K, and an intra-strand NOE cross peak was 
found at low temperature between CH3(9) and NH(12). These two parameters, NOE contacts and 
temperature coefficient, found for NH(12) suggest a preferred H-bonding pattern involving 
NH(12) and CO(8) of 42 at low temperature. 
 
 
Investigations on the ring conformation 
 
The γ-butyrolactone system possesses great importance in the chemistry of natural products.58,59 
Therefore, considerable interest is given at the synthesis and structural characterization of 
substituted γ-butyrolactones.  
One advantage of using γ-butyrolactone as synthetic intermediate is the low conformational 
flexibility: indeed, one needs to consider only the interconversion between two envelope forms A 
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and B, in which α  = β = H60 (Figure VIII.32). In this case the interconversion barrier is quite low 
and the lactone adopts both shapes in solution. However, when substituents are introduced on 
such a small ring, both the ring structure and the equilibrium between the A and B forms are 
greatly affected, and the analysis in NMR spectra of ring protons turns into a complicated task.  
 
Figure VIII.32 Interconversion of γ-lactone A in B 
 
To evaluate the substituted γ-lactone conformer distribution in solution several methods have 
been developed based on experimental vicinal and geminal coupling constants combined with 
conformational studies by molecular mechanics.60-62 In our case, experimental data gave a really 
large value of J3-4 for both disubstituted 41 and monosubstituted 42 monomers, which was 12.3 
and 13.1 Hz, respectively. Such large coupling constants are in agreement with trans protons 3 
and 4 occupying both a diaxial position on the lactone ring. We then compared these values with 
the one of the coupling constant from the dimethylated lactone 43 (Figure VIII.33), which was 
previously synthesized by Delatouche in our group. In this case the coupling constant value 
between H3 and H4 was 9.8 Hz. It has been earlier demonstrated on 2,4 disubstituted lactones that 
1-3 diaxial strains are quite disfavouring in term of energy in γ-butyrolactones.60 Thus, in our 
dimethylated compound 43 the conformer A that shows a 1-3 diaxial strain between the methyl 
group in position 2 and the lactone arm in position 4 should be unstable, while the predominant 
conformation in solution should be the conformation B, in which H4 and one methyl group in 
position 2 are diaxial (Figure VIII.33). 
 
1.16 Kcal/mol 
A B 
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Figure VIII.33 Interconversion between the two envelope conformations A and B of 43. 
 
 
The results suggested by the coupling constants were then supported by molecular mechanics 
calculations using MMFF force field in the program Spartan,63 which gave the conformation with 
the two arms in an equatorial position as energetic minimum for both lactones 41 and 42 (Figure 
VIII.34).  
 
 
 
 
 
 
 
 
 
Figure VIII.34 Energy minimum of 41 and 43 based on a molecular mechanics study with the force field MMFF of 
the Spartan program.   
 
 
 
E=-67,84Kcal/mol 
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H3CCH4         -162.71 
               125 
E=-57,62Kcal/mol 
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Finally, analysis of the crystal structure data37 obtained by Haque gave further evidence of the 
equatorial distribution of the two lactone arms (Figure VIII.35). 
 
 
 
Figure VIII.35  X-ray structure of compound 22. 
 
 
VIII.7 Influence of the (R,R)-δ-lactone amino acid on the α-helix 
stability 
 
VIII.7.1   Aim of the study 
 
As it as been described before, on the one hand, this cyclic scaffold 23 can be described as δ-
amino acid bearing a lactone ring at β- and γ-positions (Figure VIII.36). On the other hand, it 
mimics a glycyl-glycyl dipeptide unit 44, in which the amide bond is replaced by a lactone ring. 
We have investigated the folding properties of these building blocks in homo-δ-oligomers37 as 
well as in hetero-α,δ-oligomers. We have previously shown that the δ-lactone amino acid unit 
possesses a tendency to build loop- or turn-like elements.  
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Figure VIII.36  Structure of pentalactone-compound 23 and of glycyl-glycine 44. 
 
The aim of the experiment described in the following paragraphs was to evaluate the influence of 
this δ-amino acid on the helical structure of α-amino acid sequences. To carry out this study we 
used as peptide reference the peptide 45, that was designed by Serrano’s group64 in 1995 and 
adopts an α-helical structure (Figure VIII.37). This peptide is composed of eighteen amino acids 
and shows in the N-terminal part two crucial motifs for the helix initiation: the hydrophobic 
staple and the capping box. The hydrophobic staple consists of residues Phe-2 and Leu-7. A 
second helix inducer effect comes from the presence of the capping box consisting of Ser-3 and 
Glu-6.65 NMR analysis of this peptide in aqueous solutions have shown that the helical part of the 
peptide starts at Lys-4 and stops around Arg-15. 
 
 
 
Figure VIII.37 Peptide reference 45 used in our studies. 
 
This peptide 45 was analysed using CD spectroscopy and led to a CD spectrum with a maximum 
at 195 nm and two minima at 208 and 222 nm (Figure VIII.38 b). Replacement of Phe-2 by Ala 
(peptide 46, Figure VIII.38 a) led to a destabilization of the helix, as indicated by the reduced 
intensity of the CD spectrum of 46 (Figure VIII.38 b).  
 
 
23 44 
45 
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a                                                                                  b 
 
Figure VIII.38 a) Peptide references used in our studies; b) CD spectra of 45 and 46 and other analogs, as reported 
by Serrano and co-workers.64(Reproduction by courtesy of  Dr. Serrano). 
 
 
Thus, we chosed these two peptides as references to carry out our studies. The reference called 
“positive” 45 included Phe-2, whereas the reference called “negative” included Ala-2 (Figure 
VIII.38 a). 
 
VIII.7.2   Design of the modified peptides 
 
In order to check the compatibility of our amino acid with the helical structure of an α-peptide, 
we decided to introduce the lactone unit in the C-terminal part of the helix of the reference 
peptide 46 (from Lys-6 to Arg-14), by substituting either the two residues Arg-11 and Ala-12 
(peptide 47) or Ala-10 and Arg-11 (peptide 48, Figure VIII.39).  
 
 
Figure VIII.39 Peptide mimics 47 and 48 containing the lactone unit in the helical part. 
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46 
45 
48 
   47 
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Moreover, we  introduced one lactone unit in the N-terminal part of the peptide: indeed, we 
substituted Ser3 and Lys-4, thus introducing the lactone between the two residues that should 
build the hydrophobic staple (peptide 49, Figure VIII.40). As a final test, we designed an analog 
of the latter peptide 49 that contains the substitution Phe-2/Ala, thus replacing one of the two 
partners of the hydrophobic staple (peptide 50, Figure VIII.40). The goal of this last test was to 
see if our lactone would be able to restore the hydrophobic staple properties and to induce the 
helix.  
 
 
 
Figure VIII.40 Peptide mimics 49 and 50 containing the lactone unit in the N-terminal part of the helix. 
 
 
VIII.8   Synthesis of peptides 45-50 
 
The synthesis of peptides 45-50 was performed on solid phase using Fmoc-chemistry on Rink 
amide MBHA resin (loading 0.6 mmol g -1) (Scheme VIII.13. The seven first amino acids were 
introduced using a single coupling procedure (75 min), whereas the following amino acids were 
introduced by a double coupling procedure (2 x 45 min). We used Fmoc-amino 
acid/HOBt/HBTU/DIPEA (5:5:5:10 equiv.) in DMF/NMP (80:20, v/v), followed by Fmoc 
removal with 25% piperidine in DMF/NMP (80:20, v/v) (2 x 15 min). To monitor the progress of 
the synthesis, test cleavages using small amounts of resin were conducted and the resulting 
samples were analyzed by MALDI-ToF-MS and analytical HPLC. The last step was the N-
terminal acetylation using acetic anhydride (8 equiv.) and DIPEA (7 equiv.). Final cleavage of 
the peptide from the resin and simultaneous side-chain deprotection was achieved by treatment 
with a TFA/water/TIS mixture (90:5:5) for 2.5 hours. The peptide was then precipitated from ice-
cold diethyl ether, centrifuged and subjected to three ether-washing/centrifugation cycles to 
remove the scavengers. 
 
   
50 
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Scheme VIII.13 Synthetic procedure for the six peptides 45-50. 
 
Each peptide was then purified by preparative HPLC. Each pure peptide was obtained in mg 
scale and submitted to circular dichroism analyses. The circular dichroism was recorded at 5 °C 
in phosphate buffer at pH 7.0 as it was described by Serrano and co-workers.64 
 
 
VIII.9   Results and discussion 
 
The CD spectra of the synthesized peptides are shown in Figure VIII.41. It can be noted, that 
introduction of the lactone led to the loss of the α-helical structure in any case. Indeed, the 
minimum at 222 nm characteristic for α-helices was replaced by a weak shoulder, while the 
minimum near 208 nm decreased intensity and was slightly blue-shifted to 205 nm.  Such CD 
curves are similar to the one reported in the literature for the 310 helix.66  
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Figure VIII.41 CD spectra recorded at 5 °C in phosphate buffer pH=7 and at 0.5 mM. The concentration of the 
peptides was controlled previously by UV measurement.  
 
 
As described before, the α-helix is the most common regular secondary structure of peptides and 
proteins. However, 310 helices are also observed in nature. The latter are more tightly bond and 
more elongated than the α-helix. The set of φ and ψ torsion angles of the α- and 310-helices does 
not differ much, falling within the same region of the Ramachandran map (Table VIII.3). 
 
 
Parameter                   α-Helix                  310-Helix 
       
       Φ (°)                       -63                        -57 
 
     Ψ  (°)                       -42                        -30 
 
Table VIII.3  Average torsion angles for α- and 310-helices based on α-amino acids. 
 
However, their intramolecular C=O… H-N H-bonding schemes are remarkably distinct, being of 
the 1←4 type (sub-type III or helical β-turn67) in the 310-helix, and of the 1←5 type (helical α-
bend68) in the α-helix69 (Figure VIII.42). 
G F S K A E L A K A Lac A K R G G Y 
                             131 
G F S K A E L A K Lac A A K R G G Y 
                             132 
G F Lac A E L A K A R A A K R G G Y 
                             133 
G A Lac A E L A K A R A A K R G G Y 
                              134 
G F S K A E L A K A R A A K R G G Y 
Ref positive          129 
G A S K A E L A K A R A A K R G G Y 
Ref negative         130 
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Figure VIII.42 a) The α-helix and its building block, the helical α-turn (or C13-conformation); b) The 310-helix and 
its building block, the helical (type III) β-turn (or C10-conformation). From Toniolo et al.69(Reproduction by courtesy 
of  Prof. Toniolo). 
 
Theoretical calculations have predicted a very low conformational energy barrier separating these 
two secondary structures.70 It has been shown that factors influencing the folding through one or 
the other conformation are: the solvent properties, the length of the peptide, the temperature, and, 
of course, changes in the amino acid composition.  
Recently, Toniolo and co-workers71 reported an example of homooligomer made of α,α-amino 
acids able to fold either in α-helix or in 310-helix depending on the solvent. As an example,71 the 
Ac-[L-(αMe)Val]7-NHiPr showed two different folding properties in MeOH, in which it adopts a 
310-helix structure, and in the acidic alcohol HFIP, where it adopts an α-helical structure (Figure 
VIII.43). 
 
Figure VIII.43  CD spectra of Ac-[L-(αMe)Val]7-NHiPr in methanol and HFIP solutions. Reported from Toniolo 
and co-workers.71(Reproduction by courtesy of  Prof. Toniolo). 
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According to the analysis of Toniolo’s group that demonstrated the different peptide folding 
behaviour depending on the solvent, we performed further CD analyses of peptides 45-50 in TFE 
that is know to be a secondary structure stabilizer, as it is a strong H-bond donor and a weak H-
bond acceptor, and, consequently, it interacts with carbonyl groups of peptides which are able to 
build bifurcated H-bonds without the necessity of breaking the intramolecular H-bond.  
In our CD analyses in TFE, we can see differences in the structural behaviour of our modified 
peptides. While 47, 49 and 50 showed α-helix-like CD profiles, 48 seemed to maintain the 
structure it already adopted in water (Figure VIII.42), showing the typical CD profile for a 310-
helix (Figure VIII.44). 
 
 
Figure VIII.44 CD spectra recorded at 5 °C in TFE and at 0.3 mM. The concentration of the peptides was controlled 
previously by UV measurement. 
 
We can conclude from these last experiments, that the introduction of the lactone in already 
existing α-helical peptides has an influence on their secondary structure preferences. In water, a 
non-stabilizing solvent, the presence of one lactone unit in the proximity of the N-end or C-end of 
a α-amino acid sequence with strong α-helix propensity seems to favour the building of the 310-
helix at the expense of the α-helix. In contrast, in the structure-stabilizing solvent TFE, the 
presence of the lactone unit does not prevent the formation of the α-helix, as indicated by the fact 
G F S K A E L A K A Lac A K R G G Y 
                             47 
G F S K A E L A K Lac A A K R G G Y 
                             48 
G F Lac A E L A K A R A A K R G G Y 
                             49 
G A Lac A E L A K A R A A K R G G Y 
                              50 
G F S K A E L A K A R A A K R G G Y 
Ref positive          45 
G A S K A E L A K A R A A K R G G Y 
Ref negative         46 
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that the CD spectra of the lactone-containing peptides 47, 49 and 50 are superimposable with the 
CD spectrum of the “negative” reference peptide 46. The striking behaviour of peptide 48, whose 
structure preference seems to be less solvent-dependent, might be due to the fact that the shift of 
the lactone position toward the central part of an α-amino acid sequence prevented the formation 
of a single α-helix segment, while favouring the formation of short 310-helical structures of α-
amino acids.  
 
 
VIII.10. Conclusion 
 
The synthetic studies performed on oligomers containing the butyrolactone δ-amino acids have 
shown that these interesting new scaffolds are compatible with the solid-phase methodology, 
which allows for a comfortable and efficient preparation of a large number of compounds. 
Moreover, the structural analyses of the synthesized peptide mimics have given insights in the 
conformational properties of peptide backbones based on alternated α/δ-units. In fact, the 
presence of the δ-residue seems to favour the formation of loops or isolated turn-like elements, 
whereas no periodic structures were observed. However, conformational analyses of δ-
homooligomers support the presence of ordered structures, like turn-like repeats stabilized by 
intra-residue CO-NH H-bonds. Moreover, introduction of a δ-amino acid unit in proximity of the 
N- or C-end of a α-helical peptide chain seems to destabilize the α-helix in water, but not to 
prevent its formation in a structure-stabilizing solvent. In contrast, the δ-amino acid unit can act 
as a helix breaker when introduced into a α-helical segment, thus favouring the 310-helix over the 
α-helix.  
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XIX - EXPERIMENTAL PART 
 
XIX-1 EXPERIMENTAL PART CHAPTER VIII 
 
General chemical techniques: 
 
The Nα-Fmoc protected amino acids and HBTU were purchased from MultiSynTech (Witten, 
Germany). Peptide-synthesis grade DMF, NMP, piperidine and diethylether, ACN and TFA for 
spectroscopy were purchased from Biosolve (Valkenswaard, The Netherlands). 
HOBt, DIPEA, TFA, DCM, DMSO, and α-cyano-4-hydroxy-cinnamic acid for mass 
spectrometry were bought from Fluka (Taufkirchen, Germany). Methanol was obtained from J.T. 
Baker (Deventer, The Netherlands), TIS from Aldrich (Steinheim, Germany) and TFE from 
Acros (Geel, Belgium). Acetic anhydride, acetic acid, NaH2PO4 and Na2HPO4 were purchased 
from Merck (Darmstadt, Germany). THF was distilled on sodium/benzophenone before use. Pure 
products were obtained after liquid chromatography using Merck silica gel 60 (40-63 µm mesh). 
TLC analyses were performed with 0.25 mm 60 F254 silica plates (Merck). The plates were 
visualized with UV light (254 nm) or with a solution of vanillin in ethanol or with a solution of 
ninhydrin in ethanol. The mass spectra were recorded on Finnigan MAT 95, Varian MAT 311A, 
Finnigan TSQ 7000 and Future GSG spectrometer (Bruchsal, Germany) for MALDI-ToF-MS 
analysis. IR spectra were recorded on a Varian 800 FT-IR spectrometer. Optical rotations were 
measured on a Perkin-Elmer-Polarimeter 241 with sodium lamp at 589 nm in the specified 
solvent. NMR spectra were recorded on a Bruker AVANCE 300 (300.13 MHz) or a Bruker 
AVANCE 400 (400.13 MHz) or a Bruker AVANCE 600 (600.13 MHz). The 2D-NMR standard 
experiments DQF-COSY, 80 ms-TOCSY and 500 ms-ROESY the water resonance was 
suppressed by using the presaturation method. The concentration of the peptide samples prepared 
for CD measurements were determined UV spectrophotometrically on a Cary 100 Conc from 
Varian (Darmstadt, Germany) using 1 cm quartz cuvettes obtained from Hellma (Müllheim, 
Germany). CD spectra were recorded at room temperature or at 5 °C on a JASCO J710 
spectropolarimeter between 300 and 200-180 nm in the specified solvent. The path length of the 
quartz cuvette was 1.0 mm. For each CD spectrum ten scans were accumulated using a step 
resolution of 1 nm, a bandwidth of 1 nm, a response time of 2 s, a scan speed of 20 nm min-1 and 
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a sensitivity of 10 mdeg, 20 mdeg, depending on the peptide concentration. The background was 
subtracted to each spectrum. The absorption value is measured as Molar Ellipticity per Residue 
(deg cm2 dmol-1). The noise reduction was obtained by a Fourier transform filter using the 
program Origin 6.0 (OriginLab Corporation, Northampton, USA). Analytical and preparative 
reverse Phase HPLC was performed on Agilent equipment (Böblingen, Germany) by using the 
columns: Luna C18(2), 3 µm, 4.60 x 150 mm and the Luna C18(2), 90 µm, 21.2 x 250 mm 
(Phenomenex, Aschaffenburg, Germany). The flow rate was 1 mL/min for the analytical HPLC 
runs and 21 mL/min for preparative applications. The binary solvent system (A/B) was: (A) 
0.012% TFA in water (B) 0.01% of TFA in ACN. The absorbance was detected at 220 nm. 
 
SYNTHESIS OF MOLECULES  37 AND 36     
 
 
(3-Aminomethyl-5-oxo-tetrahydro-furan-2-yl)acetic acid, trifluoroacetic acid salt 121.
 
 
 
 
OO
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O
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1
2 3
4
5
6
7
8 9
 
 
 
Compound 23 (100 mg, 0.37 mmol) was dissolved in dry CH2Cl2 (5 mL) and trifluoroacetic acid 
(1.7 mL, 22.0 mmol, 60.0 eq) was added dropwise at room temperature. The reaction mixture 
was stirred for 2 h. Solvent was evaporated under reduced pressure to yield a brown solid oil 37 
(106 mg). This crude product was used without further purification in the course of the synthesis.  
 
1H NMR (300 MHz, CD3OD) δ ppm 4.69 (m, 1H, H4), 3.20 (m, 2H, H8), 2.96-2.71 (m, 4H, H3, 
H6, H 2a), 2.51 (dd, J  = 17.0 and 6.9 Hz, 1H, H2b). 
13C NMR (75 MHz, CD3OD) δ ppm  177.1 (C7), 173.4 (C1), 80.0 (C4), 42.7 (C8), 39.9 (C6), 39.3 
(C2), 33.6 (C3). 
 
 
 
37 
C7H11NO4.CF3COOH 
M =287.09 g/mol 
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{3-[(9H-Fluoren-9-ylmethoxycarbonylamino)-methyl]-5-oxo-tetrahydro-furan-2-yl}acetic acid 120.
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To a cold (0°C) solution of 37 (106 mg, 0.37 mmol) in dioxane /1M aqueous solution of K2CO3 
(2 ml /4 ml) was added portionwise FmocOSu (187.2 mg, 0.55 mmol, 1.5 eq.). The reaction was 
allowed to come at room temperature and stirred overnight. The mixture was poured in water (7 
mL ) and extracted with EtOAc (3 x 9 mL). 
The combined organic layers were dried over Na2SO4, filtered and evaporated in vacuo to give a 
sticky solid wich was purified by column chromatography (PE:EtOAc 2:1) to obtain 36 (86.9 mg, 
60%) as a sticky, colorless solid. 
 
 
1H NMR (300 MHz, CD3OD) δ ppm  7.80 (d, J = 7.4 Hz, 2H, H17, H20), 7.63 (d, J = 7.2 Hz, 2H, 
H14, H23), 7.40-7.27 (m, 4H, H15, H16, H21, H22), 4.64 (m, 1H, H4), 4.39 (d, J = 6.6 Hz, 2H, H11), 
4.20 (m, 1H, H12), 3.23 (m, 2H, H8), 2.73-2.47 (m, 4H, H3, H6, H2a), 2.35 (dd, J = 17.2 and 7.0 
Hz, 1H, H2b). 
13C NMR (75 MHz, CD3OD) δ ppm  128.8, 128.2, 126.2, 121.0 (C14, C15, C16, C17,C20, C21, C22, 
C23), 81.0 (C4), 68.2 (C11), 48.6 (C12),43.1 (C8), 41.9 (C3), 39.9 (C2), 33.2 (C6). 
 
 
 
 
 
 
 
 
C22H21NO6 
M =395.14 g/mol 
 
36 
 215 
SYNTHESIS OF MOLECULES 41 AND 42     
 
 
 
(5-Oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-butyl ester; compound with 
N,N-diethyl-
propionamide 40
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To a solution of 22 (142 mg, 0.52 mmol) and diethylamine (41.8 mg, 0.57 mmol, 1.1 eq) in DMF 
(8 mL) was added DIPEA (180 µL, 1.04 mmol, 2.0 eq), HOBt (88 mg, 0.57 mmol, 1.1 eq) and 
HBTU (218 mg, 0.57 mmol, 1.1 eq). The mixture was stirred at room temperature under argon 
atmosphere for 25 h. After removal of the solvent under reduced pressure, the residue was 
dissolved in EtOAc (20 mL). The organic solution  was successively washed with 10% aqueous 
citric acid (20 mL), water (20 mL), 10% aqueous K2CO3 (20 mL), brine (20 mL). The organic 
layer was dried over Na2SO4, filtered and concentrated. A purification by chromatography on 
silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 110 mg (65%) of 40 a as a sticky  light 
yellow solid. 
  
 
1H NMR (300 MHz, CDCl3) δ ppm 5.40 (br s, 1 H, H12), 4.78 (m, 1H, H4), 3.43-3.15 (m, 6H, 
H11, H14, H9), 2.86 (dd, J  = 16.3 and 4.3 Hz, 1H, H6a), 2.73-2.58 (m, 2H, H6b, H2a), 2.52 (m, 1H, 
H3 ), 2.38 (dd, J  = 18.1 and 5.9 Hz, 1H, H2b), 1.43 (s, 9H, CH3Boc), 1.22-1.0 (m, 6H, H10, H15).  
13C NMR (75 MHz, CDCl3) δ ppm  175.5 (C7), 168.1 (C1), 156.3 (C13), 80.0 (CBoc), 79.6 (C4), 
42.1, 41.6 (C9, C14), 40.3 (C3), 37.9 (C11), 32.4 (C6), 28.3 (CH3Boc), 14.2, 13.0 (C10, C15).   
Rf: 0.4 (CH2Cl2/MeOH: 90/10)  
C16H28N2O5 
M =328.20 g/mol 
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HRMS (EI) m/e: [M]+ calcd 328.1998, found 328.1996 
 
2-[3-(Acetylamino-methyl)-5-oxo-tetrahydro-furan-2-yl]-N,N-diethyl-acetamide 41.
 
 
 
N
O
N
H
O
OO 1
4
5
11 12 13
2
3
6 7
8 9
10
14
15
16
 
 
 
Compound 40 a (54 mg, 0.18 mmol) was dissolved in dry CH2Cl2 (6 mL) and trifluoroacetic acid 
(3.0 mL, 10.8 mmol, 60.0 eq) was added dropwise at room temperature. The reaction mixture 
was stirred for 2 h. Solvent was evaporated under reduced pressure to afford the corresponding 
TFA salt. 
A solution of this salt in dry THF (5 mL) was heated at 70 °C and acetic anhydride (32 µL, 0.22 
mmol, 1.2 eq) was added dropwise to this solution. The reaction mixture was stirred for 2 hours 
at 70 °C. The solvent of reaction was evaporated under reduced pressure. A purification by 
chromatography on silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 29 mg (60%) of 42 as a 
colorless solid oil. 
 
1H NMR (600 MHz, CD2Cl2) δ ppm 7.1 (br s, 1H, H12), 4.77 (m, 1 H, H4), 3.41-3.21 (m, 6H, H9, 
H14, H11), 2.88 (dd, J  = 16.3 and 4.3 Hz, 1H, H6a), 2.72 (dd, J  = 18.1 and 9.3 Hz, 1H, H2a), 2.66 
(dd, J  = 16.3 and 8.8 Hz, 1H, H6b), 2.49 (m, 1H, H3 ), 2.30 (dd, J  = 18.1 and 5.9 Hz, 1H, H2b), 
1.94 (s, 3H, C16), 1.19 (t, J = 7.3 Hz, 3H, H10), 1.11 (t, J = 7.2 Hz, 3H, H15).  
13C NMR (150 MHz, CD2Cl2) δ ppm  175.6 (C7), 170.7 (C1), 168.8 (C13), 80.3 (C4), 42.4, 42.3 
(C9, C14), 40.7 (C11), 40.6 (C3), 38.3 (C6), 32.4 (C2), 23.1 (C16), 14.2, 13.1 (C10, C15).   
IR in CH2Cl2 (cm-1 ): 3447 (NH), 3312 (NH), 1781 (C=O), 1671 (C=O), 1629 (C=O). 
 
 
 
C13H22N2O4 
M =270.16 g/mol 
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(2S, 3S)-(2-Ethylcarbamoylmethyl-5-oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-
butyl ester 40 b. 
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To a solution of 22 (71 mg, 0.26 mmol) and ethylamine hydrochloride (23.6 mg, 0.29 mmol, 1.1 
eq) in DMF (4 mL) was added DIPEA (90 µL, 0.52 mmol, 2.0 eq), HOBt (44 mg, 0.29 mmol, 1.1 
eq) and HBTU (109 mg, 0.29 mmol, 1.1 eq). The mixture was stirred at room temperature under 
argon atmosphere for 23 h. After removal of the solvent under reduced pressure, the residue was 
dissolved in EtOAc (10 mL). The organic solution  was successively washed with 10% aqueous 
citric acid (10 mL), water (10 mL), 10% aqueous K2CO3 (10 mL), brine (10 mL). The organic 
layer was dried over Na2SO4, filtered and concentrated. A purification by chromatography on 
silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 33 mg (42%) of  40 b as a sticky, light 
yellow solid. 
 
1H NMR (300 MHz, CDCl3) δ ppm 6.10 (br s, 1 H, H8), 5.22 (m, 1 H, H12), 4.64 (dd, J = 12.6 
and 6.3 Hz, 1H, H4), 3.31-3.22 (m, 4H, H9, H11), 2.65 (dd, J  = 16.6 and 8.3 Hz, 1H, H2a), 2.57 (d, 
J = 6.0 Hz, 2H, H6), 2.52 (m, 1H, H3 ), 2.39 (dd, J  = 16.6 and 7.7 Hz, 1H, H2b), 1.42 (s, 9H, 
CH3Boc), 1.12 (t, J = 7.2 Hz, 3H, H10).  
 
13C NMR (75 MHz, CDCl3) δ ppm  175.8 (C7), 168.8 (C1), 156.4 (C13), 80.0 (CBoc), 79.8 (C4), 
41.6 (C3), 41.2 (C6, C11), 34.5 (C9), 32.4 (C2),  28.3 (CH3Boc), 14.63 (C10). 
Rf: 0.3 (CH2Cl2/MeOH: 90/10)  
IR in CH2Cl2 (cm-1 ): 3443 (NH), 1782 (C=O), 1714 (C=O), 1673 (C=O). 
HRMS (EI) m/e: [M]+ calcd 300.1685, found 300.1685 
[α]25D: -19.3 (c 1.0, CHCl3) 
 
 
 
C14H24N2O5 
M = 300.17 g/mol 
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2-[3-(Acetylamino-methyl)-5-oxo-tetrahydro-furan-2-yl]-N-ethyl-acetamide 42. 
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Compound 40 b (27 mg, 0.09 mmol) was dissolved in dry CH2Cl2 (3 mL) and trifluoroacetic acid 
(1.5 mL, 5.4 mmol, 60.0 eq) was added dropwise at room temperature. The reaction mixture was 
stirred for 2 h. Solvent was evaporated under reduced pressure to afford the corresponding TFA 
salt. 
A solution of this salt in dry THF (3 mL) was heated at 70 °C and acetic anhydride (16 µL, 0.11 
mmol, 1.2 eq) was added dropwise to this solution. The reaction mixture was stirred for 2 hours 
at 70 °C. The solvent of reaction was evaporated under reduced pressure. A purification by 
chromatography on silica gel, eluting with CH2Cl2/MeOH (9/1), afforded 14 mg (65%) of 42 as a 
colorless solid oil. 
  
1H NMR (600 MHz, CD2Cl2) δ ppm 6.67 (br s, 1 H, H12), 6.07 (br s, 1 H, H8), 4.63 (m, 1H, H4), 
3.33 (m, 2H, H11), 3.25 (m, 2H, H9), 2.66 (dd, J = 17.5 and 8.9 Hz, 1H, H2a), 2.58 (d, J = 6.2 Hz 
2H, H6), 2.53 (m, 1H, H3), 2.34 (dd, J  = 17.5 and 7.5 Hz, 1H, H2b), 1.95 (s, 3H, H14), 1.12 (t, J = 
7.3 Hz, 3H, H10).  
13C NMR (150 MHz, CD2Cl2) δ ppm  175.7 (C1), 171.0 (C13), 169.2(C7), 80.3 (C4), 41.3 (C6), 
41.2 (C11), 41.0 (C3), 34.8 (C9), 32.7 (C2), 23.2 (C14), 14.8 (C10). 
Rf: 0.3 (CH2Cl2/MeOH: 90/10)  
IR in CH2Cl2 (cm-1 ): 3441 (NH), 3331 (NH), 1781 (C=O), 1673 (C=O), 1629 (C=O). 
HRMS (EI) m/e: [M]+ calcd 242.1267, found 242.1269 
[α]25D: -17.3 (c 1.0, CHCl3) 
 
 
 
C11H18N2O4 
M = 242.13 g/mol 
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METHODS FOR PEPTIDE CHARACTERIZATION  
 
Analytical HPLC 
 
For the analytical HPLC measurements a small amount of the peptide was dissolved in methanol 
or in millipore water containing 0.1% TFA The binary elution system consisted of 0.012% (v/v) 
TFA in water (eluent A) and 0.01% (v/v) TFA in ACN (eluent B). The following gradients were 
applied: 15% B for 3 min, 15-70% B over 40 min, 70-95% B over 50 min and 95% B over 55%   
(peptides 29 and 30); 5% B for 5 min, 5-55% B over 45 min, 55-65% B over 50 min and 65-95% 
B over 60 min (peptides 33, 34, 45-50). 
 
MALDI-ToF-MS 
 
For the mass spectrometry MALDI-ToF measurements a small sample of the peptide was 
dissolved in methanol or in millipore water containing 0.1% TFA and mixed with a solution of α-
cyano-4-hydroxycinnamic acid in MeOH/ACN (1:1, v/v). 
 
UV spectroscopy 
 
The concentration of the peptide samples prepared for CD measurements were determined UV 
spectrophotometrically. By measuring the tyrosine absorption at 280 nm the concentration was 
calculated according to the Lambert-Beer law using an extinction coefficient of 1480 M-1 cm-1 
per tyrosine residue. The ratio between the peptide concentration values obtained by UV and by 
weight gave the peptide content. In case of peptides lacking tyrosine or tryptophan residues the 
peptide contents of similar peptides containing these residues were applied to calculate the 
concentration. 
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Boc-F-(S,S)-Lac-F-(S,S)-Lac-F-Bn 29.  
 
 
O
O
O
N
H
O
N
H
O
O
O
N
H
O
O
N
H
ONH
O
O
1 2 3
4
5 6 7
8
9
10
11
12 13 14 15
16
17
18
20
19
21
22
23
24 25
26
27
28
29
30
 
 
 
1H NMR (600 MHz, CD3OH, 283 K) δ ppm 8.51 (d, J = 8.4 Hz, 1H, H26), 8.39 (d, J = 7.2 Hz, 
1H, H14), 8.23 (m, 2H, H18, H6), 7.31-7.11 (m, 20H, Har), 6.89 (d, J = 7.8 Hz, 1H,  H2), 5.46 (s, 
2H, H30), 4.70 ( m, 1H, H26), 4.48 (m, 1H, H14), 4.37 (m, 2H, H6, H18), 4.18 (m, 1H, H2), 3.10-
3.30 (m, 6H, H9, H7a, H19a, H21), 3.10-2.97 (m, 6H, H4a H16a, H28, H7b, H19b), 2.95-2.79 (m, 2H, 
H4b, H16b), 2.65-2.59 (m, 2H, H12a, H24a), 2.47-2.34 (m, 2H, H12b, H24b), 2.31-2.17 (m, 2H, H8, 
H20), 1.43 (s, 9H, CH3Boc). 
IR in CH2Cl2 (cm-1 ): 3420 (NH), 3314 (NH), 1783(C=O), 1731(C=O), 1672(C=O). 
MALDI-ToF-MS: 983 [M+Na]+, 999 [M+K]+        
tR: 36.0 min 
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Boc-F-(R,R)-Lac-F-(R,R)-Lac-F-Bn 30.  
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1H NMR (600 MHz, CDCl3, 288K) δ ppm 8.56 (d, J = 7.8 Hz, 1H, H26), 8.42 (d, J = 7.6 Hz, 
1H, H14), 8.22 (m, 1H, H6), 8.04 (m, 1H, H18), 8.38-7.10 (m, 20H, Har), 6.90 (d, J = 7.8 Hz, 1H, 
H2), 5.04 (s, 2H, H30), 4.70 (m, 1H, H27), 4.54 (m, 1H, H15), 4.52-4.42 (m, 2H, H11, H23),  4.26-
4.17 (m, 2H, H3, H11), 3.22-3.16 (m, 3H, H7, H19a), 3.16-3.10 (m, 3H, H19b, H28a, H16a), 3.0-2.90 
(m, 2H, H4a, H28b), 2.93-2.81 (m, 2H, H4b, H16b), 2.56-2.44 (m, 6H, H12, H24, H9a, H21a), 2.35-2.25 
(m, 2H, H20, H8), 2.23-2.14 (m, 2H, H9b, H21b), 1.36 (s, 9H, CH3Boc).  
IR in CH2Cl2 (cm-1 ): 3421 (NH), 3314 (NH), 1783(C=O), 1733(C=O), 1669(C=O). 
HRMS (EI) m/e: [M+H]+ calcd 960.4395, found 960.4417  
tR: 37.0 min 
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Boc-F-(R,R)-Lac-F-(R,R)-Lac-F-(R,R)-Lac-F-Bn 31. 
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1H NMR (600 MHz, CDCl3, 292K) δ ppm 8.54 (d, J = 5.8 Hz, 1H, H14), 8.49 (br s, 1H, H26), 
8.34 (d, J = 9.5 Hz, 1H, H18), 8.0 (d, J = 9.5 Hz, 1H, H6), 7.74 (d, J = 6.8 Hz, 1H, H38), 7.52 (d, J 
= 9.1 Hz, 1H, H30), 7.46-7.0 (m, 25H, Har), 5.22 (d, J = 8.5 Hz, 1H, H2), 5.17 (d, JAB = 12.1 Hz, 
1H, H42a), 5.12 (d, JAB = 12.3 Hz, 1H, H42b), 4.81 (m, 1H, H39), 4.73-4.65 (m, 2H, H23, H15), 4.63 
(m, 1H, H35), 4.57 (m, 1H, H11), 4.47 (m, 1H, H3), 4.22 (m, 1H, H27), 3.90-3.80 (m, 2H, H19a, 
H7a), 3.72 (m, 1H, H31a), 3.17-2.80 (m, 15H, H4, H16, H24, H36, H28, H40, H31b, H19b, H7b), 2.80-
2.60 (m, 3H, H9a, H21a, H33a), 2.50 (m, 1H, H8), 2.43-2.10 (m, 5H, H33b, H21b H9b, H20, H32), 1.40 
(s, 9H, CH3Boc).  
IR in CH2Cl2 (cm-1 ): 3420 (NH), 3302 (NH), 1783 (C=O), 1732 (C=O), 1652 (C=O). 
MALDI-ToF-MS: 1284 [M+Na]+, 1300 [M+K]+         
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Ac-K-(S,S)-Lac-Q-(S,S)-Lac-K-CONH2 32. 
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1H NMR (600 MHz, CD3OH, 303 K) δ ppm 8.36 (d, J = 6.3 Hz, 1H, H19), 8.32 (m, 1H, H26), 
8.27 (m, NH, 1H, H11), 8.22 (d, J = 7.4 Hz, 1H, H34), 8.19 (d, J = 6.3 Hz, 1H,  H3), 7.74 (br s, 
4H, H9,  H40), 7.65-7.45 (m, 2H, H24 or H42), 7. 10-7.0 (m, 1H, H24 or H42), 6.82 (br s, 1H, H24 or 
H42), 4.71-4.63 (m, 2H, H16, H31), 4.39 (m, 1H, H35), 4.26-4.22 (m, 2H, H20, H4), 3.38-3.32 (m, 
2H, H12, H27), 2.99-2.90 (m, 4H, H8, H39), 2.79-2.67 (m, 4H, H14a, H17a, H29a, H32a), 2.64-2.50 (m, 
4H, H13, H17b, H28, H32b), 2.47-2.39 (m, 2H, H14b, H29b), 2.34 (m, 2H, H22), 2.11 (m, 1H, H21a), 
2.0; 1.96 (s, 3H, H1, 2 conf.), 1.95-1.87 (m, 2H, H21b, H36a), 1.82 (m, 1H, H5a), 1.73-1.61 (m, 6H, 
H7, H38, H5b, H36b), 1.57-1.36 (m, 4H, H37, H6).  
MALDI-ToF-MS: 753 [M]+, 776 [M+Na]+, 792 [M+K]+       
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Ac-(R,R)-Lac-K-(R,R)-Lac-A-(R,R)-Lac-Y-CONH2 33. 
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1H NMR (600 MHz, CD3OH, 280 K) δ ppm 9.20 (br s, 1H, H46), 8.51 (d, J = 6.4 Hz, 1H, H27), 
8.34-8.30 (m, 3H, H3, H19, H39), 8.25 (d, J = 7.9 Hz, 1H, H11), 7.90 (m, 1H,  H31), 7.71 (br s, 2H, 
H17), 7.65 (br s, 1H, H50a), 7.22 (br s, 1H, H50b), 7.10 (d, J = 8.6 Hz, 2H, H45, H47), 6.70 (d, J = 
8.4 Hz, 2H, H44, H48), 4.70 (m, 1H, H36), 4.66-4.58 (m, 2H, H8, H24), 4.51 (m, 1H, H40), 4.29 (m, 
1H, H12), 4.22 (m, 1H, H28), 3.45 (m, 2H, H20a), 3.39-3.27 (m, 2H, H4a, H32a), 3.26-3.17 (m, 3H, 
H32b, H20b, H4b), 3.04 (dd, J = 5.3 and J = 14.0 Hz, 1H, H41a), 2.90 (br s, 2H, H16), 2.78 (dd, J = 
9.3 and J = 13.9 Hz, 1H, H41b), 2.75-2.65 (m, 4H, H6a, H9a, H22a, H34a), 2.64-2.51 (m, 7H, H5, H9b, 
H21,H25, H37), 2.47-2.37 (m, 3H, H6b, H22b, H33), 1.94 (s, 3H, H1), 1.78 (m, 1H, H13a), 1.70-1.61 
(m, 2H, H15a, H13b), 1,58 (m, 1H, H15b), 1.41 (m, 2H, H14), 1.33 (d, 3H, J = 7.3 Hz, H29). 
 HRMS (EI) m/e: [M+H]+ calcd 887.4151, found 887.4143 
tR: 11.5 min 
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Ac-L-(R,R)-Lac-K-(R,R)-Lac-A-(R,R)-Lac-Y-CONH2 34. 
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1H NMR (600 MHz, CD3OH, 303 K) δ ppm 9.10 (br s, 1H, H53), 8.37 (d, J = 6.5 Hz, 1H, H34), 
8.25 (m, 1H, H10), 8.19-8.12 (m, 4H, H3, H18, H26, H46), 7.84 (m, 1H,  H38), 7.70 (br s, 2H, H24), 
7.52 (br s, 1H, H57a), 7.10-7.05 (m, 3H, H57b, H54,  H51), 6.7 (d, J = 8.6 Hz, 2H, H55, H50), 4.80-
4.59 (m, 3H, H15, H31, H43), 4.54 (m, 1H, H47), 4.32 (m, 1H, H19), 4.30-4.22 (m, 2H, H35, H4), 
3.48-     3.37 (m, 3H, H11a, H27a, H39a), 3.36-3.22 (m, 3H, H11b, H27b, H39b), 3.05 (dd, J = 5.5 and J 
= 14.0 Hz, 1H, H48a), 2.93 (m, 2H, H23), 2.80 (dd, J = 9.1 and J = 13.9 Hz, 1H, H48b), 2.76-2.63 
(m, 6H, H13a, H16a, H29a, H32a, H41a, H44), 2.63-2.54 (m, 6H, H12, H16b, H28,H32b, H40, H44b), 2.49-
2.35 (m, 3H, H13b, H29b, H41b), 1.98 (s, 3H, H1), 1.82 (m, 1H, H20a), 1.72-1.58 (m, H, H20b, H22, 
H6), 1,58 (m, 2H, H5), 1.43 (m, 2H, H21), 1.34 (d, J = 7.3 Hz, 3H, H36), 0.96 (d, J = 6.7 Hz, 3H, 
H7 or H8), 0.92 (d, J = 6.7 Hz, 3H, H7 or H8). 
MALDI-ToF-MS: 1000 [M]+, 1023 [M+Na]+, 1039 [M+K]+        
tR: 16.3 min 
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Ac-G-F-S-K-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 45. 
MALDI-ToF-MS: 1923 [M+H]+ 
tR: 20.18 min 
 
Ac-G-A-S-K-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 46. 
MALDI-ToF-MS: 1846 [M+H]+ 
tR: 17.51 min 
 
 
Ac-G-F-S-K-A-E-L-A-K-A-Lac-A-K-R-G-G-Y-CONH2 47. 
MALDI-ToF-MS: 1849  [M]+              
tR: 21.0 min 
 
Ac-G-F-S-K-A-E-L-A-K-Lac-A-A-K-R-G-G-Y-CONH2 48. 
MALDI-ToF-MS: 1849  [M+H]+              
tR: 20.51 min 
 
 
Ac-G-F-Lac-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 49. 
MALDI-ToF-MS: 1785  [M]+              
tR: 18.82 min 
 
 
Ac-G-A-Lac-A-E-L-A-K-A-R-A-A-K-R-G-G-Y-CONH2 50. 
MALDI-ToF-MS: 1862 [M+H]+           
tR: 21.89 min 
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